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Summary 
 
The African potato is used as an African traditional medicine for its nutritional and medicinal 
properties.  Most research has been carried out on H.  hemerocallidea, with very little or 
nothing on other Hypoxis spp.  The main aim of this project was to provide scientific data on 
the anticancer, anti-inflammatory and antioxidant properties of H. hemerocallidea, H. 
stellipilis and H. sobolifera chloroform extracts and their active compounds.   
 
The hypoxoside and phytosterol contents of the three Hypoxis spp. were determined using 
TLC, HPLC and GC.  H. hemerocallidea and H. sobolifera chloroform extracts contained the 
highest amounts of hypoxoside and β-sitosterol, respectively.   
 
For the anticancer properties, cytotoxicity of the Hypoxis extracts and its purified compounds 
were determined against the HeLa, HT-29 and MCF-7 cancer cell lines (using MTT), and 
PBMCs (using CellTiter-Blue
®
).  H. sobolifera had the best cytotoxicity against the three 
cancer cell lines, whereas H. stellipilis stimulated HeLa and HT-29 cancer cell growth.  IC50 
values of hypoxoside and rooperol were determined.    DNA cell cycle arrest (using PI 
staining) occurred in the late G1/early S (confirmed by increased p21
Waf1/Cip1
 expression) and 
G2/M phases after 15 and 48 hrs, respectively, when treated with Hypoxis extracts and 
rooperol.     H. sobolifera and rooperol activated caspase-3 and -7 (using fluorescently 
labelled antibodies) in HeLa and HT-29 cancer cells, and caspase-7 in MCF-7 cancer cells 
after 48 hrs.  Annexin V binding to phosphatidylserines in rooperol treated U937 cells 
confirmed early apoptosis after 15 hrs.  The TUNEL assay showed DNA fragmentation in the 
three cancer cell lines when treated with H. sobolifera and rooperol for 48 hrs.  A shift pass 
the G2/M phase has led to the investigation of endoreduplication, which was confirmed by 
cell/nucleus size, and anti-apoptotic proteins (Akt, phospho-Akt, phospho-Bcl-2 and 
p21
Waf1/Cip1
).   
 
U937 cell differentiation to monocyte-macrophages was optimized using PMA and 
1,25(OH)2D3, which was confirmed by morphological and biochemical changes.  For the 
anti-inflammatory properties, Hypoxis extracts and rooperol significantly increased NO 
production in monocyte-macrophages (pre-loaded with DAF-2 DA) and phagocytosis of 
pHrodo
TM
 E. coli BioParticles
®
.  The treatments had no effect on COX-2 expression in 
monocyte-macrophages.  The phytosterols significantly increased IL-1β and IL-6 secretion 
xv 
 
(using the FlowCytomix Multiplex human Th1/Th2 10plex Kit I) in the PBMCs of one 
donor.   
 
For the antioxidant properties, Hypoxis extracts and rooperol significantly increased ROS 
production in undifferentiated and differentiated U937 cells, which were pre-loaded with 
DCFH-DA.  Hypoxis extracts and purified compounds had ferric reducing activities, but only 
rooperol had ferric reducing activities significantly greater than ascorbic acid.  β-sitosterol, 
campesterol and cholesterol significantly increased SOD activity in Chang liver cells, while 
H. stellipilis, H. sobolifera and rooperol decreased SOD activity. 
 
Anticancer, anti-inflammatory and antioxidant properties of the Hypoxis extracts may be 
attributed to the β-sitosterol content, because Hypoxis chloroform extracts contained very 
little or no hypoxoside.  Unidentified compounds, and synergistic and additive effects of the 
compounds may have contributed to the biological effects.  This study confirms previous 
reports that rooperol is the active compound.  Results provide scientific data on the medicinal 
properties of one of the most frequently used medicinal plants in South Africa.   
 
Keywords:  Hypoxis spp.; hypoxoside; phytosterols; anticancer, anti-inflammatory and 
antioxidant activities 
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CHAPTER 1 
LITERATURE REVIEW 
 
1.1.  Traditional medicine 
 
African traditional medicine is regarded as the oldest and possibly the most diverse of all 
the world‟s traditional medicines, but it is the most poorly recorded (Gurib-Fakim, 2006).  
Approximately 75-80% of Africa‟s population relies on traditional medicine.  People 
living in developing countries face shortages of medical facilities, funds and newly 
developed medicine, which force them to be more reliant on natural resources (Louw et 
al., 2002).  Traditional medicines are preferred, due to its affordability, accessibility and 
cultural and religious beliefs (Steenkamp, 2003a).  In North America the use of medicinal 
plants has risen from 3% in 1991 to 37% of the population in 1998.  This may be due to 
the availability of phytomedicine in retail stores, advertisements and an increase in 
pharmaceutical companies (Briskin, 2000).  An increased interest in herbal or traditional 
medicine may be due to adverse reactions and side effects often seen with synthetic drugs 
(Erasto et al., 2005).   
 
Natural products are regarded as a more environmentally friendly alternative to 
commercially produced medicines, resulting in a worldwide interest in medicinal plants. 
It is estimated that only 15% of the world‟s plants have been screened for their 
therapeutic values (Louw et al., 2002; McGaw and Eloff, 2008).  South Africa has 
approximately 24 000 flora species, which is about 10% of the world‟s vascular plant 
flora (McGaw and Eloff, 2008; van Wyk, 2008). 
 
It is estimated that between 35 000 and 70 000 tonnes of renewable (e.g. leaves, flowers, 
fruits, stems) and non-renewable (e.g. bark, bulbs, rhizomes) resources are collected and 
distributed between 50 and 100 million consumers, with a trade value of between US$75-
150 million in southern Africa.  Between 200 000 and 300 000 people are involved in the 
trade of medicinal plants, which include collectors, traders, healers and wholesalers.  In 
1998, an estimated 20 000 tonnes of plant material were traded in South Africa.  These 
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figures are based on the informal herbal market trade in KwaZulu-Natal (Makunga et al., 
2008).  In the Eastern Cape 525 tonnes of medicinal plants are traded annually in a region 
which include Port Elizabeth/Uitenhage, East London, King Williamstown, Queenstown 
and Umtata, with a value of approximately R 27 million (US$6 million; at time of study) 
(Dold and Cocks, 2002).  The natural plant product and organic sector is the fastest 
growing sector in the agribusiness industry, and nutrition products a multi billion dollar 
business world wide.  Even in the United States (US) an increase of US$15 billion in 
1999 to US$23 billion in 2002 was seen.  World wide, approximately 85 000 plant 
species are reported as medicinally useful.  In South Africa approximately 1 000 plant 
species are traded with a value of US$50-100 million per annum in the informal sector 
(Makunga et al., 2008).      
 
Traditional medicine in the health care lacks safety, efficacy and quality control 
(Steenkamp, 2003b).  A plant‟s potency, harvested from the wild or cultivated, is affected 
by the biochemistry of individual species, external factors (including season, geographic 
location, climate), ecological and growth conditions, and storage and preparation of 
extracts (Fennell et al., 2004).  The following sections give an introduction to Hypoxis 
and its compounds, which are one of the most frequently used medicinal plants in South 
Africa.  
 
1.2.  Overview of Hypoxis 
 
1.2.1.  Identification, classification and distribution 
 
Hypoxis, the „miracle‟ medicinal plant of southern Africa, has become a household name 
for many South Africans.  Hypoxis hemerocallidea (previously known as H. rooperi) 
topped the list of the 60 most frequently traded plant species in the Eastern Cape, South 
Africa, when studies were conducted among street traders, traditional healers, store-
owners and clinic patients (Drewes and Khan, 2004).  Hypoxis is known by a variety of 
common names including magic muthi, yellow stars, star lily, star flower, star grass, 
African potato, sterretjie, Afrika patat, sterblom, inkbol, gifbol (Afrikaans); inkon(m)fe, 
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ilabatheka, inkonfe-enkula, igudu (Zulu); moli, molikharatsa (Sesotho); tshuka (Tswana); 
lilabatseka, zifozonke (Swazi); and lotsane (Drewes et al., 2008; Katerere and Eloff, 
2008; Mills et al., 2005; Singh, 1999).  Hypoxis species are tuberous perennials with 
long, strap-shaped leaves and yellow star-shaped flowers.  The brownish-black corms, 
which are yellow inside when freshly cut, have abundant adventitious roots to survive 
high-stress conditions like drought and fire (Figure 1.1).  The corms are used as medicine 
(Nicoletti et al., 1992; van Wyk et al., 1997).  Hypoxis belongs to the small family, 
Hypoxidaceae, which consists of 9 genera and about 152 species.  About 60% of the 
species belong to the genus, Hypoxis, which is distributed on all the continents except 
Europe (Singh, 1999).  In southern Africa, including South Africa, Namibia, Botswana, 
Lesotho and Swaziland, 30 species are found, which are mainly confined to the eastern 
region (Singh, 2007).  It is found growing in grasslands, low scrubs, meadows and 
mountainous areas (Nicoletti et al., 1992). 
 
 
Figure 1.1:  Characteristics of H. hemerocallidea.  Strap-shaped leaves and yellow star-
shaped flowers (left) (van Wyk, 2008), and brownish-black corms with adventitious roots 
(right) (Drewes et al., 2008).  
 
1.2.2.  Medicinal and other uses of Hypoxis  
 
Hypoxis spp. are used by the indigenous population groups of South Africa, including the 
Zulus, Xhosas and Sothos.  Medicinal uses include the treatment of intestinal parasites, 
urinary infections, infertility, vomiting, nausea, cough, palpitations, heart weakness, 
impotency, anxiety, insanity, lice, common cold, yuppie flu, flu, wounds, arthritis, 
cancers, human immunodeficiency virus (HIV)/acquired immune deficiency syndrome 
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(AIDS)-related diseases, hypertension, diabetes, cancer, psoriasis, gastric and duodenal 
ulcers, tuberculosis, asthma, some central nervous system (CNS) disorders (including 
epilepsy and childhood convulsions), depression, laxative, vermifuge, burns, prostatitis, 
benign prostate hyperplasia, prostate adenoma and many more (Buwa and van Staden, 
2006; Drewes et al., 2008; Erasto et al., 2005; Koduru et al., 2007; Mills et al., 2005; 
Ojewole, 2006; Ojewole, 2008; Risa et al., 2004; Singh, 1999; Steenkamp, 2003a; 
Steenkamp, 2003b; van Wyk et al., 1997; Van Wyk and Gericke, 2000).  Weak infusions 
and decoctions of Hypoxis are used as convalescent and strengthening tonics for wasting 
diseases (van Wyk et al., 1997; van Wyk and Gericke, 2000).  Certain Hypoxis spp. have 
antibacterial activities against Eschericia coli, which is associated with acute bacterial 
prostatitis, and Klebsiella pneumoniae (Buwa and van Staden, 2006; Potgieter et al., 
1988; Steenkamp et al., 2006).  Veterinarian uses include fertility enhancement, general 
ailments, heartwater, abortion, red water (babesiosis) and gallsickness in cattle (Erasto et 
al., 2005; McGaw and Eloff, 2008). 
 
Certain Hypoxis spp. are also used as an emetic against fearful dreams; a charm against 
thunder, lightning and storms; the leaves are used to make rope; and the corms are used 
to make black polish to apply to the floors of huts.  The corms of some species are boiled 
or roasted for food in times of famine by Xhosa and Sotho people (Singh, 1999).   
 
1.2.3.  Glycosides isolated from Hypoxis 
 
Glycosides are the main compounds isolated from Hypoxis spp.  Table 1.1 summarizes 
the different glycosides identified in Hypoxis spp. (Nicoletti et al., 1992).  Glycosides 
isolated from Hypoxis spp. have a common pent-1-en-4-yne backbone or a slight 
modification of it (Figure 1.2).   
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Table 1.1:  Different Hypoxis spp. found in Africa and the glycosides they contain. 
 
     Species                                          Origin                                  Glycosides 
 
     Hypoxis obtusa Burch                        Mozambique                            Hypoxoside 
                                                                                                                  Obtusides A and B   
     Hypoxis obtusa Burch.-                      Kenya and                                Hypoxoside 
     Complex                                             Zimbabwe                                Mononyasines A and B   
                                                                                                                  Obtusides A and B 
                                                                                                                  Nyasoside 
     Hypoxis nyasica Bak.                         Malawi                                     Hypoxoside 
                                                                                                                  Nyasoside 
                                                                                                                  Nyasicoside 
                                                                                                                  Mononyasines A and B 
                                                                                                                  Nyaside 
     Hypoxis angustifolia Lam.                  Zimbabwe                               Hypoxoside 
                                                                                                                  Nyasoside 
                                                                                                                  Mononyasines A and B 
                                                                                                                  Nyaside 
                                                                                                                  Nyasol 
     Hypoxis interjecta Nel                        South Africa                            Hypoxoside    
                                                                                                                  Obtusides A and B 
                                                                                                                  Interjectin   
     Hypoxis multiceps Buching.               South Africa                            Hypoxoside 
     Ex Krauss                                                                                            Obtusides A and B 
     Hypoxis rooperi T. Moore                  South Africa                            Hypoxoside 
     Hypoxis acuminata Eckl.                    South Africa                            Hypoxoside 
     Hypoxis nitida Verdoorn                     South Africa                            Hypoxoside 
     Hypoxis rigidula Baker                       South Africa                            Hypoxoside 
     Hypoxis latifolia Hook.                       South Africa                            Hypoxoside         
        
 
Adapted from Nicoletti et al. (1992)  
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                               Hypoxoside                                                         Nyasoside 
        
                           Mononyasine A                                                  Mononyasine B 
         
                            Nyasicoside                                                              Nyasol 
 
                               Obtuside A                                                           Obtuside B 
 
                                 Nyaside                                                             Interjectin 
 
Figure 1.2:  Chemical structures of the known glycosides isolated from Hypoxis spp.  OGl 
indicates glucose linked to the benzene rings through O-glycosidic bonds (Marini-Bettolo et 
al., 1985; Marini-Bettolo et al., 1991; Messana et al., 1989; Sibanda et al., 1990).  
 
1.2.4.  Hypoxoside and rooperol: the compounds of interest 
 
The first pentynene derivative isolated from Hypoxis was hypoxoside [(E)-1, 5-bis(4‟-β-
D-glucopyranosyloxy-3‟-hydroxyphenyl) pent-4-en-1-yne] and its aglycone, rooperol 
(Drewes et al., 1984; Drewes et al., 1989; Marini-Bettolo et al., 1982; Nicoletti et al., 
1992).  Hypoxoside is regarded as a natural product, containing two protective groups in 
the form of glucose units at the ends of the two benzene rings of the pentynene backbone 
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(Drewes et al., 2008).  Rooperol is formed when the glucose units are removed by β-
glucosidase or cellulase (Drewes et al., 1984; Theron et al., 1994).  β-glucosidase is 
mainly found in the gastrointestinal tract and is released by rapidly dividing cancer cells.  
The synthesis of rooperol has been achieved with limited success due to the sensitivity of 
the pentynene backbone when basic and acidic conditions were used for deprotonation, 
resulting in rearrangement of the pentynene backbone (Drewes et al., 1989; Mills et al., 
2005; Potgieter et al., 1988).   
 
Several studies – including anticancer (Albrecht et al., 1995a), anti-inflammatory 
(Guzdek et al., 1996; Laporta et al., 2007a; van der Merwe et al., 1993), antioxidant 
(Laporta et al., 2007b; Nair et al., 2007b) and antibacterial (Laporta et al., 2007a) – have 
shown that rooperol, and not hypoxoside, is the active compound.  Rooperol is an unique 
compound in having (i) two ortho phenolic groups on the benzene rings, which make it a 
better anti-oxidant than hypoxoside; (ii) four exposed acidic phenolic groups, which 
enhances its biological reactivity with cytotoxic action; (iii) a prochiral center at the 
central -CH2- group, which can be recognized by enzymes (Drewes et al., 2008). 
 
Hypoxoside and rooperol are absent in the circulation after oral ingestion.  Only the 
phase II metabolites of rooperol, glucuronides and sulphates, are present in the blood.  
The mixed glucuronide-sulphate is the major component, whereas the diglucuronide and 
disulphate metabolites appear as minor metabolites (20% of major metabolite) due to a 
shorter half-life (20 hrs) compared to the major metabolite (50 hrs) (Figure 1.3; Albrecht 
et al., 1995b).  Like hypoxoside, these metabolites are non-toxic to cells in tissue culture, 
but are activated when treated with glucuronidase (Smit et al., 1995).  The metabolizing 
activity of the gastrointestinal system (particular the colon) and the liver determine the 
extent of conversion of hypoxoside to rooperol, and rooperol to phase II metabolites 
(Albrecht et al., 1995b). 
 
Kruger et al. (1994) have identified hypoxoside and rooperol analogues – containing 2 
(bis-dehydroxy)-, 3 (dehydroxy)- and 4 hydroxyl groups – by high performance liquid 
chromatography  (HPLC).  Hypoxoside analogues were identified in a H. hemerocallidea 
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methanol (MeOH) extract and rooperol analogues were identified when hypoxoside 
analogues were treated with β-glucosidase.  They found that (i) hypoxoside and rooperol 
were absent in the blood after oral ingestion of hypoxoside; (ii) hypoxoside was 
converted to rooperol (found in faeces) due to bacterial glucosidase in the colon; (iii) 
rooperol phase II metabolites (diglucuronide, disulfate and glucuronide-sulfate 
conjugates) were present in the blood.  
 
 
 
Figure 1.3:  Conversion of hypoxoside to rooperol and rooperol to phase II metabolites in in 
vitro and in vivo studies, respectively.  The presence of rooperol metabolites in the bile of 
experimental animals (mouse, rat, dog), excluded their use as in vitro anticancer models for 
hypoxoside (Smit et al., 1995). 
 
  
1.2.5.  Commercial products of Hypoxis and its compounds 
 
Harzol
®
.  The first commercial product of Hypoxis, Harzol
®
, dates back to 1967 when 
Liebenberg and Pegel became interested in the chemical constituents of H. 
hemerocallidea.  Harzol
® consisted of β-sitosterol and its sterolin, β-sitosterol glucoside, 
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which were isolated from Hypoxis.  In Germany it was used for the treatment of benign 
prostate hypertrophy [non-cancerous enlargement of the prostate in males (Drewes et al., 
2008)].  The mechanism of action involved the inhibition of 5α-reductase or preventing 
binding of dihydrotestosterone within the prostate (Drewes and Khan, 2004; Hostettmann 
et al., 2000; Pegel, 1997; Singh, 1999; van Wyk, 2008).    
Moducare
®. β-sitosterol and its sterolin (100:1 mass ratio) in Moducare® were first 
isolated from Hypoxis, but these compounds are now isolated from pine oil and soya.  It 
enhances the in vitro proliferative response of human T cells, hence its use as an immune 
system booster (Drewes et al. 2008; Drewes and Khan, 2004; Singh, 1999). 
Hypo-Plus. Hypo-Plus is used as a food supplement, energy booster and immunity 
modulator.  It contains amino acids, vitamins C, B6 and B12, anti-oxidant components and 
phytosterols from Hypoxis.  It is used for the treatment of diabetes, impotency, gout, 
arthritis, HIV/AIDS and memory loss (Drewes et al., 2008; Drewes and Khan, 2004).  
Prostone.  Sold as an immune system booster in Europe and contains Hypoxis derived 
phytosterols (Abegaz et al., 1999). 
 
Hypoxis extracts are commercially found, on its own or in combination with other plant 
extracts, in products such as Vuselela, Vikilela, Nutriherb, Down to Earth (Appendix 1), 
Smart Hypoxis, and many more.  It is generally found in capsule form, but also in creams, 
soaps, and more.     
 
Several patents for Hypoxis extracts, its compounds and uses have been published 
between 1970 and 1990.  Some of these include: 
 
 Pharmaceutical corm extract of Hypoxis, anti-inflammatory and for the treatment 
of prostate gland hypertrophy by Liebenberg, 1969 (Nicoletti et al., 1992). 
 Extraction of phytosterol glycosides from Hypoxis tubers by Pegel and 
Liebenberg, 1973 (Nicoletti et al., 1992). 
 Extraction of sterolins from plant material (Pegel, 1976). 
 Active plant extracts of Hypoxidaceae and their use (Pegel, 1979). 
 Sterolins and their use (Pegel, 1980). 
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 Rooperol derivatives by Drewes and Liebenberg, 1982 (Nicoletti et al., 1992). 
 Extracts of plants of the Hypoxidaceae family for the treatment of cancer by 
Drewes and Liebenberg, 1983 (Nicoletti et al., 1992). 
 Rooperol and its derivatives (Drewes and Liebenberg, 1987). 
 Process for the preparation of rooperol (Wenteler et al., 1991). 
 
1.3.  (Phyto)sterols and sterolins 
 
1.3.1.  Structural characteristics 
 
Cholesterol (C27H45OH) is an important component of animal fat and some vegetable fats 
(including palm oil, soybean oil, rapeseed oil).  It is taken up via nutrition or can be 
synthesized and stored endogenously in the liver, intestines, adrenal glands and 
reproductive organs (De Brabander et al., 2007).  Plant sterols, also known as 
phytosterols or 4-demethylsterols, are synthesized in plants and must be consumed via 
the diet by humans and animals (Ling and Jones, 1995).  The most commonly found 
phytosterols are sitosterol (65%), campesterol (30%) and stigmasterol (5%) 
(Moghadasian, 2000; Pegel, 1997) (Figure 1.4).  Phytosterols are structurally and 
functionally similar to cholesterol.  All sterols are derived from hydroxylated polycyclic 
isopentenoids (Abidi, 2001) and have a characteristic fused 1,2-
cyclopentanophenanthrine ring structure, which form the steroid nucleus with a 3β-
hydroxyl group and 5,6-double bond.  Although the nucleus structures of phytosterols 
resemble those of cholesterol, they differ regarding the side chain at C-17, double bond at 
C-22 and substituted methyl or ethyl groups at C-24.  β-sitosterol and campesterol have 
ethyl and methyl groups at C-24, respectively.  Stigmasterol is characterized by an ethyl 
group at C-24 and a double bond at C-22.  Sterols, which have undergone 5α-reduction of 
the double bond (also known as saturation), are known as stanols (e.g. sitostanol, 
campestanol, cholestanol).  Phytosterols are found in free form or as conjugates, where 
the 3β-hydroxyl group is esterified to fatty acids or glycosides (De Brabander et al., 
2007; Kritchevsky and Chen, 2005; Lagarda et al., 2006; Ostlund, 2002; Quilez et al., 
2003).  In nature, plants contain sterols with their associated sterolins.  Sterolins are 
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glucosides joined to sterols, which are easily destroyed.  Sterols lose their immune-
enhancing benefits when sterolins are lost (Pegel 1997). 
 
 
 
Figure 1.4:  Chemical structures of cholesterol and the three most commonly found 
phytosterols (β-sitosterol, campesterol and stigmasterol) in plants (Awad and Fink, 2000). 
 
1.3.2.  Sources, intake and absorption of (phyto)sterols 
 
Phytosterols are found in unrefined vegetable oils (e.g. sunflower, corn, safflower, olive 
and soybean), nuts (e.g. walnuts, almonds, Brazil nuts, hazelnuts, peanuts and macadamia 
nuts), vegetables and fruits, bread, cereals (e.g. wheat and corn), margarines, seeds (e.g. 
sesame seed and wheat germ) and legumes.  The estimated daily phytosterol consumption 
is between 160-400 mg/day, which vary among populations for example Finland: 140-
360 mg/day, United Kingdom (UK): 163 mg/day, US: 180 mg/day and Japan: 400 
mg/day (de Jong et al., 2003; Lagarda et al., 2006; Moghadasian, 2000; Ostlund, 2002) 
 
Up to 95% of dietary phytosterols entering the colon will be excreted (Ling and Jones, 
1995).  The percentage of phytosterols absorbed in the intestine ranges between 0.5-5% 
and that of phytostanols may be 10% of free phytosterols.  These percentages are 
significantly lower compared to cholesterol (35-70%).  Phytostanols may lower free 
phytosterol absorption and vice versa (de Jong et al., 2003; Kritchevsky and Chen, 2005; 
Ling and Jones, 1995; Ostlund, 2002).  Phytosterol absorption increases when esterified 
to form esters (Moghadasian, 2000; Ostlund 2002).  The low absorption of phytosterols 
and -stanols may be explained by (i) poor esterfication [low affinity of acyl-coenzyme A 
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cholesterol acyltransferase (ACAT)]; (ii) side chain length and presence of Δ5 double 
bond (saturation); (iii) mutations and polymorphisms in adenosine triphosphate (ATP)-
binding cassette (ABC)G5/ABCG8 transporters, which transport free phytosterols back 
into the intestinal tract; (iv) micellar solubility; (v) slower transfer rate of sitosterol from 
the cell surface to intracellular site compared to cholesterol (de Jong et al., 2003; Igel et 
al., 2003; Moghadasian, 2000; Ostlund 2002).  Increased phytosterol levels are found in 
the adrenal glands, intestinal epithelia, ovaries and testis, and in trace amounts in the 
aorta, muscle, skin subcutaneous adipose tissue and liver (de Jong et al., 2003).  
 
The presence of low phytosterols in the serum and tissues of healthy humans may be due 
to (i) binding of sterol(in)s to plant fibers making absorption of digested food in the gut 
difficult; (ii) modern diet consisting of over-processed food and minimal fruit and 
vegetables (Moghadasian, 2000).  Phystosterol concentrations in the plasma range 
between 7 and 41 μM (von Holtz et al., 1998).  Most β-sitosterol research uses 8-16 μM 
of β-sitosterol, which is within the physiological range. 
 
1.3.3.  Cholesterol lowering effects of phytosterols 
 
Coronary heart disease is the leading cause of death in developed countries (Andersson et 
al., 2004).  Cholesterol, cholesterol esters and other lipids cause the narrowing and 
hardening of arteries, which may lead to atherosclerosis and thrombosis.  Absorbed 
plasma sterols circulate the plasma via lipoproteins.  Atherosclerosis is characterized by 
an increase in low-density lipoprotein (LDL) cholesterol and a decrease in high-density 
lipoprotein (HDL) cholesterol.  Blood LDL cholesterol levels are an indicator of heart 
attack risk (Tapiero et al., 2003). Phytosterols and -stanols decrease atherosclerotic lesion 
size and complexity (de Jong et al., 2003). 
 
Phytosterols lower serum‟s total and LDL cholesterol, without affecting HDL cholesterol 
and triglycerides.  LDL-cholesterol is reduced between 5% and 15% when consuming 
1.5-3g of phytosterols daily.  LDL-cholesterol lowering by phytosterols depends on the 
dose of phytosterols consumed, form of phytosterol, vehicle in which phytosterol is 
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solubilized, diet, genetic factors and starting cholesterol concentration.  Lowering of 
cholesterol by phytosterols is achieved by daily treatment over long periods (> three 
weeks) of time.  Cholesterol lowering activity by phytosterols and -stanols depends on 
solubilization and incorporation into micelles.  Phytosterols increase the pharmaceutical 
action of the cholesterol lowering agents, statins and fibrates.  Phytosterols and statins 
increase cholesterol elimination and reduce cholesterol biosynthesis, respectively.  It is 
estimated that a 10% decrease in blood cholesterol levels will reduce the risk of 
cardiovascular diseases by 19-54% depending on a person‟s age (Andersson et al., 2004; 
De Brabander et al., 2007; Ostlund 2002; Quilez et al., 2003; Richelle et al., 2004).  
Jakulj et al. (2005) have shown that combination treatment of high cholesterol with 
phytosterols and -stanols, and ezetimbe had a greater total cholesterol and LDL-
cholesterol lowering effect than either treatment alone.    
 
The cholesterol-lowering activity of phytosterols and -stanols may be explained by (i) the 
displacement of cholesterol from mixed micelles by phytosterols and -stanols due to 
greater hydrophobicity than cholesterol; (ii) a reduced esterfication rate of cholesterol in 
the enterocytes and cholesterol excretion via chylomicrons; (iii) the upregulation of 
ABC-transporter expression in intestinal cells by stanols, which may increase cholesterol 
excretion by enterocytes back into the lumen; (iv) displacing cholesterol from the bile (de 
Jong et al., 2003; Ostlund 2002; Richelle et al., 2004; Tapiero et al., 2003). 
 
Cholesterol reduction may cause an increase in endogenous cholesterol synthesis; higher 
LDL-receptor expression and lower circulating LDL-cholesterol concentrations (Ostlund 
2002; Tapiero et al., 2003). 
 
1.3.4.  Benefits/function and roles of sterols 
 
Sterols play an important role in the structure and function of cell membranes.  
Cholesterol in its free form is an important membrane component and when esterified to 
fatty acids, plays an important transport and storage role (Pegel, 1997).  Phytosterols and 
-stanols are incorporated into cellular membranes and may influence membrane 
 14 
properties (de Jong et al., 2003).  β-sitosterol influences membrane fluidity by altering 
the lipid composition and influencing signal transduction pathways, which affect cell 
growth and differentiation (Tapiero et al., 2003).  Cholesterol is a precursor of sex 
steroids and corticosteroids in animals, and cardenolides and bufadienolides in plants (De 
Brabander et al., 2007; Pegel, 1997).   
 
β-sitosterol has anti-inflammatory, antioxidant, antipyretic, anti-atherosclerotic, anti-
ulcer, anti-neoplastic, anti-complement, antidiabetic, and immune modulating properties 
(Bouic and Lamprecht, 1999; Lagarda et al., 2006; Pegel, 1997).  Populations with high 
soybean-based diets, which are rich in phytosterols, have lower cancer (especially colon 
and prostate) mortality rates (de Jong et al., 2003).  Several researchers have shown that 
β-sitosterol has anticancer activity against several human cancer cell lines, including 
colon [HT-29 (Awad et al., 1996; Awad et al., 1998)], prostate [LNCaP (von Holtz et al., 
1998)] and breast [MDA-MB-231 (Awad et al., 2001a; Awad et al., 2003a/b) and MCF-7 
(Awad et al., 2007)] cancer cells.  Phytosterols decrease prostatic 5α-reductase and 
prostatic aromatase activities in rats, which is associated with prostate metabolism and 
growth (Awad et al., 1998; Tapiero et al., 2003).   
 
β-sitosterol and its sterolin increase the in vitro proliferation of T-cell production, natural 
killer (NK) cell activity, and secretion of interleukin (IL)-2 and interferon (IFN)γ (Bouic 
et al., 1996; Breytenbach et al., 2001).  Phytosterols may enhance the activity of Th1 
cells and decrease or have no effect on Th2 cells (Bouic and Lamprecht, 1999).  
Phytosterols decrease IL-4, IL-6 and IL-10 involved in B-lymphocyte differentiation and 
inflammation, cortisol:DHEA ratio in marathon runners (lower inflammatory response), 
and overreactive antibody response (Bouic and Lamprecht, 1999; de Jong et al., 2003).  
Increased phytosterol intake may have therapeutic benefits for diseases like tuberculosis, 
allergies, cancer, chronic viral infections, autoimmune diseases and rheumatoid arthritis 
(Bouic and Lamprecht, 1999).      
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Phytosterols are used as emulsifiers, steroidal intermediates and precursors for hormone 
production, and antipolymerization agents for frying oils in the cosmetic, pharmaceutical 
and food industry, respectively (Abidi, 2001). 
 
1.3.5. Functional foods 
 
It is estimated that global cardiovascular disease deaths will increase from 14 million 
(1990) to 23 million (2020), which accounts for one third of all deaths.  The serum LDL-
cholesterol lowering properties of phytosterols have led to the development of functional 
foods.  Phytosterol esters have been approved as safe in functional foods.  The US Food 
and Drug Administration (FDA) and The Scientific Committee on Food (Europe) have 
approved the use of phytosterol esters in spreads at 13.3% and 8% by weight, 
respectively (Lagarda et al., 2006).  Examples of functional foods are spreadable fats, 
milk, soy milk, yogurts, yogurt drinks, mayonnaises, bars, meat and soups, vegetable oils, 
orange juice and green teas (Berger et al., 2004; Lagarda et al., 2006). 
 
Functional foods are designed and developed to reduce a specific disease risk by 
enhancing or promoting health.  During 2000, Pro-active (a spread or margarine with 
added phytosterols) was developed in The Netherlands and launched in South Africa.  
Phytosterols are present in the diet at low levels, but can be increased when added to a 
suitable food vehicle.  Pro-active‟s manufacturer claimed that the daily intake of 20g of 
spread (~2g plant sterol) will lower total and LDL cholesterol by 10-15%, and lower 
ischaemic heart disease by 25% after 2 years.  Esterification of sterols with fatty acids 
increases solubility in lipids and increase incorporation in the lipid phase of food vehicles 
(Vorster et al., 2003).  Food vehicles are fat or oil based and include spreads, salad 
dressings, cream cheese, yogurt, low fat milk products, chocolate, and many more 
(Berger et al., 2004; Vorster et al., 2003). 
   
1.3.6.  Adverse/side effects of phytosterols 
 
 
Phytosterols are non-toxic and rarely associated with side effects (Pegel, 1997).  
Phytosterols may decrease plasma concentrations of carotenoids (α- and β-carotene), 
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lycopene, calcium, and fat-soluble vitamins A, D, E, and K.  Phytosterolaemia/ 
sitosterolaemia is a rare inherited genetic disorder associated with abnormally high 
plasma concentrations of phytosterols/sitosterol due to increased absorption rates and 
decreased elimination rates, which may be due to mutations in the ABC transporters 
expressed in the intestinal and liver cells.  Patients develop Achilles tendon xanthomas, 
accelerated atherosclerosis (acute myocardial infarction), haemolytic episodes, arthritis 
and arthralgias (de Jong et al., 2003; Moghadasian, 2000; Ostlund, 2002; Richelle et al., 
2004; Vorster et al., 2003).  The carotenoid lowering effect of phytosterols can be 
prevented by a higher intake of fruits or vegetables rich in carotenoids (Berger et al., 
2004).  
 
Increased phytosterol concentrations in erythrocyte membranes may cause increased 
fragility and haemolysis.  Replacement of cholesterol with phytosterols increases 
membrane rigidity, which may lead to possible haemorrhagic stroke when serum 
cholesterol levels are too low.   A decrease in intestinal cholesterol and related lipid 
absorption may influence cellular cholesterol and steroid metabolism and function 
(Moghadasian 200l; Vorster et al., 2003).    
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CHAPTER 2 
AIMS OF THE STUDY AND OVERVIEW OF CHAPTERS 
 
The use of the African potato has been controversial over the last few years.  South 
Africa‟s previous minister of health, dr. Mantho Tshabalala-Msimang has promoted the 
use of the African potato not only in South Africa, but also abroad.  The following 
statement has elicited criticism from around the world:  
 
„…and eating garlic, olive oil, beetroot and the African potato boosts the immune system to 
ensure the body is able to defend itself against the virus (HIV) and live with it…‟  
 
 
In a country with the highest percentage of HIV, statements like these must be proven 
scientifically. 
 
The main aim of this study was to provide scientific data on the medicinal – including 
anticancer, anti-inflammatory and antioxidant – properties of three Hypoxis spp. and its 
purified compounds.   
 
The objectives of this study were: 
 
 To identify sterols and sterolins in three Hypoxis spp. 
 To quantify and compare sterol(in)s and hypoxoside in three Hypoxis spp. 
 To compare the in vitro anticancer activities of three Hypoxis spp. and its purified 
compounds against the HeLa, HT-29 and MCF-7 cancer cell lines. 
 To determine the anticancer mechanism(s) of action involved. 
 To determine the anti-inflammatory activities of the Hypoxis extracts and its 
purified compounds. 
 To determine the antioxidant activities of the Hypoxis extracts and its purified 
compounds. 
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Chapter 3 focuses on Hypoxis spp. selection, extract preparation and the analytical 
analysis of hypoxoside and (phyto)sterol(in)s in three Hypoxis spp.  Qualitative and 
quantitative analysis of (phyto)sterols were performed using TLC and GC, respectively.  
Quantitative analysis of hypoxoside was performed using HPLC. 
 
Chapter 4 focuses on the anticancer properties of Hypoxis spp. and its purified 
compounds.  β-glucosidase and hypoxoside-to-rooperol conversion in HeLa, HT-29 and 
MCF-7 cancer cells were determined.  Cytotoxicity of Hypoxis extracts and its purified 
compounds on HeLa, HT-29 and MCF-7 cancer cells, and PBMCs were performed using 
MTT and CellTiterBlue
®
 assays, respectively.  IC50 values of hypoxoside and rooperol 
were determined for HeLa, HT-29 and MCF-7 cancer cells, and PBMCs.  Mechanism(s) 
of action investigated include DNA cell cycle arrest (confirmed by increased p21
Waf1/Cip1
 
expression), caspase-3 and/or -7 activation, phosphatidylserine translocation and DNA 
fragmentation. 
 
Chapter 5 focuses on endoreduplication, a cell survival strategy, in HeLa, HT-29 and 
MCF-7 cancer cells induced by Hypoxis extracts and its purified compounds.  Anti-
apoptotic proteins investigated include phospho-Akt, phospho-Bcl-2 and p21
Waf1/Cip1
.  In 
this study, endoreduplication was first seen in the histograms of DNA cell cycle arrest.  
Phase-contrast light and DAPI fluorescence microscopy confirmed the presence of 
apoptotic cells and cells undergoing endoreduplication in these three cancer cell lines.  
 
Chapter 6 focuses on the anti-inflammatory properties of Hypoxis extracts and its purified 
compounds.  Differentiation of U937 cells to monocyte-macrophages was optimized by 
using PMA and 1,25(OH)2D3 over different time periods.  Monocyte-macrophage 
differentiation was confirmed by phase-contrast light microscopy, and CD11b and CD14 
cell surface marker staining.  The effect of Hypoxis extracts and its purified compounds 
on NO production, COX-2 expression and phagocytosis on monocyte-macrophages, and 
pro- and anti-inflammatory cytokine production in PBMCs were investigated. 
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Chapter 7 focuses on the antioxidant properties of Hypoxis extracts and its purified 
compounds.  The effect of Hypoxis extracts and its purified compounds on ROS 
production in undifferentiated and differentiated U937 cells, antioxidant potential (using 
the FRAP assay) and SOD activity in Chang liver cells were investigated. 
 
Chapter 8 summarizes the findings of this study. 
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CHAPTER 3 
 
PLANT SELECTION, EXTRACTION AND ANALYTICAL ANALYSIS OF 
COMPOUNDS IN HYPOXIS SPP 
 
3.1.  Plant selection 
 
Corms of H. hemerocallidea (voucher number: PEU 14798) and H. stellipilis (PEU 
14841) were purchased in Port St Johns and Port Elizabeth (Xhosa traditional medicine 
shop), respectively, in the Eastern Cape, South Africa.  Corms of H. sobolifera var 
sobolifera (PEU 14840) were collected near Plettenberg Bay in the Southern Cape, South 
Africa.  Corms of the three Hypoxis spp. were planted in the same soil type and exposed 
to equal amounts of sunlight, humidity and water for at least six months before they were 
harvested and used fresh.  The Hypoxis spp. were identified by Y. Singh from the South 
African National Biodiversity Institute (SANBI) and voucher specimens were deposited 
in the Nelson Mandela Metropolitan University herbarium. 
 
H. hemerocallidea Fisch., C.A. Mey. and Avé-Lall (Figure 3.1) has a broad distribution 
in the Eastern Cape, KwaZulu-Natal, Gauteng and Limpopo provinces of South Africa, 
Lesotho, Mozambique, Zimbabwe and further northwards into east Africa.  The corms 
may reach diameters of 100-150 mm (Drewes et al., 2008).  H. hemerocallidea has 
broad, slightly hairy leaves, which are arranged one above the other and spreading 
outwards from the center of the plant.  The bright yellow, star-shaped flowers are borne 
on long, green and slender pedicels from October to January (van Wyk et al., 1997).  
 
H. stellipilis Ker-Gawl. (Figure 3.1) is mainly found in the grassy areas of the 
southeastern part (Eastern Cape) of South Africa and is the most commonly sold Hypoxis 
species in the traditional herbal shops of Port Elizabeth, Eastern Cape.  H. stellipilis 
grows up to 300 mm.  The leaves form a thick, slightly twisted rosette and have dark 
green upper surfaces with slightly wavy edges and the reverse side is silvery due to the 
presence of hairs.  The bright yellow star-shaped flowers have six orange stamens and are 
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borne on pinkish, hairy pedicels from March to November.  H. stellipilis has long 
adventitious roots (Vanderplank, 1998). 
 
H. sobolifera var sobolifera (Jacq.) Nel. (Figure 3.1) is distributed in the Western Cape, 
Eastern Cape and KwaZulu-Natal, and is mainly found along the coast, where it grows in 
dune vegetation and open grasslands.  The leaves (4-12) are arranged in three ranks and 
are evenly covered with hairs on both sides.  Leaves of plants growing in the shade are 2-
3 times longer and broader than those growing in open grassland.  Two to six flowers per 
inflorescence are borne on 40-70 mm long pedicels throughout the season.  It grows in 
clumps via stolon formation and can be easily propagated via rootstock division (Singh et 
al., 2007).      
 
   
Figure 3.1:  Pictures of H. hemerocallidea (left), H. stellipilis (middle) and H. sobolifera var 
sobolifera (right). 
 
3.2.  Hypoxis extracts 
 
3.2.1.  Background 
 
Traditional healers use mainly water and boiling to prepare extracts from medicinal 
plants, due to limited access to lipophilic solvents (Buwa and van Staden, 2006; Louw et 
al., 2002).  Inexpensive and freely available alcohols [including ethanol (EtOH) and 
MeOH] are also used to prepare extracts, which possess antimicrobial and anti-
inflammatory properties (Louw et al., 2002).  All of the active compounds may not be 
extracted when using a single extraction solvent, for example non-polar solvents will 
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extract more non-polar compounds, whereas polar solvents will extract more polar 
compounds.  The dosage depends on the solvent used during extraction, for example 
higher dosages of water extracts can be administered, while the same dosage of a 
lipophilic solvent extract may be dangerous (Buwa and van Staden, 2006).  The bulbs and 
tubers of bulbous, tuberaceous and rhizomatous plants can be kept for longer periods and 
herbalists claim that these storage organs contain the highest concentration of medicinal 
compounds (Louw et al., 2002).    
 
3.2.2.  Materials and Methods 
 
H. sobolifera extracts.  Corms of H. sobolifera were crushed using a mortar and pestle, 
and homogenizer.  Polar solvents used for extraction included water, EtOH, MeOH and 
acetone, whereas the non-polar solvents used for extraction included chloroform (CHCl3) 
and dichloromethane.  Solvents were added to the plant material in a 10:1 (v/w) ratio, 
vortexed and extracted for 24, 48 and 72 hrs.  The supernatants were removed by 
evaporation in vacuo (EtOH, MeOH, acetone, CHCl3 and dichloromethane extracts) and 
freeze-dried (water extract).  H. sobolifera was chosen to prepare polar extracts to test if 
more polar solvents would yield any hypoxoside, because hypoxoside was absent in the 
chloroform extracts (section 3.3.3.2).    
 
Chloroform extracts.  Corms of H. hemerocallidea, H. stellipilis and H. sobolifera were 
washed, peeled, grated and crushed using a mortar and pestle.  CHCl3 was added to the 
plant material in a 1:1 (v/w) ratio, vortexed (five min), extracted (15 min) and centrifuged 
(3600 x g for five min) at room temperature.  The supernatant was removed and the 
extracting method repeated with the same plant material.  The CHCl3 was evaporated in 
vacuo and the mass of extracts determined.  After mass determination the extracts were 
redissolved in CHCl3 until further use. 
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3.2.3.  Results and Discussion 
 
Different solvents were used to extract compounds and to optimize extraction from H. 
sobolifera.  The percentage yield for each solvent extract of H. sobolifera is summarized 
in Table 3.1.  
 
Table 3.1:  Percentages of yield for H. sobolifera extracts, using different polar and non-
polar solvents over different time periods. 
 
Solvent  Crushing method % Plant extract yield* over time 
24 hrs 48 hrs 72 hrs 
Water Mortar and pestle 4.0 6.0 6.5 
Homogenizer 4.5 4.5 5.8 
EtOH Mortar and pestle 4.5 5.5 7.5 
Homogenizer 3.5 5.25 4.5 
MeOH Mortar and pestle 4.5 6.5 6.0 
Homogenizer 3.3 6.0 6.3 
Acetone Mortar and pestle 1.0 4.0 5.0 
Homogenizer 7.0 6.0 4.5 
CH3CN Mortar and pestle 25 32 55 
Homogenizer 15 36 30 
Dichloromethane Mortar and pestle 22 21 43 
Homogenizer 5.3 21 31 
* Dry weight of extract as percentage of wet weight of starting material 
 
Most of the previous studies focused on water, MeOH and EtOH extracts of Hypoxis, in 
particular H. hemerocallidea.  In this study we were interested in phytosterols in addition 
to the already identified compound, hypoxoside.  Phytosterols are non-polar compounds; 
hence more non-polar solvents (including CHCl3 and dichloromethane) would give the 
highest percentages of yield (as seen in Table 3.1).  The yield of chloroform extracts of 
H. hemerocallidea, H. stellipilis and H. sobolifera is presented in Table 3.2. 
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Table 3.2:  Percentages of yield for Hypoxis extracts, using chloroform.  Plant material was 
extracted twice for 15 min. 
 
Hypoxis spp. Initial weight of fresh 
plant material (g)* 
Final dry weight 
(g)* 
Percentage yield (w/w) 
H. hemerocallidea 342 1.34 0.39 
H. stellipilis 532 3.01 0.57 
H. sobolifera 348 0.57 0.16 
* average of three extractions 
 
Percentages of yield for chloroform extracts were low, which may be due to the shorter 
extraction period.  H. stellipilis and H. sobolifera yielded the highest and lowest 
percentages of extract, respectively.  Standard deviations of the three extractions are not 
shown due to high variability.  Variability may be due to the degree of grating, crushing 
with mortar and pestle, and vortexing.  
 
3.3.  Analytical Analysis of Compounds in Hypoxis spp. 
 
3.3.1. General Background 
 
Quality, safety and efficacy data on plants, their extracts and active ingredients, and 
correct identification of species concerned (fresh, dried or powdered form) are urgently 
needed in a country where traditional medicine is used by the majority of the population.  
In South Africa, a relatively small number of plant species has been scientifically 
validated.  Recently, pharmaceutical monographs containing identity standards and 
quality control profiles for 60 indigenous plant species (including H. hemerocallidea), 
used in traditional medicine were drawn up, based on World Health Organization (WHO) 
guidelines (Springfield et al., 2005).   
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3.3.1.1.  (Phyto)sterol(in)s isolation 
 
Phytosterols are qualitatively and quantitatively analyzed in food to evaluate their 
contribution to the overall diet intake and used in certain control processes (e.g. 
adulteration in vegetable oils).  The cholesterol lowering and beneficial physiological 
effects (Chapter 1, section 1.3.3) of phytosterols and -stanols have led to their 
quantification in foods and diets.  Phytosterols are found in food as free sterols, steryl 
esters, steryl glycosides (syn. sterolins) and acylated steryl glycosides.  No reference 
method has been developed for phytosterol and -stanol analysis in sterol-enriched food 
(Lagarda et al., 2006; Piironen et al., 2000).  Phytosterols are separated with great 
difficulty from cholesterol and from each other due to the similarity in structures when 
using physical methods, unless powerful methods [gas chromatography (GC) and HPLC] 
with thousands of theoretical plates are used (Ostlund, 2002).  Sterol analysis involves 
the extraction of a lipid fraction from homogenized sample material, saponification 
(alkaline hydrolysis), extraction of non-saponifiables, extract clean up, sterol 
derivatization and separation with quantification. 
 
(i) Sterol isolation and extraction.  Most methods used to extract lipids will also extract 
phytosterols.  Phytosterol extraction depends on the matrix (nature of source), physical 
state (liquid or solid) and form (free, esterified or glycosylated) of phytosterols.  Different 
solvent systems used for phytosterol extraction include acetonitrile (CH3CN): MeOH 
(high sterol yield), CH3CN: MeOH: water, hexane, methylene chloride, and acetone.  
CH3CN and MeOH can be replaced by dichloromethane and isopropanol, respectively.  
Supercritical fluid extraction (SFE) and supercritical fluid fractionation (SFF) give high 
sterol yields of approximately 95-100% (Abidi, 2001; Lagarda et al., 2006; Moreau et al., 
2002; Piironen et al., 2002).  Non-polar solvents extract free phytosterols and phytosteryl 
fatty-acid esters, whereas more polar solvents extract steryl glycosides (many 
carbohydrate groups) and fatty-acylated steryl glycosides (Moreau et al., 2002; Piironen 
et al., 2002). 
 
 26 
(ii) Saponification.  Saponification or alkaline hydrolysis with ethanolic potassium 
hydroxide is used to hydrolytically cleave phytosterol conjugates to release free sterols.  
This process is laborious and cannot be used to hydrolyze the hemiacetyl bond between 
the sterol and carbohydrate moiety of steryl glycosides.  Acid hydrolysis with 
hydrochloric acid (HCl) is used to liberate sterols from their glycosides, but is not 
suitable for certain phytosterols (e.g. fucosterol) found in certain plant families due to 
decomposition and isomerization (Moreau et al., 2002; Piironen et al., 2000).  Enzymatic 
methods (e.g. β-glucosidase and cholesterol ester hydrolase) have been used to solve the 
problems associated with alkaline and acid hydrolysis and to cleave steryl glycosides to 
yield free phytosterols (Moreau et al., 2002).  Solvent removal with anhydrous sodium 
phosphate and alumina yields an unsaponifiable residue suitable for chromatographic 
quantification (Abidi, 2001; Lagarda et al., 2006).  The unsaponifiable fraction represents 
approximately 1% of total material in food lipids and contains phytosterols, carotenoids, 
tocopherols, and other hydrocarbons.  These can be further extracted with non-polar 
solvents (hexane, cyclohexane and hexane/diethyl ether) (Piironen et al., 2000).  
 
(iii) Separation/purification of sterols.  Thin layer chromatography (TLC) and column 
chromatography (CC) are accessible and affordable procedures used for sample clean up 
and purification.  TLC is a simpler technique but is only appropriate for small quantities 
of compounds (<200 mg), while CC is more complex but can be used to separate and 
purify larger quantities.  These techniques can be used for qualitative analysis and sterol 
estimates but not for quantification due to inadequate analytical precision.  These 
techniques are laborious, time-consuming, lack automation and large volumes of organic 
solvents are required.  Solid phase extraction (SPE) is more often used to isolate sterols, 
because it is faster, many samples can be separated or purified, and less solvents are 
required (Abidi, 2001; Lagarda et al., 2006; Piironen et al., 2000).   
 
(iv) Forming sterol derivatives.  Sterol and stanol separation is possible without 
derivatization, but resolution of sterols and their corresponding stanols is not as good as 
that of their trimethylsilyl (TMS) derivatives.  Derivatives yield better peak shape, 
resolution, sensitivity and higher stability with thermally labile unsaturated sterols 
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(Lagarda et al., 2006; Moreau et al., 2002; Piironen et al., 2000).  Derivatizing agents 
used include TMS, acetate, N-methyl-N-trimethyl-silyltrifluoroacetamide (MSTFA) in 
anhydrous pyridine and bis(trimethylsilyl)-trifluoroacetamide (BSTFA) containing 1% of 
trimethylchlorosilane (TMCS) (Lagarda et al., 2006).  The former two derivatizing agents 
are the most commonly used (Abidi, 2001).  
 
(v) Analysis.  Sterol peaks are represented by retention times relative to a reference 
standard or internal standard (Abidi, 2001).  Examples of internal standards are 5α-
cholestane, betulin, cholestane, 5 β-cholestan-3α-ol (epicoprostanol) and 5α-cholestan-
3β-ol.  The internal standard must be structurally similar to the analyte‟s structure e.g.   
epicoprostanol resembles sterol‟s structure (Lagarda et al., 2006).  The use of standards is 
important to eliminate analytical errors like fluctuations in instrument operating 
conditions and other experimental variables.  The two most commonly used methods for 
sterol analysis are GC and HPLC.  GC is the technique of choice due to shorter analysis 
time (capillary columns), less peak interference, better resolution and sensitivity 
(detecting individual sterols in the low nanogram range).  GC separation depends on the 
sterols‟ polarity and volatility.  Partitioning between the sterol and stationary liquid phase 
is influenced by both polarities.  Volatility (related to molecular mass, size and volume) 
can be increased by derivatization.  Increasing the polarity of the stationary phase will 
improve the resolution of a sterol mixture with similar structures.  Non-polar stationary 
phases (100% polysiloxane) are the most commonly used, but better resolution is 
achieved with slightly more polar stationary phases (e.g. 95% dimethylpolysiloxane: 5% 
diphenyl). The SAC-5 column (Supelco) has been specially developed for reproducible 
analysis of sterols.  Very few packed GC columns have been used for phytosterol 
analysis.   
 
HPLC operates under milder column temperatures and non-destructive detection 
conditions compared to GC.  It is more suitable for analyzing thermally unstable sterols 
(Abidi, 2001), but high lipophilicity of sterols makes sample processing and 
chromatography difficult (Lagarda et al., 2006).  Reverse phase (RP) HPLC is more 
frequently used than normal phase (NP) HPLC.  RP-HPLC uses low volatile polar 
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organic solvents in water, which equilibrate the bonded silica stationary phase; gives 
reproducible chromatographic peak characteristics, good column selectivity; hydrophobic 
interaction between the analyte and stationary phase increase with increasing molecular 
mass and decreasing number of double bonds in sterols. Alkylsilica stationary phases 
[e.g. octadecylsilica (ODS)] and polar organic solvents (e.g. CH3CN and MeOH) are 
most frequently used.  An isocratic system is mostly used, while a gradient system is used 
for the analysis of a wide range of compounds (Abidi, 2001).  HPLC is not selective 
enough to separate sterols and their stanols (Piironen et al., 2000).  NP-HPLC separates 
phytosterol lipid classes (free sterols, fatty acyl sterols, steryl glycosides and acylated 
steryl glycosides), while RP-HPLC separates molecular species (individual compounds) 
comprising a lipid class.  Although methods are available for the simultaneous analysis of 
non-polar (free sterols and fatty acyl sterols) and polar (steryl glycoside and acylated 
steryl glycoside) sterol lipid classes, the most accurate way of quantification is to analyze 
these classes separately (Moreau et al., 2002).  
 
Sterols can be detected by ultraviolet (UV; 200-210 nm), photodiode array detection 
(DAD), mass spectroscopy (MS), nuclear magnetic resonance (NMR), infrared (IR), 
evaporative light scattering detection (ELSD) and flame ionization detection (FID) 
(Abidi, 2001; Lagarda et al., 2006).  It is important to note that sterols are unstable and 
best stored in non-lyophilized form at -20 ºC.  Sterol oxidation can be prevented by 
removing oxygen via nitrogen. The sensitivity of a technique depends on the sterol 
structures and detectors coupled to the chromatographic instrument (Lagarda et al., 
2006).  
 
3.3.1.2.  Hypoxoside isolation 
 
Marini-Bettolo et al. (1982) isolated and identified the first glycoside, hypoxoside, from 
H. obtusa Bush (found widespread in southeast Africa, especially Mozambique).  
Hypoxoside has been identified in several Hypoxis spp. including H. acuminata, H. 
angustifolia, H. interjecta, H. latifolia, H. multiceps, H. nitida, H. nyasica, H. rigidula 
and H. hemerocallidea.  Other glycosides identified in the family Hypoxidaceae include 
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obtusides A and B, mononyasines A and B, nyasoside, nyasicoside, nyaside and nyasol 
(Chapter 1, Table 1.1) (Galeffi et al., 1987; Marini-Bettolo et al., 1982; Marini-Bettolo et 
al., 1985; Marini-Bettolo et al., 1991; Messana et al., 1989; Nicoletti et al., 1992; 
Sibanda et al., 1990).   
 
Hypoxoside, also known as the diglucoside of (E)-1,5-bis(3‟,4‟-dihydroxyphenyl)pent-4-
en-yne, has a characteristic pentynene backbone, two benzene rings and two glucose units 
(at C-4 position of the benzene rings).  The molecular structure is C29H34O14 with a 
molecular mass of 606.59 g/mol and is very soluble in water and MeOH.  Hypoxoside is 
hydrolyzed (removing the glucose moieties) by β-glucosidase or cellulase to form an 
aglycone, rooperol, with a molecular structure of C17H14O4 (Figure 3.2) (Drewes et al., 
1984; Marini-Bettolo et al., 1982). Drewes et al. (1984) described the isolation of 
hypoxoside from H. hemerocallidea and the chemical synthesis of a tetramethoxy 
derivative of hypoxoside. 
 
                        
               
       
                    Hypoxoside                                                                                           Rooperol    
 
Figure 3.2: Chemical structures of hypoxoside and rooperol, where the former is converted 
to the latter by β-glucosidase in vitro (Albrecht et al., 1995a). 
 
Hypoxoside was first extracted from Hypoxis using MeOH, partitioned between H2O and 
n-butanol (BuOH), and purified through countercurrent distribution (CCD) between H2O: 
ethyl acetate (AcOEt): n-BuOH using a Craig Post apparatus.  NMR was used to 
determine the chemical structure of hypoxoside (Marini-Bettolo et al. 1982; Nicoletti et 
al., 1992).  HPLC is the method of choice for hypoxoside isolation and purification 
(Drewes et al., 1984; Drewes et al., 1989; Kruger et al., 1994; Nair and Kanfer, 2006).  
 
Hypoxoside is present at high concentrations in Hypoxis spp.  Marini-Bettolo et al. 
(1982), Drewes et al. (1984) and Kruger et al. (1994) found hypoxoside yields of 3.7%, 
β-glucosidase 
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3.5-4.5% and 10%, respectively.  Seasonal variation (Drewes et al., 1994) and method of 
Hypoxis drying (Nair and Kanfer, 2006) may influence hypoxoside concentrations.  
 
The hypoxoside and (phyto)sterol(in) content of H. stellipilis and H. sobolifera has not 
been measured in previous studies.  This chapter focuses on the identification and 
quantification of (phyto)sterols, sterolins and hypoxoside in chloroform extracts of three 
Hypoxis spp.   
 
3.3.2.  Materials and Methods 
 
Reagents and chemicals.  Sterol standards [β-sitosterol (purity > 90%), campesterol 
(purity > 65%), cholesterol (purity > 99%), desmosterol (purity ≥ 85%), ergosterol 
(purity ≥ 95%), fucosterol (purity ~ 95%), stigmasterol (purity ~ 95%) and stigmastenol 
(purity > 95%)] were purchased from Sigma Chemical Co. (MO, USA).  HPLC grade 
CH3CN and MeOH were purchased from Romil Ltd. (Cambridge, UK).  Water was 
obtained from a Milli-Q Compact System (Millipore, Bedford, MA).  MODUCARE
® 
was 
purchased from a pharmacy. 
 
3.3.2.1. TLC   
 
Sterol(in)s.  A MODUCARE
®  
(Aspen Pharmacare) tablet (containing 20 mg sterols and 
0.2 mg sterolins) was used as a standard to identify sterol(in)s in Hypoxis extracts, due to 
the unavailability of commercial sterolin standards.  A MODUCARE
®
 tablet was 
dissolved in chloroform (1 mL), vortexed for five min, extracted for 15 min at room 
temperature, centrifuged using an Eppendorf 5804R centrifuge at 18 000 x g for five min 
at room temperature and the supernatant, containing the sterol/sterolins, removed.  
MODUCARE
®
 (5 μg), β-sitosterol (2 μg) and stigmasterol (2 μg) standards (Supelco, 
USA), and Hypoxis extracts (500 μg) dissolved in chloroform were spotted onto 20 x 20 
cm silica coated aluminum plates (Merck, Germany) and air dried.  Chromatogram tanks 
were equilibrated for one hour using toluene: diethyl ether (40:40, v/v) and CH3CN: ethyl 
acetate: formic acid (5:4:1, v/v/v) as mobile phases for sterol and sterolin identification, 
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respectively.  TLC plates were developed for ±20 min or until the solvent front was ±1 
cm from the top of the plate.  Detection of sterols and sterolins was performed as 
described by Scott and Springfield (2004).  In brief, TLC plates were dried at room 
temperature and developed by firstly dipping into a solution containing 5% sulfuric acid 
in 96% EtOH for 15 s followed by a solution containing 1% vanillin in 96% EtOH for 15 
s and dried at room temperature.  Once dried, plates were heated at 80 - 100 ºC for five 
min.  Photos of the developed TLC plates were taken with the AlphaImager
TM
 3400 
(Alpha Innotech.). 
 
3.3.2.2.  HPLC 
 
Hypoxoside.  HPLC analysis of hypoxoside was performed using a Beckman System 
Gold high performance liquid chromatograph equipped with Solvent Module 128 and 
Diode Array Detector Module 169.  The column used for HPLC hypoxoside separation 
was a Nucleosil C18 column (Supelco, 5 μm, 150 x 4.6 mm i.d.).  Detection of 
hypoxoside was performed as described by Nair and Kanfer (2006).  In brief, CH3CN: 
H2O (20:80, v/v, degassed) was used as mobile phase in isocratic mode at a flow rate of 1 
mL/min and the injection volume was 10 μL.  Detection was achieved in the range of 200 
- 400 nm and hypoxoside was detected at a wavelength of 260 nm.  Stock solutions of 
hypoxoside (1 mg/mL), H. hemerocallidea (5 mg/mL), H. stellipilis (10 mg/mL) and H. 
sobolifera (10 mg/mL) were prepared in MeOH and filtered through 0.2 μm syringe 
filters (Corning Incorporated, New York, USA).  Dilutions (10-100 μg/mL) of 
hypoxoside for the standard curve were also prepared in MeOH. 
 
Sterols.  The above mentioned HPLC system was used for sterol analysis.  Optimization 
of sterol separation included the testing of different isocratic, flow and gradient methods 
using Hypersil 5 C8 300Å (Phenomenex, 5μm, 250 x 4.60mm i.d.) and Nucleosil C18 
columns.  An isocratic system of CH3CN: MeOH (90:10; v/v; degassed) at a flow rate of 
0.5 mL/min, using the Nucleosil C18 column, was used to separate a sterol mixture 
consisting of 100 μg/mL each of β-sitosterol, desmosterol, stigmastenol and stigmasterol.  
Hypoxis chloroform extracts (same concentration as for hypoxoside analysis) and sterol 
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standards were dissolved in MeOH.  Detection wavelengths were 210 nm and 290 nm for 
sterols and internal standard (thymol), respectively.  Standards and plant extracts (50-500 
μL) were injected and chromatographic separation performed at room temperature. 
  
3.3.2.3.  GC   
 
Stock solutions (1 mg/mL) of each sterol standard (β-sitosterol, campesterol, cholesterol, 
desmosterol, ergosterol, fucosterol, stigmasterol and stigmastenol) were prepared using 
MeOH.  Stock solutions (5 mg/mL) of the Hypoxis chloroform extracts (H. 
hemerocallidea, H. stellipilis and H. sobolifera) were also made using MeOH.  Dilutions 
(2.5-100 μg/mL) were prepared in MeOH for all of the sterol standards.  For β-sitosterol 
an additional 200 μg/mL concentration was prepared.  GC analysis of sterols was 
performed using a Thermo Finnigan Focus gas chromatograph equipped with a FID and 
an Autoinjector AI3000, with Delta Chromatography 5.0 software.  The column used for 
GC separation was a SAC
TM
-5 capillary column (Supelco, 30 m x 0.25 mm i.d. x 0.25 
μm film thickness).  The thermal conditions were: 80 ˚C for 2 min; 10 ˚C/min to 300 ˚C; 
300 ˚C for 14 min. The carrier gas was helium (1 mL/min constant flow) and the 
injection volume was 2 μL (splitless).  Sensitivity was set at 1.  Standard curves were 
prepared for each of the eight sterol standards. Sterols were identified by spiking the 
sterol mixture (containing 100 μg/mL of each sterol standard) with each sterol standard 
[adding 10, 20, 30, 40, 50, 60, 70 and 80 μL (10 μL = ± 9.9 μg of sterol standard) of the 1 
mg/mL stocks of β-sitosterol, campesterol, cholesterol, desmosterol, ergosterol, 
fucosterol, stigmasterol and stigmastenol, respectively].  An increase in peak area was 
used as criteria to identify each peak. 
 
3.3.3.  Results and Discussion 
 
3.3.3.1.  TLC analysis of (phyto)sterol(in)s 
 
Chloroform has been shown to be very effective in dissolving sterols (Toivo et al., 2000) 
due to its non-polar nature.  The presence of (phyto)sterols and sterolins in the 
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chloroform extracts of H. hemerocallidea, H. stellipilis and H. sobolifera was confirmed 
via TLC.  Modification of the mobile phase, toluene: diethyl ether: 1.75 M acetic acid 
(1:1:1, v/v/v) used by Scott and Springfield (2004), to toluene: diethyl ether (40:40, v/v) 
resulted in better sterol separation (Figure 3.3).  
  
 
                                    1            2            3               4            5             6  
 
 
Figure 3.3: TLC plate of the sterols found in Hypoxis spp. chloroform extracts. (1) 
MODUCARE
®, (2) β-sitosterol, (3) stigmasterol, (4) H. hemerocallidea, (5) H. sobolifera and 
(6) H. stellipilis.  Red arrow represents most probably β-sitosterol, which is the main sterol 
found in MODUCARE
®
. 
 
The spots of the phytosterol standards (stigmasterol and β-sitosterol) had the same Rf 
value of 0.53.  Cholesterol, campesterol, desmosterol, ergosterol, fucosterol and 
stigmastenol migrated the same distance on the TLC plates, with the spots differing only 
in colour ranging from pink to blue (data not shown).  This made it impossible to identify 
and quantify individual phytosterols in the Hypoxis extracts, using TLC.  Phytosterols can 
be separated by using silver ion chromatography (silver impregnated TLC or HPLC), 
which will separate phytosterols based on their total number of carbon-carbon double 
bonds (Moreau et al., 2002).  Sterol separation can also be improved by two-dimensional 
TLC, which uses multiple solvents for development.  Sterol content (as seen from the 
intensity of the spots) was the greatest for the H. sobolifera extract followed by the H. 
hemerocallidea extract.   
 
Sterols 
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The mobile phase used for sterolin identification consisted of CH3CN: ethyl acetate: 
formic acid (5:4:1, v/v/v).  The sterolins in the Hypoxis extracts could not be identified or 
quantified due to the unavailability of sterolin standards (Figure 3.4).  Sterolins present in 
the chloroform extracts of Hypoxis were compared to those found in a MODUCARE
®
 
tablet. 
 
 
                                        1             2             3             4            5             6 
 
Figure 3.4: TLC plate of the sterolins found in Hypoxis spp. chloroform extracts. (1) 
MODUCARE
®, (2) β-sitosterol, (3) stigmasterol, (4) H. hemerocallidea, (5) H. sobolifera and 
(6) H. stellipilis.  Red arrows represent most probably β-sitosterol glycoside, which is the 
main sterolin found in MODUCARE
®
. 
 
From the results obtained, different sterolins (based on Rf values) were detected and 
differences in sterolin composition could clearly be seen between the three Hypoxis spp. 
(Figure 3.4, lanes 4 - 6).  Sterolin content (as seen from the intensity of the spots) was the 
greatest for the H. sobolifera extract followed by the H. hemerocallidea extract.  
Extraction of sterols with polar (water, EtOH, MeOH, acetone) and nonpolar (CH3CN, 
dichloromethane) solvents yielded more sterolins and sterols, respectively (Appendix 3).   
 
Similar phytosterol structures, differing only in the number and position of the double 
bond(s), and number of carbons in the side chain, make separation very difficult.  Only a 
few purified phytosterols are commercially available at a very high price (Zhang et al., 
2005).  Unavailability of all phytosterols and their analogues (e.g. sterolins) make 
identification and quantification almost impossible.   
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3.3.3.2.  HPLC analysis of hypoxoside and (phyto)sterols  
 
HPLC-DAD is becoming the method of choice for screening drugs, vitamins, natural 
products and identification of active compounds in plants (Springfield et al., 2005). 
 
Hypoxoside.  The presence of hypoxoside has been identified in several South African 
Hypoxis spp. (Nicoletti et al., 1992; Chapter 1, Table 1.1) including H. hemerocallidea 
(Drewes et al., 1984; Drewes et al., 1989; Kruger et al., 1994; Nair and Kanfer, 2006), 
but not in H. stellipilis or H. sobolifera.  The HPLC method described by Nair and 
Kanfer (2006) was used to quantify hypoxoside content in the chloroform extracts of 
three Hypoxis spp.  (Figure 3.5). 
 
Figure 3.5: HPLC chromatogram overlays of the hypoxoside content of Hypoxis chloroform 
extracts.  The Nucleosil C18 column, a mobile phase of CH3CN: H2O (20:80; v/v) and a flow 
rate of 1 mL/min were used for hypoxoside separation.  Retention times (min) of 
unidentified compounds were (A) 5.3; (B) 6.3; (C) 7.5; (D) 10.3; (E) 13.55; (F) 14.1.  
Hypoxoside standard eluted at Rt of 12.5 min.  One representative of three experiments 
performed.  Stock solutions of H. hemerocallidea, and H. stellipilis and H. sobolifera were 5 
and 10 mg/mL, respectively. 
 
Hypoxoside was detected after 12.5 min and quantified from a standard curve (Appendix 
3) of hypoxoside concentration (ranging between 5 - 100 μg/mL) as a function of peak 
area (R
2
 = 0.9971, Rt = 12.5 min).  Hypoxoside content of the three Hypoxis spp. is 
summarized in Table 3.3.  Of the three Hypoxis species tested for hypoxoside content, 
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only H. hemerocallidea and H. stellipilis contained hypoxoside.    H. sobolifera, which 
showed the highest anticancer activity (Chapter 4, section 4.3), had undetectable levels of 
hypoxoside.  
 
HPLC chromatograms were overlaid to allow for more direct analysis of similar and 
different compounds found in the three Hypoxis spp. (Figure 3.5).  The compound 
representing peak A (5.3 min) was found in H. hemerocallidea and H. sobolifera, 
whereas compounds representing peaks B (6.3 min) and C (7.5 min) were only found in 
H. hemerocallidea and H. sobolifera, respectively.  Peaks A, B and C may represent 
novel or previously identified glycosides.  Glycosides differ from species to species 
(Chapter 1, Table 1.1).  
 
Since chloroform, the solvent used in this study, is not the best solvent for hypoxoside 
extraction, the presence of this glycoside in H. sobolifera was investigated using more 
polar solvents.  A water extract of H. sobolifera has shown no hypoxoside content (data 
not shown), whereas EtOH, MeOH and acetone extracts of H. sobolifera yielded 2.05, 
2.06 and 2.04 µg/mg of extract respectively (Appendix 3).  Previous studies have used 
EtOH (Drewes et al., 1984; Drewes et al., 1989; Pegel, 1979) and MeOH (Kruger et al., 
1994; Nair and Kanfer, 2006) to extract hypoxoside from H. hemerocallidea.  Traditional 
healers and herbalists use water and boiling to prepare Hypoxis extracts, which may yield 
more hypoxoside and sterolins (Pegel, 1976).  Due to the polar nature of hypoxoside it 
would be better to use more polar solvents for extractions in future, if more emphasis is 
placed on the effect of hypoxoside in the Hypoxis extracts.  Two analogues of hypoxoside 
have been identified by Kruger et al. (1994), namely dehydroxyhypoxoside (one -OH 
group) and bis-dehydroxyhypoxoside (no -OH groups).  Dehydroxyhypoxoside and bis-
dehydroxyhypoxoside eluted after hypoxoside (two -OH groups), because a decrease in -
OH groups is associated with an increase in retention times (in RP-HPLC).  Shifts for 
rooperol and its analogues were greater when glucose moieties were removed (Kruger et 
al., 1994).  Peaks E and F may represent one or both of hypoxoside‟s analogues. 
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(Phyto)sterols.  TLC was used for the qualitative analysis of sterols but due to its poor 
resolution properties HPLC and GC were used for sterol quantification.  HPLC operates 
under non-destructive detection conditions and is suitable for the analysis of thermally 
unstable sterols.  A mobile phase of CH3CN: MeOH (90:10, v/v) at a flow rate of 0.5 
mL/min, using the Nucleosil C18 column, separated a sterol mixture (consisting of 100 
μg/mL each of β-sitosterol, desmosterol, stigmasterol and stigmastenol) (Figure 3.6).  
 
   
 
Figure 3.6:  HPLC chromatogram of the separation of a sterol mixture.  The Nucleosil C18 
column, a mobile phase of CH3CN: MeOH (90:10; v/v) and a flow rate of 0.5 mL/min were 
used for sterol separation.  Retention times (min) of DESMO, STIG, STN and BSS were 9.0, 
10.0, 10.6 and 11.1, respectively.  Abbreviations: DESMO = desmosterol, STIG = 
stigmasterol, STN = stigmastenol, BSS = β-sitosterol 
 
(Phyto)sterols in the chloroform extracts of the Hypoxis spp., could not be identified and 
quantified.  Overlaid HPLC chromatograms of the sterol mixture and H. sobolifera 
chloroform extract are shown in Figure 3.7.  Overlays of H. hemerocallidea and H. 
stellipilis are shown in Appendix 3. 
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Figure 3.7:  HPLC chromatogram overlays of the separation of a sterol mixture and H. 
sobolifera.  The Nucleosil C18 column, a mobile phase of CH3CN: MeOH (90:10; v/v) and a 
flow rate of 0.5 mL/min were used for sterol separation.  Stock solution of H. sobolifera was 
10 mg/mL.  Abbreviations: DESMO = desmosterol, STIG = stigmasterol, STN = 
stigmastenol, BSS = β-sitosterol 
 
Sterol standards were dissolved in MeOH, hence separation of the standard mixture, 
whereas Hypoxis chloroform extracts were redissolved in MeOH.  Poor solubilization of 
the chloroform extract in MeOH and separation at room temperature may have 
contributed to poor sterol separation. 
   
3.3.3.3.  GC analysis of (phyto)sterols 
 
GC is the technique of choice to analyze the presence of sterols in food (Contarini et al., 
2002; Cunha et al., 2006; Goudjil et al., 2003; Lagarda et al., 2006; Toivo et al., 2000) 
due to shorter analysis times, less peak interference, improved resolution, greater 
detection sensitivity (low nanogram range) and thermal stability of the capillary columns 
(Abidi, 2001).  Although the Hypoxis chloroform extracts were also redissolved in MeOH 
(as was the case for HPLC), sterol separation with GC did occur due to separation at very 
high temperature (300 ºC) compared to separation at room temperature with HPLC.  The 
SAC-5
TM
 capillary column, consisting of 95% dimethylpolysiloxane and 5% phenyl, is 
specially packed for the analysis of plant and animal sterols.  The sterol mixture (100 
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μg/mL of each sterol), consisting of β-sitosterol (30.6 min), campesterol (29.3 min), 
cholesterol (27.8 min), desmosterol/ergosterol (28.9 min), fucosterol (28.3 min), 
stigmasterol (29.7 min) and stigmastenol (30.9 min) was well separated, except for 
desmosterol and ergosterol, which eluted at the same retention time, with good resolution 
on the SAC-5
TM
 column within a period of 32 min (Figure 3.8).  
 
From GC analysis, it was clear that β-sitosterol was the main phytosterol found in the 
chloroform extracts of H. hemerocallidea, H. stellipilis and H. sobolifera.  Trace amounts 
(<2 μg/mg of Hypoxis extract) of campesterol and stigmastenol were found in all three 
Hypoxis spp. extracts, whereas trace amounts of desmosterol/ergosterol and stigmasterol 
were found in certain Hypoxis spp. only.  A standard curve (Appendix 3) of β-sitosterol 
concentration (ranging between 10 - 100 μg/mL) as a function of peak height (R2 = 
0.9531, Rt = 30.6 min) was used to quantify β-sitosterol content.  H. sobolifera contained 
the most β-sitosterol with ±2.5 and 7.5 times more β-sitosterol compared to H. 
hemerocallidea and H. stellipilis, respectively (Table 3.3).  
 
The presence of β-sitosterol and campesterol as the two major phytosterols in Hypoxis 
correspond to published data (Moghadasian, 2000; Pegel, 1976).  According to a 
minireview by Moghadasian (2000), 95% of dietary phytosterols consist of sitosterol and 
campesterol (approximately 65 and 30%, respectively), whereas the other phytosterols 
(mainly stigmasterol) and stanols make up the other 5%.  This was the first time that GC 
was used to identify and quantify the presence of sterols in Hypoxis extracts.  Nair et al. 
(2006) have used HPLC to determine the presence of β-sitosterol, stigmasterol and 
stigmastenol in commercially available oral dosage forms reported to contain material or 
extracts of Hypoxis.  Using the SAC-5
TM
 capillary column in the present study eliminated 
time-consuming preparation steps, for example extraction of lipid fraction from sample 
material, saponification (alkaline hydrolysis), extraction of nonsaponifiables and 
derivatization of the sterol standards and Hypoxis extracts (Toivo et al., 2000). 
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Figure 3.8:  GC chromatograms of a sterol standard mixture and Hypoxis chloroform 
extracts. The SAC
TM
-5 capillary column, temperature gradient and helium at a flow rate of 
1 mL/min were used for sterol separation.  One representative of three experiments 
performed.  Abbreviations:  CHOL = cholesterol, FUCO = fucosterol, DESMO/ERGO = 
desmosterol/ergosterol, CAMP = campesterol, STIG = stigmasterol, BSS = β-sitosterol, STN 
= stigmastenol  
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Retention times of sterols depend on the ring double bond(s), alkyl substituents and side-
chain double bond(s).  Saturation of phytosterols (i.e. phytostanols) causes an increase in 
the analyte‟s retention time (e.g. stigmastenol elutes after stigmasterol).  Sterols with a 
double bond at the C-7 position have longer retention times than those at the C-5 position 
(e.g. stigmasterol elutes before stigmastenol).  Additional methyl or ethyl groups 
influence the sterol‟s hydrophobicity, thus increasing the retention time [e.g. campesterol 
(methyl) elutes before sitosterol (ethyl)].  The structure-retention relationship also 
depends on molecular mass and polarity.  Campesterol is less polar than the highly 
unsaturated ergosterol and will elute after ergosterol.  Cholesterol with one double bond 
and without a 24-ethyl group will elute after polar ergosterol, but before stigmasterol (24-
ethyl group and 22-double bond) (Abidi, 2001).   
 
Table 3.3:  Summary of the (phyto)sterol and hypoxoside content of H. hemerocallidea, H. 
stellipilis and H. sobolifera chloroform extracts. 
 
Compound Content (μg/mg) 
H. hemerocallidea H. stellipilis H. sobolifera 
Hypoxoside 2.45 ± 0.05 1.59 ± 0.04 ND
*
 
β-sitosterol 5.88 2.01 14.94 
Campesterol Trace
**
 Trace Trace 
Cholesterol ND ND ND 
Desmosterol/ 
Ergosterol 
ND ND Trace 
Fucosterol ND ND ND 
Stigmasterol Trace ND Trace 
Stigmastenol Trace Trace Trace 
*  ND = not detected 
** Trace amounts (< 2 μg/mL) 
 
3.4.  Conclusion 
 
This was the first time that hypoxoside and phytosterol contents were quantified in H. 
stellipilis and H. sobolifera.  Both the hypoxoside and phytosterol contents were shown 
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to vary between the three Hypoxis spp.  The H. sobolifera chloroform extract contained 
the highest content of β-sitosterol, followed by H. hemerocallidea and H. stellipilis.  The 
H. hemerocallidea chloroform extract contained the highest content of hypoxoside 
followed by H. stellipilis, whereas hypoxoside was absent in the H. sobolifera chloroform 
extract.  Kruger et al. (1994) have also shown a difference in the content of hypoxoside, 
dehydroxyhypoxoside and bis-dehydroxyhypoxoside found in the MeOH extracts of H. 
hemerocallidea and H. latifolia.  The presence of unidentified compounds (Figures 3.5 
and 3.8) in the Hypoxis chloroform extracts needs further investigation.  The presence of 
hypoxoside, β-sitosterol, trace amounts of phytosterol(in)s and unidentified compounds 
in Hypoxis spp. may have synergistic and/or additive effects on biological activities. This 
may explain the different in vitro biological activities seen in the next few chapters. 
 
Hypoxis extraction with more polar solvents will yield greater quantities of hypoxoside.  
It was the first time that phytosterols were identified and quantified (β-sitosterol) in 
Hypoxis spp. using a GC method.  The presence of β-sitosterol as the major phytosterol in 
Hypoxis spp. was confirmed.  The other phytosterols identified were present in trace 
amounts, which did not allow for quantification. 
 
Further investigation is required to determine the implications of these findings in the 
uses of Hypoxis as a traditional remedy.  Consumption of the three different Hypoxis 
spp., which have different sterol(in)s and hypoxoside content, may have adverse or 
favorable effects.   
 
Peer-reviewed journal article published from this chapter 
 
Boukes, G.J., van de Venter, M., Oosthuizen, V. 2008. Quantitative and qualitative 
analysis of sterols/sterolins and hypoxoside contents of three Hypoxis (African potato) 
spp. Afr. J. Biotechnol. 7 (11): 1624-1629. 
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CHAPTER 4 
IN VITRO ANTICANCER ACTIVITY AND MECHANISM(S) OF ACTION OF 
THREE HYPOXIS SPP. 
 
4.1.  General Background 
 
4.1.1.  Cancer definition 
 
Cell homeostasis requires a balance between cell proliferation and programmed cell death 
(Simstein et al., 2003).  Cancer is characterized by a succession of genetic mutations, 
each contributing to one or different types of growth advantages (Fadeel and Orrenius, 
2005).  Genetic changes of the apoptotic machinery cause unregulated proliferation of 
cells, which preserve genetic mutations and give rise to tumourigenesis (Collins et al., 
1997; Simstein et al., 2003; Srivastava et al., 2005).  
 
Two classes of cancer genes are found, namely oncogenes and tumour suppressor genes.  
Oncogenes are associated with a dominant gain-of-function.  Mutant forms of normal cell 
protooncogenes are involved in signalling pathways in cell proliferation.  Suppressor 
genes are associated with a recessive loss-of-function.  In normal cells, tumour 
suppressor genes encode for proteins that negatively regulate cell cycle progression e.g. 
pRb and p53.  Mutations play a major role in spontaneous and hereditary cancers (Collins 
et al., 1997; Hanahan and Weinberg, 2000). 
 
Cancer cells have the following characteristics:  
 
 Evade apoptosis by altering the components of the apoptotic machinery.  
 Self-sufficient in providing growth signals to proliferate.  
 Insensitive to anti-growth signals to be able to continuously divide and survive.  
 Sustained angiogenesis – growth of blood vessel formation – for constant supply 
of oxygen and nutrients.  
 Immortality by multiplying without limit. 
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 Tissue invasion and metastasis – cancer cells escape the primary tumour mass and 
colonize a new area where nutrients and space are abundant. Metastasis is 
responsible for 90% of human cancer death (Hanahan and Weinberg, 2000). 
 
Carcinogenesis is a multistage process where normal cells are transformed into cancerous 
cells, involving initiation [reaction between carcinogen and deoxyribonucleic acid (DNA) 
of cell resulting in DNA damage], promotion (increased cell proliferation) and 
progression (additional genetic mutations and spread of cancer) (Balunas and Kinghorn, 
2005; Reddy et al., 2003). 
 
4.1.2.  World and South African cancer statistics 
 
Cancer is amongst the three most common causes of death in developed countries, with 
an increase seen in developing countries (Houghton et al., 2007).  
 
The 2000-2001 National Cancer Registry (NCR), containing South African cancer 
statistics, has shown that males and females have a lifetime risk of 1 in 6 and 1 in 8 
chance of getting cancer, respectively.  The five leading cancers in males were prostate (1 
in 23), lung (1 in 69), oesophageal (1 in 82), colorectal (1 in 97) and bladder (1 in 108).  
The five leading cancers in females were breast (1 in 29), cervix (1 in 35), uterus (1 in 
144), colorectal (1 in 162) and oesophageal (1 in 196).  The most common cancer, not 
necessary resulting in death, in South Africa is skin cancer (basal/squamous cell 
carcinomas and malignant melanoma) with 20 000 reported new cases and 700 deaths 
(mainly malignant melanoma) each year (www.cansa.org.za).         
 
It is estimated that over 10 million cancer cases (excluding non-melanoma skin) and 6 
million deaths worldwide occurred in 2000.  This represents a 22% increase in cancer 
incidence and mortatility rate since 1990.  Cancer is the second leading cause of death 
after cardiovascular diseases in the US (Balunas and Kinghorn, 2005, Srivastava et al., 
2005).  According to 2005 statistics released by the World Health Organization (WHO), 
7.6 million (13.6%) of a total of 58 million deaths worldwide were due to cancer.  The 
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leading cancer types resulting in overall mortality include lung-, stomach-, liver-, colon- 
and breast cancer.  In South Africa, approximately 41 000 deaths were due to cancer in 
2005.  More than 70% of the deaths occurred in low to middle-income countries, where 
resources for cancer diagnosis, treatment and prevention are limited or non-existent.  It is 
estimated that the annual cancer death rate will rise to 12 million deaths in 2030.  It is 
estimated that 84 million people will die in the next decade (2006-2016) if action is not 
taken against cancer.  The most frequent cancer deaths in men globally are lung, stomach, 
liver, colorectal, oesophagus and prostate, and in women are breast, lung, stomach, 
colorectal and cervical (www.who.int).      
 
Three main factors contribituing to cancer are incorrect diet (section 4.1.4.), genetic 
predisposition and, physical- (UV or ionizing radiation), chemical- (asbestos, tobacco 
smoke, aflatoxin and arsenic) and biological [viruses (e.g. hepatitis B virus (HBV), 
human papiloma virus (HPV) and HIV); bacteria (e.g. Helicobacter pylori), parasites 
(e.g. schistosomiasis)] carcinogens (Reddy et al., 2003; WHO).  Cancer risk factors in 
low to middle income countries include tobacco and alcohol use, low fruit and vegatable 
consumption and chronic infections [HBV, hepatitis C virus (HCV) and HPV].  In high 
income countries risk factors include tobacco and alcohol use, and obesity.  Avoiding 
these risk factors can prevent more than 40% of cancers (www.who.int).     
 
4.1.3.  Treatments available 
 
The type of cancer treatment depends on the cancer type, the site, tumour size, metastasis 
and how it is affecting normal body functions.  Most common treatments available 
include: 
 
 Surgery – physical removal of cancerous growth or tissue. 
 Radiotherapy – stream of high energy particles (neutrons or protons) or 
radioactive source, which damage or destroy cancer cells. 
 Cytotoxic chemotherapy – administration of natural or synthetic compounds, 
which directly target cancer cells.  
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 Hormonal manipulation – influencing cell growth by altering the production or 
activity of cells. 
 Biological therapy (syn. immunotherapy, biotherapy or biological response 
modifier therapy) – boosts body‟s natural defense or immune system against 
cancer. 
 Combinational therapy (Houhton et al., 2007; www.cansa.org.za; www.who.int). 
 
Advanced treatments may have a 5-year survival rate of 75% or more for certain cancers 
e.g. breast, testis, melanoma and uterine corpus, whereas survival rates are less than 15% 
for pancreas-, lung-, liver- and stomach cancer (WHO).  
 
Like any other anticancer agents, plant-based agents lack specificity to kill cancer cells 
and drug resistance occur with time.  Combination therapy is used to combat resistance, 
but is only temporary (Srivastava et al., 2005). 
 
4.1.4.  Cancer and diet 
 
The importance of a healthy diet to combat disease has been recognized for centuries. 
Hipprocrates (480 BC) described the relationship between a diet and health as follows: 
 
“Positive health requires a knowledge of man‟s primary constitution (genetics) and the 
powers of various foods, both those natural to them and those resulting from human skill 
(diet).” 
   
It is estimated that nutritional factors contribute to 20-60% of cancer worldwide and a 
third of cancer in Western countries (McCullough and Giovannucci, 2004).  Cancer 
incidence and mortalilty rates vary dramatically across the globe.  Cancer rates among 
populations migrating from low (e.g. Japanese or Chinese) to high (e.g. US) incidence 
countries change significantly, reaching the same cancer rates within 3 generations.  For 
example the risk of colon cancer, which may be associated with high fat diets, changes 
within a few decades of migration, and that of breast cancer changes within the second 
generation.  Thus environmental and lifestyle rather than genetic factors, which are 
unlikely to occur within a few decades, play a role in cancer development and rates 
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(Persky and van Horn, 1995; Willett, 2001).  Factors contributing to cancer development 
include excessive energy intake (associated with rapid growth in children and obesity in 
adults), physical inactivity, high alcohol consumption, smoking, food preparation 
(pickling, salting and smoking of foods; high temperature cooking) and high 
polyunsaturated and animal or saturated fat intake.  Many of these factors are also 
associated with diabetes and cardiovascular diseases.  Changing the diet by consuming 
more fruit, vegetables, dietary fiber, monounsaturated fats (e.g. olive oil); less red meat 
and animal fat; moderate alcohol consumption; minimizing consumption of salt-cured, 
pickled and smoked foods; increasing physical activity; and taking supplements or 
micronutrients (selenium, folic acid, vitamins C/D/E, β-carotene, calcium) may decrease 
the high incidence of cancer.  Protective effects of fruits and vegetables are controversial 
and contradictable due to conflicting research studies.  Phytochemicals – carotenoids, 
organosulfur (e.g. allicin in garlic), phenolic/polyphenols (e.g. isoflavones in soybeans, 
catechins in tea, phenolic esters in coffee, phenolic acid in red wine, quercetin in onions), 
vitamins C and E, phytoestrogens, lignans, isothiocyanates, terpenes, glucosinolates and 
fiber – are possible anticancer and chemopreventive constituents (Willett, 2000; 
Greenwald et al. 2001; Riboli and Norat, 2003; Reddy et al., 2003; McCullough and 
Giovannucci, 2004).   
 
A Mediterranean diet – consisting of high monounsaturated: saturated dietary fat ratio; 
moderate alcohol consumption; high consumption of legumes, fruit, vegetable and 
cereals; low consumption of meat and meat products; moderate consumption of milk and 
dairy products – has shown a decrease in cancer incidence rates when compared to diets 
in Scandinavian countries, the UK and the US (Trichopoulou et al., 2000).  Cancers 
related to high fat diets (e.g. breast cancer) is higher in the US than Japan.  Low breast, 
prostate and colon cancer incidence in the Japanese and Chinese population is associated 
with low fat diets and high soyfood (genistein) intake (Persky and van Horn, 1995). 
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4.1.5.  Cancer and plants (natural products) 
 
Plants have played a pivotal role in the development of effective anticancer agents.  More 
than 60% of the currently used anticancer agents are derived from natural sources, 
including plants, marine organisms and microorganisms (Cragg and Newman, 2005). 
Table 4.1 summarizes the plant derived antitumour agents in clinical use and -
development stages.  
 
Table 4.1:  Summary of the plant-derived antitumour agents in clinical use and -
development stages (Balunas and Kinghorn, 2005; Cragg and Newman, 2005; Srivastava et 
al., 2005). 
 
 
Plant-derived antitumour agents 
 
Clinical use 
 
Vinca alkaloids i.e. vinblastine and vincristine (vinorelbine, 
vindesine); camptothecin (topotecan, irinotecan); taxanes i.e. 
paclitaxel/taxol
®
 (docetaxel); podophyllotoxin (etoposide, 
teniposide); elepticine (elliptinium); homoharringtonine.  
 
Clinical development Olomucine (roscovitine), combretastatins (combretastatin A4 
phosphate), rohitukine (flavopiridol).  
 
Preclinical development Bruceantin, pervilleine A, betulin (betulinic acid), naphthaquinones 
(β-lapachone), triterpenoid acids i.e. oleanolic and ursolic acids 
(CDDO), thapsigargin, indirubins (3´-monooxime and 5-
bromoindirubin derivatives), maytansine.   
() = derivatives/analogs 
 
4.1.6.  Apoptosis versus necrosis 
 
Apoptosis and cell proliferation play important roles in maintaining homeostasis in 
various cell populations.  During normal physiology, approximately 10 billion cells are 
made in the human body each day to balance cells that die during apoptosis.  These 
numbers increase significantly during aging or disease when apoptosis increases.  
Apoptosis is important during various developmental processes, removal of pathogen-
invaded cells, embryogenesis, removal of autoreactive T cells and low responsive B cells, 
immune responses, and wound healing.  Insufficient, excessive or unregulated apoptosis 
leads to diseases such as cancer, AIDS, ischaemia, neurodegenerative diseases 
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(Parkinson-, Alzheimer-, Huntington‟s disease), amyotrophic lateral sclerosis (ALS), 
autoimmune lymphoproliferative syndrome and autoimmune diseases (Elmore, 2007; van 
Engeland et al., 1996). 
 
Necrosis occurs during pathological processes mediated by viruses, bacteria and 
protozoa.  It is associated with the secretion of cytokines (resulting in inflammation and 
infection), nitric oxide (NO) and reactive oxygen species (ROS) production, and 
physiological processes (tissue renewal, embryogenesis and immune response).  In the 
presence of excess ROS and NO, apoptosis can be switched to necrosis (Proskuryakov et 
al., 2003). 
 
Apoptosis and necrosis can occur simultaneously, independently and sequentially. 
Morphological and biochemical features of both apoptosis and necrosis may be present in 
the same cell.  Induction of apoptosis or necrosis may be determined by signal type and 
degree.  Table 4.2 summarizes the morphological features of apoptosis and necrosis.  
Many biochemical features (caspase activation and oligonucleosomal DNA 
fragmentation), associated with apoptosis, are usually absent in necrosis (Proskuryakov et 
al., 2003).  The focus of this study was on apoptosis and only the biochemical features of 
apoptosis are summarized in section 4.1.6.1.  Apoptosis activation is triggered by various 
stimuli e.g. growth factor withdrawal, chemotherapeutic drugs, crosslinking of death 
signal transmitting signals, and others (Murphy et al., 2000). 
 
Table 4.2:  Comparison of the morphological features occurring during apoptosis and 
necrosis (Elmore, 2007; Fadeel and Orrenius, 2005; Gorczyca, 1999; Kroemer et al., 2009; 
Proskuryakov et al., 2003).  
 
Apoptosis Necrosis 
Energy dependent  
Controlled process 
Energy independent  
Uncontrolled and passive process 
Effect single cells/small clusters of cells Effect field of cells 
Intact plasma membrane and „blebbing‟ Disrupted plasma membrane/loss in 
integrity/leaky  
Cell shrinkage (round cells, dense 
cytoplasm, tightly packed organelles, 
Cell and organelle (mitochondria) swelling 
(oncosis)  
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chromatin condensation) 
 
Cytoplasm retained in apoptotic bodies Cytoplasm released 
Pyknosis*, karyorrhexis** 
 
Minor modifications of cytoplasmic 
organelles 
 
Karyolysis***, pyknosis, karyorrhexis 
 
 
Cytoplasmic vacuolization, nuclear 
swelling, rupture of plasma and nuclear 
membranes 
Apoptotic body† formation/phagocytosis 
 
No inflammation 
Cell contents released into surrounding 
environment 
 
Inflammation 
  
  
* nuclear and cytoplasmic volume reduction 
** nuclear fragmentation 
***
 
DNA dissolution 
† membrane-enclosed particles containing organelles and nuclear fragments  
 
4.1.6.1.  Biochemical features of apoptosis 
 
Biochemical features of apoptosis include caspase activation (section 4.2.5), 
phosphatidylserine (PS) translocation and externalization in membranes (section 4.2.6), 
oligonucleosomal DNA fragmentation (section 4.2.7), reduction or loss in mitochondrial 
membrane potential  (ΔΨm), activation of pro-apoptotic Bcl-2 family proteins, 
intracellular acidification, ROS production, selective proteolysis or cleavage of subset of 
cellular proteins and ssDNA accumulation (Cryns and Yuan, 1999; Kroemer et al., 2009).  
 
Apoptosis is divided into the extrinsic (receptor-mediated), intrinsic (mitochondrial), 
execution and perforin/granzyme pathways. Figure 4.1 summarizes the key events of 
apoptosis. 
   
Extrinsic (receptor-mediated) pathway.  Death receptors are members of the tumour 
necrosis factor (TNF) receptor gene superfamily and have cysteine-rich extracellular 
domains and cytoplasmic domains (~80 amino acids) known as death domains (DDs).  
DDs transmit death signals from the cell‟s surface to intracellular signalling pathways.  
Examples of ligands and their corresponding death receptors are FasL/CD95/Apo1-FasR, 
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TNF-α-TNFR1, Apo3L-DR3, Apo2L-DR4 and Apo2L-DR2.  One or more cytoplasmic 
DD-containing adapter proteins (e.g. FADD/ MORT1 and TRADD for FasL/FasR and 
TNF-α/TNFR1, respectively) are recruited and bind receptors, via corresponding DDs, 
upon ligand-receptor binding.  FADD associates with procaspase-8 via dimerization of 
death effector domains (DEDs) and form a death-inducing signalling complex (DISC), 
which autocatalytically activates procaspase-8.  Caspase-8 activates the execution 
pathway and/or cleaves cytosolic Bid (Figure 4.1).  Bid translocates from the cytosol to 
the mitochondria and incorporates into the mitochondrial membrane, where it plays a role 
in the intrinsic pathway.  Mitochondria can act as an amplifier in CD95-induced 
apoptosis when the mitochondrial pathway is activated via Bid cleavage by caspase-8 
(Cryns and Yuan, 1999; Elmore 2007; Fadeel and Orrenius, 2005; Nagata, 2000; 
Simstein et al., 2003; Sun et al., 1999).  Viral proteins (containing two DEDs) may 
inhibit death receptor binding by competing with procaspase-8 or -10 for binding to DED 
of FADD/MORT1.  FLIP (also known as Casper/I-FLICE/FLAME-1/CASH/CLARP/ 
MRIT) is expressed in mammalians and contains two DEDs resembling viral proteins.  
FLIP resembles caspase-8 and -10 in structure, but is devoid of protease activity.  FLIP 
binds FADD/MORT1 and caspase-8 or -10 (Cryns and Yuan, 1999). 
 
 
Figure 4.1:  Schematic representation of the biochemical events associated with the four 
pathways involved in apoptosis (Elmore, 2007).  See text for more detail. 
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Intrinsic (mitochondrial) pathway.   Negative (absence of certain growth factors, 
hormones and cytokines) and positive stimuli (e.g. radiation, toxins, hypoxia, 
hypothermia, viral infections and free radicals) directly act on targets in the cell, causing 
internal cell damage and initiate mitochondrial events.  Stimuli target the inner 
mitochondrial membrane leading to a loss in mitochondrial transmembrane potential 
(ΔΨm; depolarization), which may be mediated by opening of mitochondrial 
permeability transition pores (PTP).  Mitochondria may also swell resulting in outer 
membrane rupturing (without loss in mitochondrial membrane potential).  Pro-apoptotic 
proteins (cytochrome c, Smac, Omi and procaspase-9) are released from the 
mitochondrial intermembrane space into the cytosol prior to depolarization.  Cytochrome 
c binds and activates the adapter molecule, apoptosis proteinase activating factor (Apaf)-
1, and in the presence of ATP/dATP binds procaspase-9 to form the apoptosome (Figure 
4.1).  The apoptosome is regarded as the counterpart of DISC formed in receptor-
mediated apoptosis and forms the central part of the mitochondrial pathway.  Procaspase-
9 undergoes autoactivation to yield active caspase-9, which activates the execution 
pathway.  Activated caspase-9 can be translocated to the nucleus and may participate in 
nuclear fragmentation.  Inhibitor of apoptosis proteins (IAPs) inhibits apoptotis by 
preventing active caspases binding to their substrates.  Smac (second mitochondrial 
activator of caspases) and Omi inhibit IAP activity, which promotes apoptosis (Blanc et 
al., 2000; Cryns and Yuang, 1999; Del Bello et al., 2004; Elmore, 2007; Fadeel and 
Orrenius, 2005; Mooney et al., 2002; Simstein et al., 2003; Sun et al., 1999; Wolf, 1999).  
 
The Bcl-2 family is regulated by the tumour suppressor protein, pRb, and consists of pro-
apoptotic (e.g. Bax, Bak, Bok, Bid, Bad, Bik, Bim, Bcl-XS, Krk, Mtd, Nip3, Noxa and 
Bcl-B) and anti-apoptotic (e.g. Bcl-2, Bcl-XL, Mcl-1, Bfl-1/Al, Bcl-W and Bcl-G) 
proteins, which regulate mitochondrial events.  Anti-apoptotic proteins are integral 
membrane proteins of the mitochondria, endoplasmic reticulum and nuclear envelope, 
whereas pro-apoptotic proteins are mainly found in the cytosol and get integrated into the 
mitochondrial membrane when activated.  Bcl-2 family members form homo- and 
heterodimers, which play an important role in cytochrome c release by influencing 
mitochondrial membrane permeability during apoptosis.  Cytochrome c release is 
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blocked by Bcl-2/Bcl-XL or promoted by Bax/Bak.  The latter may be involved in 
formation of membrane pores to release cytochrome c.  Bid is more potent in inducing 
cytochrome c release than Bax (Cryns and Yuang, 1999; Elmore, 2007; Fadeel and 
Orrenius, 2005; Hanahan and Weinberg, 2000; Mooney et al., 2002; Simstein et al., 
2003; Sun et al., 1999).  Bcl-2 inhibits Bax ability to form lipid channels.  Bcl-XL binds 
cytochrome c and secludes it in the mitochondria, thus preventing osmotic swelling of 
mitochondria and outer membrane disruption induced by stimuli, which may lead to 
cytochrome c efflux into the cytosol.  Depolarization cannot be inhibited by Bcl-2.  
Apoptotic and necrotic stimuli induce mitochondrial swelling and rupturing of the outer 
membrane releasing cytochrome c.   Overexpression of procaspase-9 blocks Apaf-1 
ability to activate caspase-3.  Bcl-2 proteins can also act directly on the caspase cascade 
e.g. Bcl-XL binds and inactivates Apaf-1, which may interfere with Apaf-1‟s ability to 
activate procaspase-9.  This may explain Bcl-2/Bcl-XL inhibition of caspase activation 
downstream of cytochrome c release.  Apaf is selective and does not interact with 
procaspase-1, -2, -3 or -8   (Cryns and Yuan, 1999; Simstein et al., 2003). 
 
Execution pathway.  The execution pathway is the converging point of the intrinsic and 
extrinsic pathways, where execution caspases (caspase-3, -6 and -7) are activated.  The 
execution caspases cleave several substrates, which play an important role in the 
morphological (Table 4.2) and biochemical features of apoptosis.  Caspase-3 is the most 
important executor caspase, which is activated by all initiator caspases (Elmore 2007).  
Caspase-3 can activate the mitochondrial pathway by directly cleaving procaspase-9.  
Procaspase-3 is also recruited to the caspase-9/Apaf-1 complex, where it undergoes 
proteolysis and gets activated (Blanc et al., 2000; Del Bello et al., 2004).            
 
Granzyme/perforin pathway.  T-cell mediated cytotoxicity is associated with the CD8
+
 
killing of antigen-bearing cells. Cytotoxic T lymphocytes (CTLs) and NK cells target 
cells via the extrinsic pathway or perforin/granzyme pathway.  The latter pathway 
involves secretion of a transmembrane pore-forming molecule, perforin, and the release 
of granules through the pore, into the target cell‟s cytoplasm.  Cytoplasmic granules 
contain granzyme A and B, which are serine proteases.   Granzyme A activates a caspase-
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independent cell death pathway via ssDNA damage, whereas granzyme B (i) cleaves 
proteins at Asp residues e.g. procaspase-10 and inhibitor of caspase-activated DNase 
(ICAD), (ii) uses the mitochondrial pathway to amplify the death signal by cleaving Bid, 
involved in cytochrome c release, and (iii) directly cleaves and activates procaspase-3 
(Figure 4.1) (Elmore, 2007; Fadeel and Orrenius, 2005).  This type of pathway occurs 
upon viral defence and immune surveillance against cancer or homeostasis (Fadeel and 
Orrenius, 2005).   
 
4.2. Anticancer mechanism(s) of action of Hypoxis spp. 
 
Albrecht et al. (1995a) investigated the anticancer properties of hypoxoside (converted to 
rooperol), isolated mainly from H. hemerocallidea.  No literature could be found on the 
anticancer mechanism(s) of action of this plant, hence the following sections focus on the 
anticancer activity and mechanism(s) of action of three Hypoxis chloroform extracts and 
its purified compounds against Hela (cervical), HT-29 (colorectal) and MCF-7 cancer cell 
lines.  Breast and cervical cancer are the two leading cancers in females, whereas 
colorectal cancer is one of the five leading cancers in both male and female in South 
Africa.  Hence the use of these three cancer cell lines to conduct the studies.   
 
4.2.1.  β-glucosidase Activity 
 
4.2.1.1.  Background 
 
Chemotherapy lacks selectivity for cancer cells, which may result in adverse side effects 
(e.g. killing normal cells).  Selectivity and efficacy of chemotherapeutic drugs may be 
enhanced by the conversion of non-toxic prodrugs to active cytotoxic agents via 
enzymes, expressed at high concentrations and specificity, at the tumour sites.  Prodrug 
activation by endogenous enzymes may be avoided by using enzymes from non-
mammalian origin (e.g. caboxypeptidase G2, β-glucosidase, nitroreductase).  Factors 
important when designing prodrugs include: (i) prodrug must be less toxic than the active 
agent; (ii) it must be chemically stable under physiological conditions; (iii) it must be a 
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suitable substrate for the enzyme; (iv) the activated agent should be highly diffusible to 
be easily taken up by tumour cell; and (v) the activated agent must have a short half-life 
within tumour cells to prevent it from leaking back to normal cells.  Increased β-
glucuronidase levels (released by monocytes, granulocytes or expressed) are found at the 
necrotic areas of tumours (bronchial-, pancreatic-, breast-, lung- and gastrointestinal tract 
carcinomas, and melanomas).  β-glucuronidase is normally expressed in the lyzosymes of 
cells and at high levels in necrotic areas of large tumours.  Examples of glucuronide 
prodrugs are p-hydroxy-aniline mustard (aniline mustard), epirubicin, paclitaxel, 9-
amino-camptothecin and 5-fluorouracil (de Graaf et al., 2002; Smit et al., 1995).  
 
Cancer cells, characterized by rapid proliferation, release more enzymes into the 
surrounding environment than normal cells, which may be a survival strategy.  Enzymes 
associated with the mitochondria, nucleus and cytoplasm are also released when cells are 
destroyed.  Enzymatic changes may be associated with metabolic changes in cancer cells.  
The rate of enzyme elimination in cancer cells may be delayed, which may explain the 
high levels of certain enzymes in cancer cells.  Cancer cells may also induce the release 
of enzymes by normal cells.  Increased β-glucuronidase and β-glucosidase activities are 
associated with stomach and colon carcinoma, respectively (Stefanini, 1985). 
 
Natural occurring compounds in plant extracts may not be active themselves, but need to 
be transformed via metabolic systems in the body to become active substances (Houghton 
et al., 2007).  Non-toxic hypoxoside is converted to cytotoxic rooperol via β-glucosidase 
or cellulase in vitro, and non-toxic rooperol phase II metabolites (glucuronide, sulphate or 
glucuronide-sulphate metabolites), which get activated by glucoronidase and sulphatase, 
in vivo (Albrecht et al., 1995a; Drewes et al. 1984; Kruger et al., 1994; Marini-Bettolo et 
al., 1982; Smit et al., 1995). 
 
As mentioned above, β-glucosidase converts non-toxic hypoxoside to cytotoxic rooperol 
in vitro.  This section focuses on the β-glucosidase levels in the spent culture medium and 
lysates of Hela, HT-29 and MCF-7 cancer cells.  This was done to determine whether or 
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not it would be necessary to add β-glucosidase to the culture medium when the effects of 
the plant extracts and hypoxoside were investigated. 
 
4.2.1.2.  Materials and Methods 
 
HeLa, HT-29 and MCF-7 cancer cells were grown to confluency in 10-cm culture dishes 
in Roswell Park Memorial Institute (RPMI) 1640 cell culture medium containing 25 mM 
Hepes, 2 mM glutamine (Lonza, Walkersville, MD, USA) and 10% foetal bovine serum 
(fbs; Gibco, Grand Island, NY, USA) without antibiotics in a humidified 5% CO2 
incubator at 37 ºC.  Fbs was not heat-inactivated.  The spent medium was removed and 
kept on ice.  The cells were scraped with a Teflon cell scraper, resuspended in 1 mL of 
sodium acetate buffer (100 mM, pH 5.5) and mechanically lysed using a syringe.  The 
cell lysates were centrifuged using an Eppendorf 5804R centrifuge at 2600 x g for two 
min at 4 ºC.  Twenty μL of sodium acetate buffer (100 mM, pH 5.5) was added to the 
medium, cell lysate or β-glucosidase standard (20 μL) in a 96 well plate and incubated for 
five min at room temperature.  ρ-nitrophenyl β-D-glycopyranoside (2.5 mM; 160 μL) was 
added to each well and incubated for 15 min at 37 ºC.  The reaction was stopped by 
adding 60 μL glycine (2 M, pH 10) to each well and the absorbance read at 412 nm using 
a BioTek
®
 PowerWave XS spectrophotometer (Winooski, VT, USA).  A β-glucosidase 
standard curve (Appendix 4), ranging between 0.1 mU/well (0.00066 μg/μL) and 2 
mU/well (0.01325 μg/μL) of β-glucosidase, was performed to determine the 
concentration of β-glucosidase.   
 
4.2.1.3.  Results and Discussion 
 
No published data could be found on the β-glucosidase content of HeLa, HT-29 and 
MCF-7 cancer cell lysates or media in which these cells are cultured.  Considering the 
importance of β-glucosidase in the metabolism and activation of hypoxoside, this 
information was essential for further studies on Hypoxis extracts and hypoxoside.  Table 
4.3 summarizes the amount of β-glucosidase in the cancer cell lysates and spent medium. 
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Table 4.3:  β-glucosidase activity and mass in cell lysates and spent medium of confluent 
monolayers of HeLa, HT-29 and MCF-7 cancer cells. 
 
Cell line  Activity (mU/plate)*  Mass (μg/plate)* 
HeLa Lysate 3.13 0.42 
Medium 41.71 5.51 
HT-29 Lysate 3.14 0.42 
Medium 40.64 5.37 
MCF-7 Lysate 3.18 0.42 
Medium 40.11 5.29 
* where 1 mU = 0.132 μg of β-glucosidase;  Plate = 10 cm culture dish containing 10 mL culture   
   medium 
 
β-glucosidase was present at very low concentrations in the medium and lysates of HeLa, 
HT-29 and MCF-7 cancer cells.  This may be because cells are growing in vitro rather 
than in vivo, where the environment surrounding the cancer cells is different and more 
complex.  The amount of enzyme also depends on the size of the tumour (de Graaf et al., 
2002).  Previous studies on Hypoxis used a β-glucosidase concentration of 100 μg/mL 
(Albrecht et al., 1995a) in in vitro anticancer assays.  It is important to note that fbs 
contains β-glucosidase, which can only be inactivated by heating at 56 ºC for at least one 
hour (Theron et al., 1994).  Fbs was not heat-inactivated for this assay and it may have 
contributed to the higher concentration of β-glucosidase in the medium.  β-glucosidase 
concentrations measured in the spent medium and cell lysates were lower than the 100 
μg/mL used in previous study by Albrecht et al. (1995a).  It was therefore decided to add 
100 μg/mL β-glucosidase to culture medium for all future investigations of the effects of 
Hypoxis extracts and hypoxoside. 
 
4.2.2.  Cytotoxicity of Hypoxis extracts and IC50
 
determination of hypoxoside and    
          rooperol 
 
4.2.2.1.  Background 
 
 
Cytotoxicity testing is based on the proliferation of cancer cells in the presence or 
absence of a test substance after a specific time period.  Selectivity of an agent is 
determined by using different cancer cell lines and normal cell lines.  Cytotoxicity can be 
used to determine if the cytotoxic effect is cytocidal (cells are killed) or cytostatic (cell 
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growth and division inhibited).  The two most common techniques used to assess cell 
growth are 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and 2,3-
bis(2-methoxy-4-nitro-5-sulphophenyl)-2H-tetrazolium-5-carboxanilide sodium salt 
(XTT).  Inhibition of mitochondrial activity by changes in the cellular levels of 
nicotinamide adenine dinucleotide (NADH), glucose and other factors may cause 
variations in the results or give negative results associated with dead or nonproliferating 
cells (Houghton et al., 2007).  This problem is overcome by using other techniques e.g. 
sulphorhodamine B (SRB), lactate dehydrogenase (LDH) leakage assay, neutral red and 
protein (Bradford) assays (indirect determination of cell viability) (Fotakis and Timbrell, 
2006; Houghton et al., 2007). 
 
The MTT-cell proliferation assay is a quantitative colourimetric assay, sensitive enough 
to measure cellular proliferation, viability and cytotoxicity (Holst-Hansen and Brünner, 
1998).  The yellow, water soluble tetrazolium MTT salt is reduced by metabolically 
active cells to insoluble dark blue-to-purple formazan crystals via the cleavage of the 
tetrazolium ring by succinate dehydrogenase within the mitochondria (Figure 4.2).  The 
formazan product accumulates in healthy cells due to its impermeability to the cell 
membranes (Fotakis and Timbrell, 2006; Holst-Hansen and Brünner 1998).  The 
formation of coloured formazan relies on mitochondrial activity (Houghton et al., 2007).      
 
 
Figure 4.2:  Reduction of MTT to formazan by succinate dehydrogenase within the 
mitochondria (www.biochem.roche.com).  
 
The CellTiter-Blue
®
 cell viability assay is based on the reduction of resazurin (dark blue; 
little intrinsic fluorescence) into highly fluorescent resorufin (pink) in metabolic active or 
viable cells (Figure 4.3).  Nonviable cells lose their metabolic capacity; hence the 
indicator dye cannot be reduced.   
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Figure 4.3:  Reduction of resazurin to highly fluorescent resorufin in metabolic active cells 
(www.promega.com). 
 
Most anticancer studies have focused on hypoxoside, which is converted to rooperol.  
Information on the anticancer properties of crude Hypoxis extracts is lacking; hence 
screening of H. hemerocallidea, H. stellipilis and H. sobolifera against three cancer cell 
lines was performed.  This section focuses on the cytotoxicity of Hypoxis extracts and its 
purified compounds on HeLa, HT-29 and MCF-7 cancer cells, and peripheral blood 
mononuclear cells (PBMCs). 
 
.4.2.2.2  Materials and Methods 
 
Cell culture conditions.  Adherent cancer cell lines (HeLa, HT-29, MCF-7) were 
routinely maintained in 10-cm culture dishes, without antibiotics in RPMI 1640 cell 
culture medium containing 25 mM Hepes, 2 mM glutamine (Lonza, Walkersville, MD, 
USA) and 10% fbs (not heat-inactivated; Gibco, Grand Island, NY, USA) in a humidified 
5% CO2 incubator at 37 ºC.   
 
Treatment.  HeLa, HT-29 and MCF-7 cancer cells were seeded at 30 000 cells/mL in 96-
well plates and left to attach overnight at 37 ºC in a humidified incubator and 5% CO2.  
PBMCs were isolated from venous blood of a healthy donor using heparinised 
Vacutainer
®
 CPT
TM
 cell preparation tubes (Beckton Dickinson, Plymouth, UK) within 30 
min of collection.  PBMCs were seeded at 500 000 cells/mL in round bottomed 96-well 
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plates.  Hypoxis chloroform extracts were dried in vacuo on the day of the assay using a 
SpeedVac SC100 (Savant Instruments, NY, USA), resuspended in 0.25% dimethyl 
sulphoxide (DMSO; v/v), sonicated for 15 min and complete medium (RPMI 1640: 10% 
fbs), containing 100 μg/mL β-glucosidase, added to reach concentrations of 125-500 
μg/mL of Hypoxis extract.   Hypoxoside and rooperol were resuspended in DMSO 
(0.25%, v/v), sonicated for 15 min and complete medium containing 100 μg/mL β-
glucosidase added to the former and only complete medium added to the latter to reach 
concentrations of 3.125-200 μg/mL and 1.25-80 μg/mL, respectively.  Cisplatin (10 μM 
and 100 μM) and DMSO (0.25%, v/v) were used as positive- and vehicle controls, 
respectively.  2-Hydroxypropyl-β-cyclodextrin [CD; Shimoda Biotech (PTY) Ltd.] was 
dissolved in saline (0.9% NaCl), filter sterilized and cytotoxicity determined at 
concentrations between 0.5-50 mM.  Sterols (β-sitosterol, campesterol, cholesterol and 
stigmasterol) were dissolved in absolute EtOH (5 mg/mL) by sonication for 15 min and 
diluted in CD, absolute EtOH and complete medium.  Dilutions were made to reach 
concentrations of 0.8-100 μM, 4 mM and 5% for sterols, CD and EtOH, respectively.  
Cells were treated for 48 hrs.  MTT assay was performed on adherent cells.  In brief, 
treatments were removed via aspiration, 200 μL MTT [0.5 mg/mL (Holst-Hansen and 
Brünner, 1998)] was added to each well and incubated for three hrs at 37 °C.  MTT was 
removed via aspiration, 200 μL DMSO was added to each well to dissolve the formazan 
crystals, and the absorbance read at 540 nm using a BioTek
®
 PowerWave XS 
spectrophotometer.  The CellTiter-Blue
®
 cell viability assay was performed on PBMCs, 
according to the kit‟s protocol, and the fluorescence read at 560Ex/590Em using a 
Fluoroskan Ascent FL fluorometer (ThermoLabsystems, Finland).  The half maximal 
inhibitory concentrations (IC50) of hypoxoside and rooperol were determined using 
GraphPad Prism Version 4 (GraphPad Software, San Diego, USA).  Statistical 
significance was determined using the two-tailed Student‟s t-test.    
 
 4.2.2.3.  Results and Discussion 
 
After 48 hrs exposure to the Hypoxis extracts, hypoxoside and rooperol, the MTT and 
CellTiter-Blue
®
 cell viability assays were performed on the HeLa, HT-29 and MCF-7 
 61 
cancer cell lines, and PBMCs, respectively, to determine cytotoxicity (Figure 4.4).  
Cytotoxicity of the Hypoxis extracts, hypoxoside and rooperol was expressed as a 
percentage of the vehicle control, which was zero.  Cisplatin (10 of 100 nM) was used as 
positive control and cytotoxicity measured at concentrations of 10 and 100 µM. 
Treatment of HeLa, HT-29 and MCF-7 cancer cells with 10 µM cisplatin killed 
85.23±0.77, 45.27±3.69 and 32.67±2.09 percent of the cells, respectively.  Treatment of 
HeLa, HT-29 and MCF-7 cancer cells with 100 µM cisplatin killed 94.34±0.29, 
92.26±0.19 and 94.12±0.47 percent of the cells, respectively (data not shown). 
 
Cytotoxicity against the MCF-7 cancer cells was seen with all three Hypoxis extracts.  H. 
hemerocallidea and H. sobolifera extracts at higher concentrations (250 and 500 μg/mL) 
had cytotoxic effects against the HeLa and HT-29 cancer cells, whereas a H. stellipilis 
extract stimulated growth at higher concentrations in these two cancer cell lines.  H. 
hemerocallidea and H. sobolifera had the highest cytotoxic effects against HT-29 cancer 
cells, while H. sobolifera had the best overall cytotoxic effect against all three cancer cell 
lines.  Treatment of PBMCs with the three Hypoxis spp. extracts showed growth 
stimulation (Figure 4.4), but the results were not statistically significant.  Due to too low 
cytotoxic effects against the three cancer cell lines, IC50 values could not be determined 
for the Hypoxis extracts.  The addition of β-glucosidase to the H. hemerocallidea extract 
(500 µg/mL) significantly increased the percentage of HT-29 (p<0.01) cancer cells killed.  
The addition of β-glucosidase to the H. sobolifera (125-500 µg/mL) extract significantly 
increased the percentage of HeLa (p<0.05 to p<0.001), HT-29 (p<0.01 to p<0.001) and 
MCF-7 (p<0.01 to p<0.05) cancer cells killed.   
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Figure 4.4:  Percentage of HeLa, HT-29 and MCF-7 cancer cells, and PBMCs killed 
when treated with H. hemerocallidea, H. stellipilis and H. sobolifera in the presence 
and absence of β-glucosidase.  Error bars indicate the SEM values of quadruplicate 
readings.  Significance was determined using the two-tailed Student t-test: *p<0.01; 
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**p<0.001; #p<0.05 (black: control vs tests with β-glucosidase; red: tests with β-
glucosidase vs tests without β-glucosidase). 
 
β-glucosidase added to the H. hemerocallidea extract had greater cytotoxic effects 
compared to H. stellipilis and H. sobolifera.  This may be explained by the higher 
hypoxoside content present in the H. hemerocallidea chloroform extract compared to the 
other two Hypoxis chloroform extracts (Chapter 3, section 3.3).  The increase in 
cytotoxicity seen when β-glucosidase was added to the H. hemerocallidea (against HeLa, 
HT-29 and MCF-7 cancer cells) and H. sobolifera (against HeLa and MCF-7 cancer 
cells) extracts may be attributed to unidentified compounds that are converted to 
cytotoxic compounds, because hypoxoside was undetectable in the H. sobolifera 
chloroform extracts (Chapter 3, section 3.3).  
 
Growth stimulation of HeLa and HT-29 cancer cells in the presence of H. stellipilis is a 
concern, because H. stellipilis is often sold in herbal shops of the Eastern Cape province, 
South Africa.  Cytotoxicity screening with an aqueous extract of H. hemerocallidea has 
shown growth stimulation of a prostate carcinoma (DU145) and non-malignant breast 
(MCF-12A) cell line, but inhibited MCF-7 cancer cell growth (Steenkamp and Gouws, 
2006).  Growth stimulation of PBMCs by the Hypoxis extracts shows the absence of 
toxicity in the extracts. 
 
Cytotoxicity of hypoxoside and rooperol was determined against the HeLa, HT-29 and 
MCF-7 cancer cell lines, and PBMCs (Figure 4.5A and B).  Fifty-percentage inhibition 
was achieved at very low hypoxoside and rooperol concentrations and IC50 values are 
summarized in Table 4.4. 
 
Hypoxoside, the non-toxic compound isolated from Hypoxis spp., is converted to 
rooperol in the presence of β-glucosidase.  Different IC50 values for hypoxoside and 
rooperol may be due to the unknown conversion rate/concentrations of hypoxoside to 
rooperol, dehydroxyrooperol and bisdehydroxyrooperol (Kruger et al., 1994).  The 
cytotoxicity of the latter two analogues of rooperol has not been investigated.  HT-29 
cancer cells had the highest IC50 value for rooperol, whereas less than 20 μg/mL (<70 
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μM) was required to kill 50% of HeLa and MCF-7 cancer cells.  Low concentrations of 
hypoxoside and rooperol stimulated growth of PBMCs (Figure 4.5), and their IC50 values 
for these cells from healthy donors were generally lower than for the cancer cell lines 
(Table 4.4).  Hypoxoside IC50 values for HeLa, HT-29 and MCF-7 cancer cells were 
26.46, 82.80 and 45.62 μg/mL, respectively, which are much higher than the 0.31 and 
0.20 μg/mL present in 125 μg/mL of H. hemerocallidea and H. stellipilis extracts, 
respectively.     
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Figure 4.5:  Cytotoxicity effects of hypoxoside and β-glucosidase (A) and rooperol (B) 
against the HeLa, HT-29 and MCF-7 cancer cell lines, and PBMCs.  Error bars indicate the 
SD values of eight replicate values.  
 
 
 65 
Table 4.4:  IC50 values [μg/mL and μM (values in brackets)] of hypoxoside plus β-
glucosidase and rooperol treatment of the HeLa, HT-29 and MCF-7 cancer cell lines, and 
PBMCs after 48 hours.   
 
Treatment 
HeLa HT-29 MCF-7 
PBMCs 
Hypoxoside 
26.46 
(43.62) 
82.80 
(136.50) 
45.62 
(75.21) 
19.31 
(31.83) 
Rooperol 13.01 
(46.09) 
29.03 
(102.83) 
18.66 
(66.10) 
12.13 
(42.97) 
 
In vitro screening of 60 human cancer cell lines by the National Cancer Institute (USA) 
and five tumour (breast, colon, uterus, melanoma and non-small-cell lung) cell lines by 
the Huntingdon Research Centre (England) have shown growth inhibition when exposed 
to purified hypoxoside.  Cytotoxicity was due to the conversion of non-toxic hypoxoside 
to cytotoxic rooperol in the presence of β-glucosidase in foetal calf serum (Albrecht et 
al., 1995a).  Albrecht et al. (1995a) have shown the absence of cytotoxicity when cancer 
cells were treated with hypoxoside at concentrations of up to 100 μg/mL.  In the presence 
of β-glucosidase, cytotoxicity was seen at concentrations of 2-10 μg/mL.  Theron et al. 
(1994) have shown cytotoxicity when B16-F10-BL6 mouse melanoma cells were treated 
with rooperol at a concentration of above 11 μM (~ 6.5 μg/mL) and an IC50 value of 20 
μM (~ 12 μg/mL).  In this study, IC50 values for HeLa and MCF-7 cancer cells, when 
treated with rooperol, were between 10-20 μg/mL.  Positive in vitro results gave rise to a 
phase I trial in lung cancer patients (Albrecht et al., 1995b; Smit et al., 1995).   
 
Cytotoxicity of sterols (β-sitosterol, campesterol, cholesterol and stigmasterol) was 
determined against the HeLa, HT-29 and MCF-7 cancer cell lines and PBMCs (Appendix 
4).  The best cytotoxicity was obtained against the HT-29 cancer cell line, with very little 
cytotoxicity against the HeLa and MCF-7 cancer cell lines.  High sterol concentrations, 
±25-40 μM and ±25-30 μM were needed for cytotoxicity against HeLa and MCF-7 
cancer cells, respectively.  Sterols had no cytotoxicity against PBMCs, even at 
concentrations as high as 100 μM.   
 
Researchers have used sterols at concentrations of 8 and 16 μM and incubation periods of 
2-16 days with frequent sterol changes (every second day) (Awad et al., 1996; Awad et 
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al., 1998; Awad et al., 2001a; Awad et al., 2003a/b; Awad et al., 2005a; Awad et al., 
2007; von Holtz et al., 1998).  Awad et al. (2005a) exposed Caco2 (a model for human 
intestinal epithelial cells) cells to cholesterol, campesterol and β-sitosterol (16 μM) for 16 
days, changing the medium every second day.  Brassinosteroids (steroid plant hormones 
with similar ring structure to phytosterols) analogues inhibited breast (MCF-7, MDA-
MB-468)- and prostate (DU-145, LNCaP) cancer cell growth at micromolar 
concentrations with minimal effects on normal cells.  Non-brassinosteroid plant sterols β-
sitosterol, stigmasterol and cholesterol had extremely weak to no detectable activities – 
even at concentrations of 50 μM.  β-sitosterol, stigmasterol and cholesterol showed some 
cytotoxicity (IC50 >30 uM) against the multiple myeloma RPMI 8226 cell line after 72 
hrs exposure (Malíková et al., 2008).   
 
β-sitosterol was not investigated as active compound in this study because several 
researchers have already shown mechanisms of action for its anticancer properties.  β-
sitosterol concentrations in the Hypoxis extracts (1.77, 0.61 and 4.50 μM in H. 
hemerocallidea, H. stellipilis and H. sobolifera, respectively) were lower than the 
concentrations (8 or 16 μM) used by Awad and co-workers.   Awad et al. (2003b) have 
shown that β-sitosterol (16 μM) inhibits MDA-MB-231 human breast cancer cell growth 
by 70%, while Awad et al. (2007) have shown that 8 and 16 μM β-sitosterol decreased 
MCF-7 breast cancer cell growth by 63 and 81%, respectively, compared to the control.  
Awad and co-workers have shown that β-sitosterol induces apoptosis by Fas signalling 
(Awad et al., 2007), activates caspases-8 (extrinsic pathway) and -9 (intrinsic pathway) in 
MCF-7 and MDA-MB-231 human breast cancer cells (Awad et al., 2003a; Awad et al., 
2007) and reduces metastasis in MDA-MB-231 cells (Awad et al., 2001a).  Choi et al. 
(2003) have shown the induction of Bax in HT116 human colon cancer cells after β-
sitosterol treatment.  β-sitosterol downregulates cholesterol synthesis from mevalonate 
and stimulates the MAPK pathway in MDA-MB-231 cells (Awad et al., 2003b).  
Furthermore, β-sitosterol alters membrane lipids (Awad et al., 1996) in HT-29 cancer 
cells and activates the sphingomyelin cycle in LNCaP human prostate (von Holtz et al., 
1998) and HT-29 colon (Awad et al., 1998) cancer cells.  Although the β-sitosterol 
concentrations in the Hypoxis chloroform extracts were lower than the concentrations 
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used in the above mentioned studies, it may have contributed to the cytotoxic effects seen 
against the HeLa, HT-29 and MCF-7 cancer cells.  
 
Researchers have found conflicting cholesterol lowering effects of phytosterols, which 
could be ascribed to their bioavailability.  Bioavailability may be influenced by slow 
dissolution rates of sterols from cyclodextrin and low solubility of sterols in aqueous and 
organic solvents.  It may take several days to weeks for highly purified phytosterols to 
dissolve in bile salt solutions.  To increase solubility, phytosterols can be dissolved in oil 
or egg fat, emulsified in aqueous medium with lecithin, and finely micronized and mixed 
with fatty foods for in vivo studies (Ostlund, 2002).  Phytosterol solubility can be 
increased by esterification to form phytosterol esters.  In the present study, poor solubility 
and release of (phyto)sterols may have contributed to the weak cytotoxicity seen against 
the HeLa, HT-29 and MCF-7 cancer cells (Appendix 4). 
 
Cyclodextrins are cyclic oligosaccharides consisting of 6 (α), 7 (β) or 8 (γ) glucopyranose 
subunits, linked by α-(1,4) bonds, with hydrophobic interiors.  They are enzymatically 
produced from starch.  Cyclodextrins have hydrophillic exteriors, making them water-
soluble, and hydrophobic interiors, which form microenvironments for non-polar 
molecules (Greenberg-Ofrath et al., 1993; Martin Del Valle, 2004).  Non-polar drugs, the 
size of the hydrophobic core, form complexes with the cyclodextrin, thus increasing their 
solubility in polar aqueous environments.  Cyclodextrins are non-toxic (due to lack of 
absorption from the gastrointestinal tract, in vivo), do not denature proteins or interfere 
with enzymatic reactions, and is rapidly reversible to release the drug.  Two factors 
influence complex formation between cyclodextrin and the drug namely, (i) the size of 
the drug to fit the cyclodextrin cavity, and (ii) thermodynamic interactions between 
cyclodextrin, the drug and the solvent.  Generally one molecule is included into one 
cyclodextrin cavity, but sometimes more than one molecule enters a cavity (low 
molecular weight molecules) or more than one cyclodextrin molecule bind the drug 
molecule (high molecular weight molecules).  Heating increases the solubility of 
complexes, but may destabilize complexes at too high temperatures (Martin Del Valle, 
2004). Greenberg-Ofrath et al. (1993) have shown that CDs can be carriers of lipids such 
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as cholesterol.  Concentrations of 5 to 10 mM of hydroxypropyl-β-CD were not toxic to 
mycoplasma cells.  Cyclodextrin carries the drug through the aqueous barrier to the 
lipophilic surface of biological membranes, where the drug partitions from the complex 
into the lipophilic membrane.  An excess of cyclodextrin may influence the permeability 
of the membranes (Másson et al., 1999).   
 
In this study, cyclodextrin concentration of 4 mM (Appendix 4) was not toxic to the cells 
investigated and corresponded to the 5 mM cyclodextrin used by Awad and other 
researchers.  The incorrect temperature and amount of sterol molecules entering 
cyclodextrin may have influenced the uptake of sterols by cyclodextrin.  The main 
reasons for failure of sterols to show cytotoxicity against HeLa, HT-29 and MCF-7 
cancer cells may be due to preparation of sterol-cyclodextrin complexes, uptake of sterols 
by cyclodextrin, too short exposure periods (two days), release of non-polar sterols from 
cyclodextrin into polar environment and sterol medium that was not replaced daily.   
  
In summary, the cytotoxicity of Hypoxis extracts and its purfied compounds were 
investigated against HeLa, HT-29 and MCF-7 cancer cells, and PBMCs.  Cytotoxicity of 
Hypoxis extracts were low, which may be due to very low concentrations (H. 
hemerocallidea and H. stellipilis) or no (H. sobolifera) hypoxoside in the Hypoxis 
chloroform extracts.  Hence very little hypoxoside was converted to rooperol by β-
glucosidase, which may have had no effect on cytotoxicity.  Hypoxis extracts were not 
toxic to PBMCs.  Purified compounds were screened for cytotoxicity to explain its role in 
the Hypoxis extracts.  Cytotoxicity of Hypoxis extracts may be due to the phytosterol 
content, especially β-sitosterol, but could not be confirmed.  Synergistic and/or additive 
effects of the purified and unknown compounds in the Hypoxis chloroform extracts may 
have caused the cytotoxicity.     
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 4.2.3.  Conversion of hypoxoside to rooperol (time study) 
 
 4.2.3.1.  Background 
 
Non-toxic hypoxoside is converted to cytotoxic rooperol in the presence of β-glucosidase, 
in vitro (Albrecht et al., 1995a).   
 
This section focuses on the conversion rate of hypoxoside to rooperol under the defined 
culture conditions in the presence of β-glucosidase, and rooperol uptake by HeLa, HT-29 
and MCF-7 cancer cells.  Albrecht et al. (1995a) investigated the morphological effects 
of hypoxoside after 12 hrs.  A time study of hypoxoside conversion to rooperol, and 
rooperol uptake may explain morphological or biochemical features of apoptosis at 
earlier time intervals in cancer cells.    
 
 4.2.3.2.  Materials and Methods 
 
HeLa, HT-29 and MCF-7 cancer cells were seeded at 30 000 cells/mL in 24-well plates 
and left to attach overnight at 37 ºC in a humidified incubator and 5% CO2.  Cells were 
treated with hypoxoside (100 μg/mL) and β-glucosidase (100 μg/mL), and 20 μL aliquots 
removed at 0, 3, 6, 9, 12 and 24 hrs.  β-glucosidase activity was inhibited by adding 1 
mM nojirimycin bisulfite (2 μL; Sigma) to the aliquots, while keeping on ice.  
Hypoxoside and rooperol were dissolved in ddH2O and loaded (5 μL = 5 μg) onto silica 
coated, aluminium TLC plates and dried.  Optimized mobile phase for rooperol 
separation was chloroform: ethylacetate: formic acid (5:4:1).  Samples (10 μL) and 
standard (rooperol) were spotted onto TLC plates, as described above and developed in 
chloroform: ethylacetate: formic acid (5:4:1).  TLC plates were dried and stained as 
described in Chapter 3 (section 3.3.2).  Densitometry was used to determine the amount 
of rooperol present in the medium over time.  A rooperol standard curve (Appendix 4), 
ranging between 0.5 μg – 10 μg, was prepared and the integrated density values (IDVs) 
determined.   
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 4.2.3.3.  Results and Discussion  
 
One hundred μg/mL of hypoxoside was used in this study, as Albrecht et al. (1995a) 
found no in vitro cytotoxicity against murine and human melanoma cell lines when serum 
was heat-inactivated.  Converted rooperol in the medium was determined from a rooperol 
concentration as a function of IDV standard curve (R
2
 = 0.9905; Appendix 4) and plotted 
as a kinetic curve (Figure 4.6).  
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Figure 4.6:  Amount of rooperol (μg/mL) present in the culture medium of each cell line 
(HeLa, HT-29 and MCF-7) after conversion of hypoxoside (100 μg/mL) to rooperol via β-
glucosidase (100 μg/mL) over a time period of 24 hrs. 
 
A large percentage of hypoxoside was converted to rooperol in the medium of HeLa, HT-
29 and MCF-7 cancer cells after three hrs of exposure.  The maximum concentration of 
rooperol in the culture medium of HeLa and MCF-7 cancer cells was 60 μg/mL, and 20 
μg/mL in the culture medium of HT-29 cancer cells.  A high percentage (~ 60 %) of 
hypoxoside was converted to rooperol in the culture medium of HeLa and MCF-7 cancer 
cells.  Morphological changes, associated with apoptosis, may occur as early as 6 hrs 
when treated with hypoxoside.  Albrecht et al. (1995a) have shown amorphous chromatin 
clumps after 12 hrs, cytoplasm vacuolization after 16 hrs and massive vacuoles and 
disintegrating cells after 24 hrs using phase contrast micrographs in BL-6 mouse 
melanoma cells exposed to 50 μg/mL hypoxoside and 100 μg/mL β-glucosidase. 
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Transmission electron micrographs have shown vacuoles in the cytoplasm, amorphous 
material in vacuoles, disintegrating mitochondria, condensed cytoplasm and fragmented 
nuclei in BL-6 cells after 24 hrs of treatment.  Scanning electron micrographs of UCT-
Mel 1 melanoma cells have shown pore formation in the plasma membranes and 
apoptotic body formation afer 24 hrs. 
 
This study provides data on the rate at which hypoxoside is converted to rooperol by β-
glucosidase.  Morphological and biochemical apoptotic features in HeLa, HT-29 and 
MCF-7 cancer cells may be detected before 12 hrs.  The conversion rate of hypoxoside to 
rooperol also forms part of optimizing the exposure time of these compounds to HeLa, 
HT-29 and MCF-7 cancer cells.  Hypoxoside conversion to rooperol and rooperol uptake 
by cancer cells need further investigation by repeating the experiment or by using more 
accurate kinetic studies. 
 
 4.2.4.  DNA cell cycle arrest 
 
 4.2.4.1.  Background 
 
DNA plays a pivotal role in the development and treatment of cancer.  DNA damage is 
associated with cancer development (mutations) and treatment (radiation therapy and/or 
chemotherapeutic agents) in normal and cancer cells, respectively.  DNA damage, 
associated with treatment, is also responsible for most side effects in normal cells (Kastan 
and Bartek, 2004).  The normal cell cycle is divided into the G0, G1, S, G2 and M phases 
(Figure 4.7).  G0/G1, G2/M and S phases are characterized by diploid (2N), tetraploid 
(4N) and intermediate (ranging from 2N to 4N) DNA content, respectively.  The DNA 
histogram represents DNA content distribution for a population of cells through the cell 
cycle (Hodgetts et al., 1988).  G0 and G1 phases are associated with growth and 
reorganization, whereas the S and M phases are associated with DNA synthesis and 
mitosis, respectively (Pestell et al., 1999; Planchais et al., 2000).   
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 4.2.4.1.1.   DNA cell cycle arrest and progression machinery 
 
Cell cycle progression is controlled by two mechanisms, namely (i) protein 
phosphorylation for cells to enter the next phase and (ii) cell cycle checkpoints, which 
monitor the completion of critical events after each phase and are able to prevent cells 
from entering the next phase (Collins et al., 1997a). 
 
CDKs.  Cyclin-dependent kinases (CDKs; ser/thr protein kinases) are activated when 
bound to cyclin subunits to form active cyclin-CDK complexes, each with unique 
substrate specificity.  CDK levels remain constant, whereas cyclin levels vary during the 
cell cycle due to expression and degradation.  Eleven CDKs are found in mammalian 
cells and the most commonly found cyclin-CDK complexes in early-to-mid G1, late G1-
to-S and G2/M phases are cyclin D-CDK4/6, cyclin A/E-CDK2 and cyclin B-CDK1, 
respectively (Figure 4.7).  Cyclin-CDK complexes function in the G1 and G2 phases to 
initiate S phase and mitosis, respectively (Chibazakura et al., 2004; Collins et al., 1997a; 
Nojima, 2004; Pestell et al., 1999).   
 
CDK-cyclin complexes are regulated by phosphorylation, dephosphorylation and CDK 
inhibitor (CDKI) binding.  Two types of CDK inhibitors are found in cells, namely the 
Ink4 and Cip1/Kip1 families.  The Ink4 family consists of p16
Ink4a
, p15
Ink4b
, p18
Ink4c
 and 
p19
Ink4d
 members and inhibits cyclin D-CDK4 complexes (early G1) by competing with 
cyclin D for binding to CDK4 and dissociates cyclin D-CDK4 complexes.  The 
Cip1/Kip1 family consists of p21
Cip1/Kip1
, p27
Kip1
 and p57
Kip2
 members and inhibits cyclin 
A/D/E-CDKs activities by associating with cyclin-CDK complexes (Nojima, 2004; 
Pestell et al., 1999).  Cip/Kip family members are found in the cytoplasm and nucleus of 
the cell and may function as (i) potential assembly factors (enhancing cyclin D and 
CDK4 binding in the cytoplasm by acting as a bridge, and promote translocation into the 
nucleus), (ii) regulators of apoptosis (anti-apoptotic or pro-survival depends on cyclin B-
CDK1 inhibition and G2 arrest; p21 is cleaved by caspase-3 and relocates from the 
nucleus to the cytoplasm, resulting in increased CDK2, (iii) transcriptional cofactors [p21 
regulates nuclear factor (NF)-κB, STAT3, Myc, E2F and C/EBP activity, and inhibits 
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genes encoding for DNA polymerase α, topoisomerase II, CDK-1 and cyclin B, which is 
involved in progression] (Coqueret, 2003). 
 
 
Figure 4.7:  DNA cell cycle representing the five phases, CDKs and cyclins involved (Collins 
et al., 1997a). 
 
Checkpoints/restriction points.  Progression from one phase to the next depends on 
passage through the cell cycle checkpoints.  Cell cycle checkpoints are mechanisms used 
by cells to ensure that earlier processes, like DNA replication (underreplicated and repair 
to damaged DNA) and mitosis (segregated chromosomes), are complete (Collins et al., 
1997a; Kastan and Bartek, 2004).  Activated checkpoints relay signals to the cell cycle 
progression machinery where cell cycle progression is delayed to prevent mutations.  Cell 
cycle checkpoints are not an essential part of the cell cycle progression machinery and are 
not activated in every cell, as is the case with kinases.  The link between cancer and the 
cell cycle is proliferation, where the former is characterized by inappropriate cell 
proliferation and the latter controls the cell cycle machinery (Collins et al., 1997a).  Cell 
cycle checkpoints rapidly induce cell cycle arrest when receiving a stress signal by 
activating damage DNA repair- and replication-stalling mechanisms.  Cell cycle arrest is 
maintained until DNA repair is complete.  Uncontrolled checkpoints may result in DNA 
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damage leading to inceased mutation rates, chromosome instability, and aneuploidy 
contributing to tumour development (Nojima, 2004).   
 
 4.2.4.1.2.  Checkpoints and progression  
 
G0/G1 phase, checkpoint and G1-S progression.  Two tumour suppressor pathways, p53 
and pRb, are involved in the G1 phase of the cell cycle.  These pathways are also 
commonly deregulated in human cancer (Kastan and Bartek, 2004). 
 
p53 tumour gene, the most commonly mutated gene in cancer (50%), encodes for a 53 
kDa transcription factor (p53), which induces gene expression associated with cell cycle 
regulation, DNA damage repair and apoptosis (Nojima, 2004; Fadeel and Orrenius, 
2005).  The ATM(ATR)/CHK2(CHK1)-p53/MDM2-p21 pathway is the most important 
checkpoint responding to DNA damage in the G1 phase.  ATM (ataxia telangiectasia 
mutated)/ATR (AMT- and Rad3-related) and checkpoint-transducer serine/threonine 
kinases (CHK)1/2 phosphorylate the p53 transcription factor, causing MDM2 (an 
ubiquitin ligase) to dissociate from p53.  This leads to stabilization and accumulation of 
p53 protein, which transcriptionally target several genes including the CDK inhibitor, 
p21
Waf1/Cip1
 (Kastan and Bartek, 2004; Nojima, 2004).  p53 expression levels are low in 
the absence of cellular stress, but increase due to different stresses (e.g. DNA damage).  
If DNA damage is too severe, p53 will induce apoptosis.  Other possible G1 checkpoints 
may involve proteosomal degradation of cyclin D resulting in p21
Waf1/Cip1
 release, which 
binds cyclin E-CDK2 and inactivates its kinase activity.  Another mechanism may 
involve an increase in p16
Ink4a
 and p21
Waf1/Cip1
, which bind and inactivate cyclin D-
CDK4/6 and cyclin E-CDK2, respectively (Nojima, 2004).  
 
The tumour suppressor, retinoblastoma (pRb) protein, plays an important role in G1 
arrest and G1-S progression.  Rb, in its un(hypo)phosphorylated form, binds the early 
gene 2 factor (E2F) to form a transcriptional repressing complex in early to mid-G1 
phase, hence G1 arrest.  Cyclin D-CDK4/6 and cyclin E-CDK2 phosphorylate the pRb 
family of nuclear phosphoproteins in mid-G1 and late G1/early S phase, respectively, 
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which become hyperphosphorylated (and inactive) and is released from the E2F complex 
resulting in G1-S progression.  E2F regulates the expression of genes required for S 
phase entry and DNA synthesis (Avni et al., 2003; Collins et al., 1997a; Nojima, 2004).  
Phosphorylation of pRB is prevented by the inhibition of cyclin-CDK activity by CDKIs.   
 
In quiescent cells, cyclin D levels are low but increase in the nucleus during the G1 
phase. Overexpression of cyclin D promotes cell progression through the G1 phase.  
When cells enter the S phase, cyclin D moves from the nucleus into the cytoplasm 
(Pestell et al., 1999).  CDC25 phosphatase removes inhibitory phosphates from CDKs 
and promotes cell cycle progression.  CDC25A overexpression activates cyclin A/E-
CDK2 (Nojima, 2004).  Cyclin E and A levels peak late in G1 phase and bind CDK2 
with maximum function at G1/S transition.  Overexpression of cyclin-E decreases the 
time it takes for the cell to finish the G1 phase and enter the S phase.  Effect of cyclin D 
and -E is dependent and independent, respectively, on pRb (Pestell et al., 1999).  During 
genotoxic stress, CHK 1/2 activity increases and phosphorylates CDC25A, which gets 
tagged for proteolysis and degradation.  Cyclin E/A-CDK2 complex activity gets 
inhibited (see below), thus inducing the G1/S checkpoint.  The CDC25A-degradation 
pathway is activated faster than the p53 pathway, because it does not need transcription 
and accumulation of newly synthesized products (Kastan and Bartek, 2004; Nojima, 
2004).  
 
p21
Waf1/Cip1
 trancription is induced by the tumour suppressor p53, antimitogenic cytokine 
transforming growth factor (TGF)-β and phorbol ester tetradecanoyl-phorbol acetate. 
p21
Waf1/Cip1
 may regulate transcription of genes involved in growth arrest, apoptosis, 
aging and senescence after DNA damage.  p21
Waf1/Cip1
 and p27
Kip1
 inhibitors are 
associated with the active form of cyclin D-CDK4/6, whereas low Kip/Cip1 
concentrations inhibit CDK2 but not CDK4/6.  G1-S progression depends on inhibitor 
free cyclin E-CDK2, but tolerates inhibitor bound cyclin D-CDK4/6.  In the nucleus more 
p21
Waf1/Cip1
 and p27
Kip1
 will bind cyclin D-CDK4/6 complexes, rendering cyclin E-CDK2 
free to be active.  During cell cycle arrest Kip/Cip protein levels increase – saturating 
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cyclin D-CDK4/6 – and binding cyclin E-CDK2, which blocks G1-S progression 
(Coqueret, 2003).  p21
Waf1/Cip1
 thus has a cell cycle arrest and progression function.   
S phase and checkpoint.  The S phase is characterized by DNA replication.  Checkpoints 
activated during the S phase may be in response to DNA replication stress (chemical 
agents e.g. aphidicolin, methyl methanesulfonate, UV), which may interfere with the 
DNA machinery (e.g. replication forks, DNA polymerase, DNA replication) or in 
response to double stranded breaks (intra-S-phase checkpoint).  CDC25A degradation is 
involved in the S-phase checkpoint, by inhibiting the S-phase promoting activity of 
cyclin E-CDK2 and blocking DNA replication.  Other proteins that get phosphorylated 
and are involved in the S phase checkpoint include the breast cancer (BRCA) 
susceptibility gene 1/2, Nijmegen breakage syndrome (NBS) gene 1, CHK1 and mediator 
of DNA damage checkpoint (Mdc) protein 1 (Nojima, 2004).  DNA synthesis can be 
halted by (i) p21
Cip1/Waf1
 binding preventing the cyclin A/E-CDK2 complex from loading 
CDC45 onto chromatin, which is necessary for recruiting DNA polymerase α into 
assembled pre-replication complexes (blocks initiation of DNA replication), (ii) 
preventing pRb phosphorylation (pRb inhibits E2F-dependent transcription of S phase 
genes for S phase entry) and (iii) ATM-mediated phorphorylation of NBS1 and SMC1 
(cohesion protein).  Other kinases may be involved in delaying DNA synthesis (Kastan 
and Bartek, 2004; Nojima, 2004).  Hypophosphorylated Rb may reappear before mitosis 
and play a role in inhibiting S phase progression, but the mechanism is poorly 
understood.  Hypophosphorylated Rb associated with G1 arrest can be prevented by 
cyclin E overexpression, but cyclin E cannot overcome S phase arrest associated with 
hypophosphorylayed Rb expression (Avni et al., 2003).  Avni et al. (2003) have shown 
the accumulation of hypophosphorylated Rb in S phase damaged chromatin and its 
existence is dependent on the phosphatase, PP2A.  Rb may interact with replication 
initiation sites after S phase damage.     
 
G2/M phase checkpoint and G2-M progression.  The M phase is characterized by the 
segregation of the genome into two daughter cells and splitting into two new cells.  The 
G2/M checkpoint targets cyclin B-CDK1, which is involved in promoting mitosis.  The 
CDK1 activity during mitotic exit is inhibited by cyclin A/B degradation via the 
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anaphase-promoting complex (APC) by initiating proteosomal cyclin degradation 
through ubiquitination.  Cyclin destruction is initiated at the metaphase and completed at 
the anaphase.  Towards the end of anaphase, CDK1 activity is extinguished to allow 
mitotic exit, reassembly of preinitiation complexes at replication origins and establishing 
the G1 state (Chibazakura et al., 2004; Kastan and Bartek, 2004; Pestell et al., 1999; 
Sivaprasad et al., 2007; Sudo et al., 2004).  CDKIs (p21
Cip1/Waf1
 and p27
Waf1
) regulate 
CDK activity during mitosis by binding mitotic cyclin B-CDK1 and persist from the mid-
M to G1 phase.  Overexpression of cyclins (e.g. cyclin A) in the absence of CDKIs 
(p21
Cip1/Waf1
, p27
 Waf1
, p107) may result in cells exiting mitosis without separation of 
sister chromatids (Chibazakura et al., 2004).  The G2/M checkpoint prevents mitosis 
initiation after detecting DNA damage during the G2 phase or cells entering G2 from 
G1/S with damaged DNA.  Maintenance of the G2 checkpoint may depend on BRCA1 
and p53, which upregulate cell cycle inhibitors (Kastan and Bartek, 2004). 
 
DNA cell cycle arrest is an important starting point in investigating the anticancer 
mechanism of action.  This section focuses on DNA cell cycle arrest in HeLa, HT-29 and 
MCF-7 cancer cells when treated with Hypoxis extracts and rooperol.  
 
 4.2.4.2   Materials and Methods 
 
DNA cell cycle arrest.  HeLa, HT-29 and MCF-7 cancer cells were seeded at 1.2 x 10
6
 
cells/10 mL in 10-cm culture dishes and left to attach overnight at 37 ºC in a humidified 
incubator and 5% CO2.   DMSO (0.25%, v/v), Hypoxis chloroform extracts (125 μg/mL) 
and rooperol [IC50 values (Table 4.4)] were added as described above.  Hypoxis extract 
concentrations above 125 µg/mL are too high for in vitro studies, whereas concentrations 
below 125 µg/mL would have shown no effects, hence 125 µg/mL was chosen.  After 15 
and 48 hrs of treatment, cells were trypsinized for 10 min, resuspended in 100 μL sheath 
fluid (Beckman Coulter) and transferred to polypropylene tubes.  The Coulter
®
 DNA 
Prep
TM
 reagents kit (Beckman Coulter) was used for DNA cell cycle analysis.  Lysis 
reagent (100 μL; containing <0.1% NaN3, nonionic detergents, saline and stabilizers) was 
added to each tube, vortexed and incubated for five min at room temperature.  Five 
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hundred μL of propidium iodide (50 μg/mL) was added and incubated in the dark for 15 
min at 37 ºC.  Samples were immediately analyzed using a Beckman Coulter Cytomics 
FC500 (Miami, FL, USA).  Biological standards (including human lymphocytes or 
granulocytes, trout red blood cells and others) are used to correct for the preparation and 
staining procedures.  Trout red blood cells are used more frequently, because it differs 
from human diploid cells with regard to DNA content (Jakobsen, 1983).  Trout red blood 
cells (Beckman Coulter, 100 μL) were treated as described above and used as internal 
reference standard. 
 
p21
Waf1/Cip1
 expression.  HeLa, HT-29 and MCF-7 cancer cells were seeded at densities of 
40 000 cells/mL in 24-well plates and left to attach overnight at 37 ºC in a humidified 
incubator and 5% CO2.  Cells were treated with DMSO (0.25%, v/v), H. sobolifera 
chloroform extract (125 μg/mL) and rooperol [IC50 values (Table 4.4)] for 15 hrs.  After 
exposure, cells were washed with PBSA, trypsinized for 10 min at 37 ºC and resuspended 
in 1 mL PBS.  Cells were centrifuged at 500 x g for five min at room temperature and the 
supernatant discarded.  Cells were washed as described above to remove any traces of 
trypsin.  Cells were fixed and permeabilized using the IntraPrep
TM
 permeabilizing reagent 
(Beckman Coulter) as described in the kit protocol.  In brief, 50 μL of IntraPrep Reagent 
1 (5.5% formaldehyde) was added to the cells, vortexed vigorously and fixed for 15 min 
at room temperature.  Fixative was removed by centrifuging cells at 300 x g for five min 
at room temperature, supernatant discarded and cells washed with 1 mL PBS by 
centrifugation.  Cells were resuspended by vortexing and permeabilized by adding 50 μL 
of IntraPrep Reagent 2 (PBS-buffered saponin-based permeabilizing and lysing medium), 
mixed without vortexing and incubated for five min at room temperature.  After 
permeabilization, the permeabilizing reagent was removed, cells washed using cold 
incubation buffer [0.5% bovine serum albumin (BSA) in PBS], supernatant discarded and 
cells blocked for 10 min in incubation buffer at room temperature.  p21
Waf1/Cip1
 (12D1) 
rabbit mAbs (Cell Signaling Technology) were added at recommended working dilutions 
to the cells and incubated for one hour at room temperature.  Cells were washed twice as 
described above.  After washing, fluorescein isothiocyanate (FITC) conjugated goat anti-
rabbit IgG (H+L chain specific) (Beckman Coulter) was added at recommended working 
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dilutions.  FITC conjugated rabbit IgG, was added to untreated HeLa, HT-29 and MCF-7 
cancer cells and used as an isotype control.  Cells were incubated for 30 min at room 
temperature in the dark and washed as described above.  Cells were resuspended in 500 
μL PBS and read on a Beckman Coulter Cytomics FC500.   
 
 4.2.4.3   Results and Discussion 
 
DNA Cell Cycle Arrest.  Cell cycle arrest is characterized by a high proportion of cells 
found in the same cell cycle event at the same time after treatment with an anticancer 
compound or agent (Planchais et al., 2000).  Distribution of DNA content in human 
tumours plays an important role in identifying mechanisms or pathways involved in 
cancer and treatment (Jakobsen, 1983).  DNA cell cycle analysis was performed on 
HeLa, HT-29 and MCF-7 cancer cells after 15 hrs (Figure 4.8) and 48 hrs (Figure 4.9) of 
exposure to H. hemerocallidea, H. stellipilis and H. sobolifera extracts, and rooperol.   
 
DNA cell cycle arrest occurred in the late G1 and/or early S-phase of HeLa, HT-29 and 
MCF-7 cancer cells when treated with Hypoxis chloroform extracts and rooperol.  The 
G0/G1 peaks were much smaller than that of the control in all the Hypoxis treated cells 
(Figures 4.8-9).  The three Hypoxis extracts had similar effects on the three cancer cell 
lines after 15 hrs of exposure.  These effects include S-phase arrest and endoreduplication 
(ER).  After 48 hrs H. stellipilis and H. sobolifera had greater effects on the three cancer 
cell lines compared to H. hemerocallidea.  Rooperol has shown greater S phase arrest in 
the HT-29 and MCF-7 cancer cells, but less endoreduplication.  The opposite was seen 
for rooperol against the HeLa cancer cell line.  After 48 hrs, S phase arrest increased in 
HeLa cancer cells, while endoreduplication decreased.  Endoreduplication increases in 
rooperol treated MCF-7 cancer cells after 48 hrs.  DNA cell cycle arrest occurred in the S 
and G2/M phases when HT-29 cancer cells were treated with rooperol for 48 hrs.  In 
general, Hypoxis extracts and rooperol caused an increase in G2/M phase arrest in the 
three cancer cells after 48 hrs.  From the results obtained, it was not clear if cell cycle 
arrest occurred in the late Gl and/or early S phase in HeLa, HT-29 and MCF-7 cancer 
cells.   DNA cell cycle arrest in the late G1 and/or early S phase of the cell cycle in HeLa, 
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HT-29 and MCF-7 cancer cells was further investigated using the CDKI, p21
Waf1/Cip1
 (see 
below).   
 
                HeLa                                             HT-29                                           MCF-7 
 
 
 
 
 
 
 
                                                   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8:  Overlay of histograms representing DNA cell cycle arrest in HeLa, HT-29 and 
MCF-7 cancer cell lines after 15 hrs treatment with DMSO (0.25%; black), Hypoxis 
chloroform extract (125 μg/mL; blue) and rooperol (IC50 values; green).  Trout red blood 
cells were used as DNA reference calibrator (Appendix 4).  10 000 events were recorded.  
The experiment was repeated twice with similar results.  Abbreviation: ER = 
endoreduplication.  No results shown for HT29 cells treated with H. sobolifera extract at 15 
hours due to contamination.  See Figure 4.9 for 48 hrs results. 
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                     HeLa                                         HT-29                                          MCF-7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9:  Overlay of histograms representing DNA cell cycle arrest in HeLa, HT-29 and 
MCF-7 cancer cell lines after 48 hrs treatment with DMSO (0.25%; black), Hypoxis 
chloroform extract (125 μg/mL; blue) and rooperol (IC50 values; green).  Trout red blood 
cells were used as DNA reference calibrator (Appendix 4).  10 000 events were recorded.  
The experiment was repeated twice with similar results.  Abbreviation: ER = 
endoreduplication 
 
Rooperol played an important role in late G1 and/or early S phase arrest in all three 
cancer cell lines.  Hypoxoside present in the H. hemerocallidea and H. stellipilis 
chloroform extracts (Chapter 3, section 3.3) may have contributed to the cell cycle arrest.  
Although hypoxoside was absent in the H. sobolifera chloroform extract (Chapter 3, 
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section 3.3), unidentified/unknown compounds may have been responsible for DNA cell 
cycle arrest.  Cancer cell lines were treated with Hypoxis extracts in the presence of β-
glucosidase.  Awad et al. (2001a) and Moon et al. (2008a) have shown G2/M phase arrest 
in MDA-MB-231 human breast cancer cells, and U937 and HL60 leukemia cells, 
respectively, when treated with β-sitosterol.  Malíková et al. (2008) described G1 phase 
arrest in MCF-7, MDA-MB-468 and LNCaP cancer cells, and G2/M phase arrest in DU-
145 cancer cells when treated with brassinosteroids.   
 
A possible cell survival strategy, endoreduplication, was seen by the shift of histograms 
past the G2/M peak.    The occurrence of endoreduplication is described in Chapter 5. 
 
p21
Waf1/Cip1
 inhibitor activation.  p21
Waf1/Cip1
, belonging to the Kip1/Cip1 family of cyclin 
kinase inhibitors, plays an important role in all phases of the cell cycle.  p21
Waf1/Cip1 
levels 
(Figure 4.10) were determined in HeLa, HT-29 and MCF-7 cancer cells after H. 
sobolifera and rooperol treatment for 15 hrs.  H. sobolifera was the Hypoxis spp. with the 
best cytotoxicity against all three cancer cell lines investigated (section 4.2.2).  Due to 
limited amounts of antibodies available, H. sobolifera and rooperol (cytotoxic compound) 
were chosen to further investigate cell cycle arrest. 
 
                    HeLa                                          HT-29                                          MCF-7 
          
 
 
 
Figure 4.10:  Overlay of histograms representing p21
Waf1/Cip1 
expression in HeLa, HT-29 and 
MCF-7 cancer cell lines after 15 hrs treatment with DMSO (0.25%; red), H. sobolifera (125 
μg/mL; blue) and rooperol (IC50 values; green).  Percentages on histograms represent the 
increase in mean fluorescence intensity of cells staining positive for p21
Waf1/Cip1 
when treated 
samples were compared to the control.  Rabbit IgG was used as isotype control (black).  10 
000 events were recorded.  One representative of three experiments performed. 
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p21
Waf1/Cip1
 expression increased when HeLa, HT-29 and MCF-7 cancer cells were 
exposed to rooperol, and HT-29 and MCF-7 cancer cells exposed to H. sobolifera.  
p21
Waf1/Cip1
 was expressed at greater levels in HT-29 and MCF-7 cancer cells compared 
to HeLa cancer cells when treated with H. sobolifera.  Hypoxoside is absent in the H. 
sobolifera chloroform extract (Chapter 3, section 3.3), hence the increase seen in 
p21
Waf1/Cip1
 levels could not be due to hypoxoside conversion to rooperol and may be due 
to unidentified compounds present in the extract.  Another explanation may be the 
presence of β-sitosterol (4.5 μM) in the H. sobolifera chloroform extract.   Moon et al. 
(2008a) have shown an increase in p21 and CDK2 expression in human leukemia U937 
and HL60 cells following β-sitosterol (20 μM) treatment.  p21Waf1/Cip1 levels in this study 
could not be compared to those reported by Moon et al. (2008a) due to flow cytometry 
and Western blotting detection, respectively.  
 
As mentioned previously, p21
Waf1/Cip1
 levels increase during cell cycle arrest to inhibit 
cyclin D-CDK4/6 and cyclin A/E-CDK2 activities involved in G1-S progression.  It 
prevents complexes from loading CDC45 onto chromatin, which is necessary for DNA 
polymerase α recruitment into assembled pre-replication complexes, thus blocking the 
initiation of DNA replication.  It also prevents pRb phosphorylation, thus pRb inhibits 
E2F-dependent transcription of S phase genes for S phase entry (Coqueret, 2003; Kastan 
and Bartek, 2004; Nojima, 2004).  Considering the increased levels of p21
Waf1/Cip1
 
observed in this study, it is likely that this mechanism was activated by rooperol and H. 
sobolifera extract.  To confirm this, future studies can focus on cell cycle control 
mechanisms by measuring the activity of CDK2/4/6; cyclin A/D/E levels and 
phosphorylated and unphosphorylated pRB in cancer cells after treatment. 
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 4.2.5.  Caspase-3 and/or -7 activation 
  
 4.2.5.1.   Background 
 
Caspases play a central role in the morphological and biochemical features of apoptosis. 
The caspase family consists of at least 14 members and has the following unifying 
characteristics:  
 
 Caspases are cysteine proteases containing a conserved QACXG pentapeptide 
sequence surrounding the active site cysteine residues. 
 Caspases are constitutively and ubiquitously expressed as inactive proenzymes, 
each consisting of a large- and small subunit, and a prodomain. The latter is 
removed by proteolytic processing at a specific aspartate (Asp) residue and leads 
to caspase activation when the large and small subunits form a heterodimer. 
 Caspases cleave substrates and other procaspases at the carboxy-terminal of an 
Asp residue.  
 Caspases are arranged in a proteolytic cascade, which transmit and amplify the 
death signal (Cryns and Yuan, 1999; Elmore, 2007; Fadeel and Orrenius, 2004; 
Kagawa et al., 2001; Mc Gee et al., 2002). 
 
Individual caspases have the following differences:  
 
 Caspases have different substrate specificities e.g. WEXD (caspase-1, -4 and -5), 
DEXD (caspase-2, -3, and -7) and (L/V)EXD (caspase-6, -8 and -9). 
 Caspases are found at different locations in the cell.  Most caspases are localized 
in the cytoplasm; caspase-2 in the nucleus and Golgi aparatus; caspase-12 on the 
outer ER membrane; and caspase-2, -3 and -9 may be present in small quantities 
in the mitochondria. 
 The length and sequence of amino terminal prodomains namely long (caspase-1, -
2, -4, -5, -8, -9 and -10) and short (caspase-3, -6, -7 and -11) domains differ 
between caspases.  Two distinct protein-protein interaction modules are identified 
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in long domains namely (i) death effector domains of caspase-8 and -10 bind 
ligand-activated death receptors via adapter proteins, (ii) prodomains of caspase-
1, -2, -4 and -9 contain a caspase-recruitment domain (CARD) and mediates 
interaction between Apaf-1 and procaspase-9.  Prodomains provide a link 
between the death stimulus and caspase activation (Bratton and Cohen, 2001; 
Cryns and Yuan, 1999; Mooney et al., 2002). 
 
Caspases are divided into initiator/upstream (caspases-2, -8, -9 and -10), 
executor/effector/downstream (caspases-3, -6 and -7) and inflammatory (caspases-1, -4 
and -5) caspases.  Initiator caspases can be activated by the extrinsic and/or intrinsic 
pathways, which convert to the executors in the execution pathway as described in 
section 4.1.6.1.  Interaction between the two pathways amplifies the apoptotic signal.  
Caspase-8 induces apoptosis directly by cleaving executor procaspases or indirectly by 
cleaving Bid, which is associated with cytochrome c release from the mitochondria and 
procaspase-9 activation (Cryns ad Yuang, 1999; Elmore, 2007; Mc Gee et al., 2002; Sun 
et al., 1999).  Bid can be cleaved by low concentrations of caspase-8 and high 
concentrations of caspase-3 (Sun et al. 1999).  
 
Executor caspases cleave substrates responsible for morphological and biochemical 
features of apoptosis e.g. cytoskeletal rearrangement, cell membrane blebbing, nuclear 
condensation and DNA fragmentation (Mc Gee et al., 2002).  More than 100 proteins are 
cleaved by caspases e.g. regulatory proteins [poly-ADP-ribose polymerase (PARP)], 
cytoskeletal or structural proteins (e.g. α-fodrin, gelsolin, cytokeratins, actin), DNA 
fragmentation (ICAD), proteins involved in DNA replication, transcription and 
translation, kinases and phosphatases.  Many of the substrates‟ functions are poorly 
understood or unknown (Cryns and Yuang, 1999; Fadeel and Orrenius, 2005; Janicke et 
al., 1998; Kagawa et al., 2001; Mooney et al., 2002).  Caspase-6 cleaves lamins A and B, 
which are components of the inner nuclear membranes, and structurally related keratin 
18, but degradation may not account for morphological changes (Cryns and Yuang, 1999; 
Kagawa et al., 2001).  Cleavage of proteins can lead either to a gain-in-function (Bcl-
2/Bcl-XL converts from anti- to pro-apoptotic proteins; activation of PLCδ) or a loss-in- 
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function [structural proteins (e.g. cytokeratins, actin and lamins)] (Bratton and Cohen, 
2001).        
    
Mammalian IAPs [e.g. neuronal apoptotic inhibitory protein (NAIP), ML-IAP, 
XIAP/hILP, cellular inhibitor of apoptosis (e.g. cIAP-1/hIAP-2, cIAP-2/hIAP-1), and 
survivin] act by interacting with receptor complexes.  Anti-apoptotic mechanisms of 
some of these proteins are unclear.  IAPs (e.g. XIAP, ML-IAP, cIAP-1/2) mainly inhibit 
caspases directly.  XIAP inhibits caspase-3, -7 and -9, but not caspase-8.  NO and its 
reactive species (eNOS, iNOS, nNOS) are also inhibitors of caspases (Bratton and 
Cohen, 2001; Cryns and Yuan, 1999). 
 
Caspases play a central role in the morphological and biochemical features of apoptosis.  
This section focuses on caspase-3 and/or -7 activation in HeLa, HT-29 and MCF-7 cancer 
cells when treated with Hypoxis extracts and its purified compounds, hypoxoside and 
rooperol. 
 
 4.2.5.2.  Materials and Methods 
 
Whole cell caspase-3/7 kit.  HeLa, HT-29 and MCF-7 cancer cells were seeded at 
densities of 37 500 cells/mL in 96-well plates at 200 μl/well and left to attach overnight 
at 37 ºC in a humidified incubator and 5% CO2.  Cells were treated with DMSO (0.25%, 
v/v; negative control), Hypoxis extracts (125 μg/mL), hypoxoside [IC50 values (Table 
4.4)], rooperol [IC50 values (Table 4.4)] and cisplatin (10 μM; positive control) for 15 hrs 
as recommended in the kit‟s manual.  β-glucosidase (100 μg/mL) was added to Hypoxis 
and hypoxoside treated cells.  Caspase-3/7 activity was determined using the CellProbe
TM
 
HT Caspase-3/7 whole cell assay kit (Beckman Coulter, CA, USA) as described in the kit 
protocol.   In brief, after the incubation period, substrate [bis-N-CBZ-L-aspartyl-L-
glutamyl-L-valyl-L-aspartic acid amide derivative of rhodamine 110 (Z-DEVD-R110)] 
was diluted using the CellProbe HT buffer and 25 μL added to each well without mixing.  
Cells were incubated for a further one to three hrs at 37 °C.  Fluorescence was measured 
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at 485Ex/518Em using a Fluoroskan Ascent FL fluorometer.  Statistical significance was 
determined using the two-tailed Student‟s t-test. 
 
Cleaved caspase-3 (Asp175) and caspase-7 (Asp198) antibodies.  HeLa, HT-29 and 
MCF-7 cancer cells were seeded at densities of 40 000 cells/mL in 24-well plates and left 
to attach overnight at 37 ºC in a humidified incubator and 5% CO2.  Due to limited 
amounts of hypoxoside, rooperol and Hypoxis chloroform extracts, only rooperol 
(cytotoxic compound) and H. sobolifera (best cytotoxicity against HeLa, HT-29 and 
MCF-7 cancer cell lines) were chosen to perform caspase-3 and/or -7 experiments.  Cells 
were treated with DMSO (0.25%, v/v), rooperol [IC50 values (Table 4.4)] and H. 
sobolifera (125 μg/mL) for 48 hrs.  After exposure, cells were washed with PBSA, 
trypsinized for 10 min at 37 ºC and resuspended in PBS.  Cells were centrifuged at 500 x 
g for five min at room temperature and the supernatant discarded.   Cells were washed as 
described above to remove any traces of trypsin.  Cells were fixed and permeabilized 
using the IntraPrep
TM
 permeabilizing reagent as described in the kit protocol (see section 
4.2.4.).  After permeabilization, cells were washed using 1 mL cold incubation buffer 
(0.5% BSA in PBS), supernatant discarded and cells blocked for 10 min in 100 μL 
incubation buffer at room temperature.  Cleaved caspase-3 (Asp175) or -7 (Asp198) 
antibodies were added at recommended working dilutions to the cells and incubated at 
room temperature for one hour.  Cells were washed twice as described above.  After 
washing, FITC conjugated goat anti-rabbit IgG (H+L chain specific) was added at 
recommended working dilutions.  FITC conjugated rabbit IgG was added to untreated 
HeLa, HT-29 and MCF-7 cancer cells and used as an isotype control.  Cells were 
incubated for 30 min at room temperature in the dark and washed as described above.  
Cells were resuspended in 500 μL PBS and read on a Beckman Coulter Cytomics FC500.              
 
 4.2.5.3.  Results and Discussion 
 
Caspase-3 plays a central role in the apoptosis pathway for DNA fragmentation to occur.  
Due to the absence of activated caspase-3 in MCF-7 cancer cells, caspase-7 was 
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investigated as a possible role player for DNA fragmentation in the three cancer cell 
lines.   
 
Whole cell caspase 3/7 kit.  The nonfluorescent bisamide substrate (Z-DEVD-R110) 
enters the cell where it is enzymatically cleaved by caspase-3/7 to fluorescent monoamide 
and then to highly fluorescent rhodamine 110 free dye molecules.  Figure 4.11 
summarizes the caspase-3/7 activation results obtained. 
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Figure 4.11:  Detection of caspase 3/7 activities with the CellProbe HT Caspase 3/7 Whole 
Cell Assay in HeLa, HT-29 and MCF-7 cancer cell lines after 15 hrs treatment with Hypoxis 
extracts (125 μg/mL), hypoxoside (IC50 values) and rooperol (IC50 values).  Positive control 
= 10 μM cisplatin; negative control = 0.25% DMSO.  Error bars represent SEM values of 
quadruplicates.  One representative of two experiments performed.  Significance was 
determined using the two-tailed Student t-test: *p<0.005; #p<0.05 
 
Caspase-3/7 activity in HT-29 cancer cells was significantly increased by hypoxoside 
(p<0.005), H. hemerocallidea (p<0.05) and H. sobolifera (p<0.05), while caspase-3/7 
activity in MCF-7 cancer cells was significantly increased by hypoxoside (p<0.005), 
rooperol (p<0.05) and H. stellipilis (p<0.05).  Non-significant increases in caspase-3/7 
activity were seen when HeLa cancer cells were treated with hypoxoside, rooperol and H. 
stellipilis, and when HT-29 cancer cells were treated with rooperol and H. stellipilis.  The 
positive control, cisplatin, did not activate any caspase-3/7 activity in MCF-7 cancer 
cells.  Studies with cisplatin have shown caspase-3 activation in Hela (Horký et al., 2000) 
and CASP3 cDNA transfected MCF-7 (Blanc et al., 2000) cancer cells.  Increase of 
  * 
  * 
 * 
 # 
  # # 
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caspase-3/7 by cisplatin treatments in HeLa and HT-29 cancer cells was not significant 
(Figure 4.11), and may have been activated before 15 hrs.  The cisplatin concentration 
used (10 µM) may have been too low to see any caspase-3/7 activation after 15 hrs.  
MCF-7 cancer cells lack the CASP3 gene (Janicke, 1998), hence no caspase-3 could be 
activated and the increased caspase-3/7 activity was probably due to caspase-7 activity.   
 
Cleaved caspase-3 (Asp175) and caspase-7 (Asp198) antibodies.  Histogram overlays 
(Figures 4.12) show the activation of caspase-3 and/or -7 in HeLa and HT-29 cancer 
cells, and caspase-7 in MCF-7 cancer cells after 48 hrs exposure to H. sobolifera and 
rooperol.   
                        
                    HeLa                                      HT-29                                   MCF-7 
  
   
 
Figure 4.12:  Histogram overlays of activated caspase-3 and/or -7 in HeLa, HT-29 and 
MCF-7 cancer cells when treated with DMSO (025%; red), H. sobolifera (125 μg/mL; blue) 
and rooperol (IC50 values; green) for 48 hrs.  Percentages on histograms represent the 
increase in median fluorescence intensity of cells staining positive for active caspase-3 or -7 
when treated samples were compared to the control.  Rabbit IgG was used as isotype 
control (black).  10 000 events were recorded.  One representative of three experiments 
performed. 
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From the above histograms a shift to the right for treated samples compared to the DMSO 
control represented activation of caspase-3 and/or -7.  Caspase-3 and -7 were activated in 
HeLa cancer cells when treated with H. sobolifera and rooperol.  In HT-29 cancer cells, 
caspase-7 was mainly activated by H. sobolifera and rooperol, while rooperol activated 
more caspase-3 than H. sobolifera.  Rooperol mainly activated caspase-7 in MCF-7 
cancer cells.  From the results obtained, H. sobolifera and rooperol treatment activated 
more caspase-7 in HeLa and HT-29 cancer cells compared to caspase-3.  Janicke et al. 
(1998) have shown a deletion of 47 bp in exon 3 of the CASP3 gene in MCF-7 cancer 
cells.   
 
Increase in caspase activity (Figure 4.12) in HeLa and HT-29 cancer cells obtained with 
H. sobolifera treatment may be due to β-sitosterol content, because no hypoxoside was 
detected in the chloroform extract of H. sobolifera (Chapter 3, section 3.3).  Awad et al. 
(2003a) have shown that β-sitosterol (16 µM) activates caspase-3, -8 (extrinsic pathway) 
and -9 (intrinsic pathway) in MDA-MB-231 human breast cancer cells after 3 days of 
treatment.  A higher percentage of caspase-9 activated compared to caspase-8, suggests 
the preferential activation of the intrinsic pathway.  The effect of sterols on apoptosis 
may be indirect, following incorporation of β-sitosterol into the cell membranes.  β-
sitosterol had no effect on the concentration of caspases, but rather on their activity.  
Awad et al. (2008) have shown caspase-8 activation via Fas signalling (extrinsic 
pathway) in MDA-MB-231 and MCF-7 human breast cancer cells with β-sitosterol (8-16 
μM) treatment after three days.  Moon et al. (2008a) have shown an increase in caspase-3 
levels in human leukemia U937 and HL60 cells after β-sitosterol (>20 μM) treatment for 
96 hrs.  Longer exposure periods of cancer cells to Hypoxis extracts may have yielded 
higher caspase-3 and/or -7 activities.   
 
In summary, H. sobolifera and rooperol activated caspase-3 and/or -7 in HeLa, HT-29 
and MCF-7 cancer cells (Figure 4.12).  Caspase-3 and/or -7 activation plays a central role 
in apoptosis.  The effect of H. sobolifera and rooperol on apoptosis was confirmed by 
phosphatidylserine translocation and DNA fragmentation.  
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 4.2.6.  Phosphatidylserine translocation: annexinV binding 
 
 4.2.6.1 Background 
 
Viable cells maintain lipid asymmetry distribution of phospholipids in the cell‟s plasma 
membrane.  The outer- and inner membrane leaflets consist of choline-containing 
phospholipids (e.g. phosphatidylcholine, sphingomyelin) and aminophospholipids (e.g. 
PS, phosphatidylethanolamine), respectively (van Engeland et al., 1998).   
 
Lipid asymmetry is maintained by an active Mg
2+
 and ATP-dependent process, facilitated 
by translocases or flippases (Martin et al., 1995; van Engeland et al., 1998).   
Aminophospholipids are translocated from the outer to the inner leaflet and maintained in 
the inner leaflet of the plasma membrane by aminophospholipid translocase in normal 
healthy lymphocytes, platelets and erythrocytes.  Downregulation and inhibition of 
translocase during apoptosis cause scramblase (non-specific lipid flipsite) activation, 
which abolishes lipid asymmetry, by translocating phospholipids from the inner to the 
outer leaflet of the plasma membrane (Krahling et al., 1999; Verhoven et al., 1995).  
Translocase inhibition and scramblase activation have been seen at elevated cytoplasmic 
Ca
2+
 concentrations (in platelets and erythrocytes), suggesting a role for Ca
2+
 as 
secondary messenger for PS presentation (Verhoven et al., 1995).  Disruption of plasma 
membrane-associated phospholipid-binding cytoskeletal proteins (e.g. spectrin, fodrin), 
which maintain lipid asymmetry, may also be involved in phospholipid translocation 
(Martin et al., 1995; van Engeland et al., 1998).  Phospholipids are rapidly distributed to 
both leaflets by flowing around rupture points during necrosis or plasma membrane 
rupture (Martin et al., 1995).      
 
PS appearance on the outer membrane leaflets lasts from the early execution phase until 
the final stages (i.e. apoptotic body formation) of apoptosis (van Engeland et al., 1998).  
PS externalization to the outer membrane leaflet occurs after disruption of the 
mitochondrial transmembrane potential and initiation of the caspase proteolytic cascade, 
but before morphological changes like cell shrinkage, chromatin condensation, 
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degradation of cytoskeletal (e.g. cytokeratin)- and nuclear proteins (e.g. nuclear lamins), 
DNA strand breaks, loss of plasma membrane integrity and membrane blebbing.    
 
PS translocation is not unique to apoptosis, but also occurs in cells undergoing necrosis 
(Martin et al., 1995; Pepper et al., 1998; van Engeland et al., 1996; van Engeland et al., 
1998).  Annexin V is a 35 kDa Ca
2+
 dependent (mM concentration), phospholipid-
binding protein binding reversibly and with high affinity to negatively charged PS 
(Figure 4.13) (Aubry et al., 1999; van Engeland et al., 1996; van Engeland et al., 1998; 
Vermes et al., 1995).  Martin et al. (1995) have shown that Annexin V binds only to PS 
and no binding occurred with phosphatidylcholine, phosphatidylinositol, phosphatidic 
acid, sphingomyelin and phosphatidylethanolamine. 
 
 
 
Figure 4.13:  Translocation of PS from the inner plasma membrane leaflet to the outer 
plasma membrane leaflet.  Annexin V binds with high affinity to PS (van Engeland et al., 
1998). 
A membrane impermeable dye [e.g. propidium iodide (PI)] is used to discriminate 
between early apoptotic and necrotic or dead cells.  PI measures the integrity of the cell 
membranes by entering necrotic cells with permeable membranes, but is excluded from 
apoptotic cells (Aubry et al., 1999; Koopman et al., 1994; Vermes et al., 1995).   Studies 
with Annexin V (labelled with the fluorochrome conjugate, FITC) and PI have revealed 
four populations of cells namely unstained or viable cells (Annexin 
neg
, PI 
neg
), early 
apoptotic cells (Annexin 
pos
, PI 
neg
), late apoptotic cells (Annexin 
pos
, PI 
pos
) and unviable, 
necrotic or permeabilized cells (Annexin 
neg
, PI 
pos
) (Aubry et al., 1999). 
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Increased membrane permeability is associated with late apoptosis (Annexin 
pos
, PI 
pos
), 
which is also known as secondary necrosis.  Late apoptotic cells normally exclude PI, as 
loss of membrane integrity does not occur until apoptotic cells are engulfed by 
macrophages in vivo.  Phagocytes are absent when cells are cultured in vitro, thus 
membrane permeability in late apoptosis occurs when dying cells detach from the culture 
dish surface and disintegrate into apoptotic bodies (Martin et al., 1995; Pepper et al., 
1998; van Engeland et al., 1996).  PS exposure is regulated by changes in energy 
metabolism (ATP dependent), bivalent cation (Mg
2+
, Ca
2+
) concentrations, cytoskeletal 
organization (Koopman et al., 1994) and can be inhibited by caspase inhibitors (Fadeel et 
al., 1999; van Engeland et al., 1998).   
 
No inflammation is associated with apoptosis because (i) apoptotic cells do not release 
their cellular constituents into the surrounding tissue, (ii) apoptotic cells are quickly 
phagocytosed by surrounding cells preventing secondary necrosis, (iii) engulfing cells do 
not produce anti-inflammatory cytokines (Elmore, 2007; Verhoven et al., 1995).  
 
PS externalization is a cell type-specific event occurring only in certain cell types (e.g. 
CEM, Jurkat, U937 but not in HL-60, P39, Raji) as shown by Fadeel et al. (1999); hence 
PS cannot be used as the only marker for apoptosis.  Translocase or scramblase PS 
externalization is not a compulsory component of apoptosis, which may explain the 
absence of PS translocation in certain cells.  Caspase activation and other proteolytic 
enzymes such as calpain may play a role in PS translocation.  It is proposed that fodrin, a 
component of the plasma membrane-associated cytoskeleton, is involved in the 
rearrangement of plasma membrane PS, but no correlation has been shown by Fadeel et 
al. (1999).  
  
PS translocation plays an important role in the elimination of apoptotic cells, via 
recognition by phagocytes.  The effects of Hypoxis extracts and rooperol on PS 
translocation were investigated in premonocytic human leukemia U937 cells in order to 
confirm apoptosis induction observed in the previous section.  
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 4.2.6.2.  Materials and Methods 
 
Premonocytic human leukemia U937 cells were seeded at 100 000 cells/mL in 24-well 
plates, treated with DMSO (0.25%, v/v), Hypoxis extracts (125 μg/mL), rooperol (20 
μg/mL) and cisplatin (50 μM), and incubated for 15 and 48 hrs at 37 ºC in a humidified 
incubator and 5% CO2.  After the incubation periods, cells were transferred to 
polypropylene tubes and cells collected by centrifuging at 500 x g for five min at room 
temperature.  Cells were washed in ice-cold Dulbecco‟s Modified Eagle‟s Medium 
(DMEM), treated and stained according to the protocol of the Annexin V-FITC 
Apoptosis Detection kit (Beckman-Coulter).  In brief, cells were washed with cold 
DMEM and centrifuged at 500 x g for five min at 4 °C.  Supernatant was discarded and 
cell pellets resuspended in ice-cold 1X binding buffer.  Annexin V-FITC (1 μL; 25 
μg/mL) and PI (5 μL; 250 μg/mL) were added to each tube.  Compensation control tubes 
contained cells with Annexin V-FITC only, PI only and combination of Annexin V-FITC 
and PI.  Tubes were gently mixed and incubated on ice for 15 min in the dark.  Samples 
were read within 30 min on a Beckman Coulter Cytomics FC500.   
 
 4.2.6.3.  Results and Discussion  
 
The suspension culture, U937 cells, was used for the investigation of membrane integrity 
to avoid false positive results caused by the dissociation of adherent cells (van Engeland 
et al., 1998).  Dot plots (Figures 4.14-15) represent annexin V binding and PI staining of 
U937 cells after treatment with H. sobolifera and rooperol. 
 
Treatment of U937 cells with rooperol (Figure 4.14ii) and cisplatin (Figure 4.14iii) 
stained Annexin-V positive and PI negative after 15 hrs of exposure.  After 48 hrs most 
of the cells stained positive for PI and negative for Annexin-V (Figure 4.15).  No changes 
were observed in Annexin-V or PI staining after 15 and 48 hrs treatment with Hypoxis 
extracts (Appendix 4).    
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A(i) (ii) (iii)  
 
 
Β(i) (ii) (iii)  
 
 
C(i) (ii) (iii)  
 
 
Figure 4.14:  Dot plots (A) and histograms (B and C) of Annexin V-FITC and PI stained 
U937 cells after 15 hrs exposure to DMSO (0.25%; i), rooperol (20 μg/mL; ii) and cisplatin 
(50 μM; iii).  Four quadrants represent unstained/viable cells (A3: Annexin V neg, PI neg), 
early apoptotic cells (A4: Annexin V 
pos
, PI 
neg
), late apoptotic cells (A2: Annexin V 
pos
, PI 
pos
) 
and necrotic cells (A1: Annexin V 
neg
, PI 
pos
).  20 000 events were recorded.  One 
representative of three experiments performed. 
 
Rooperol altered the plasma membranes of U937 cells, as was evident from the 
translocation of PS from the inner to the outer leaflet of the plasma membranes.  Binding 
of Annexin V to PS after 15 hrs of rooperol and cisplatin treatment is an indication of 
early apoptosis (Figure 4.14ii-iii).   
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A(i) (ii) (iii)  
 
Β(i) (ii) (iii)  
 
C(i) (ii) (iii)  
 
Figure 4.15:  Dot plots (A) and histograms (B and C) of Annexin V-FITC and PI stained 
U937 cells after 48 hrs exposure to DMSO (0.25%; i), rooperol (20 μg/mL; ii) and cisplatin 
(50 μM; iii).  Four quadrants represent unstained/viable cells (A3: Annexin V neg, PI neg), 
early apoptotic cells (A4: Annexin V 
pos
, PI 
neg
), late apoptotic cells (A2: Annexin V 
pos
, PI 
pos
) 
and necrotic cells (A1: Annexin V 
neg
, PI 
pos
).  20 000 events were recorded.  One 
representative of three experiments performed. 
 
After 48 hrs exposure to rooperol and cisplatin, late apoptosis and necrosis were seen 
with more cells stained by PI.  Annexin V is used to measure early apoptosis (Aubry et 
al., 1999); hence the best staining of PS by Annexin occurred after 15 hrs of treatment.  It 
is important to use PI (or similar dye) with Annexin V to show that the integrity of the 
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cell membrane is still maintained.  During early apoptosis the plasma membrane is still 
intact, but becomes leaky with the onset of late apoptosis in vitro.  This is referred to as 
secondary necrosis.  Exposed PS is recognized by macrophages in vivo for phagocytosis 
of the dying cell (Aubry et al., 1999; van Engeland et al., 1998).  This data is supported 
by Albrecht et al. (1995a) who have shown the formation of pores in the outer 
membranes of UCT-Mel 1 melanoma cells after hypoxoside treatment, hence 
destabilizing the outer membranes, while phase contrast and scanning electron 
micrographs have shown the formation of vacuoles and cells undergoing blebbing, 
respectively.  H. hemerocallidea, H. stellipilis and H. sobolifera showed no early or late 
apoptosis with Annexin V.  This was expected as these Hypoxis chloroform extracts 
contained very little or no hypoxoside (Chapter 3, section 3.3).  The major suspected 
active compound in the Hypoxis chloroform extracts used in this study is β-sitosterol 
(Chapter 3, section 3.3), which will rather be incorporated in the cell membranes over 
time where it may influence signalling pathways.   
  
 4.2.7.  DNA fragmentation 
 
4.2.7.1.   Background 
 
Caspases-3 and -7 are the only caspases that activate the DNA fragmentation factor, 40-
kDa subunit (DFF40 in humans)/caspase-activated DNase (CAD in mice) by cleaving the 
DNA fragmentation factor, 45-kDa subunit (DFF45)/inhibitor of CAD (ICAD).  ICAD 
has a bifunctional role in the cytoplasm by inhibiting CAD‟s endonuclease activity and 
ensuring correct folding of CAD – a chaperone-like function (Fadeel and Orrenius, 2005; 
Janicke et al., 1998; Nagata, 2000; Wolf et al., 1999; Yuste et al., 2001).  CAD, 
synthesized on ribosomes during protein synthesis, requires Mg
2+
 for DNase activity and 
functions at neutral pH (Nagata, 2000).  ICAD is cleaved at two Asp residues (Asp 117 
and Asp 224) to release active CAD, which will degrade DNA at internucleosomal 
regions.  This can be detected as a DNA ladder on an agarose gel (Yuste et al., 2001).  
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DNA fragmentation is a two-step process where DNA is firstly cleaved (randomly; but 
prefer AT-rich sequences) into 50-300 kbp fragments (high molecular weight DNA 
degradation) and secondly degraded into smaller inter(oligo)nucleosomal fragments 
(DNA ladder) of 180-200 bp (Marini et al., 1996; Nagata, 2000; Oberhammer et al., 
1993; Yuste et al., 2001).  Initial DNA degradation, due to DNA cleavage at nuclear 
scaffolds, may unfold the chromatin structure to expose spacer regions of nucleosomes 
(Nagata, 2000).  Three hundred kbp and 50 kbp fragments may arise due to the release of 
rosettes or loops of chromatin, respectively, as they detach from attachment points on the 
nuclear scaffolding proteins (Oberhammer et al., 1993).  In contrast to CAD, 
mitochondrial or pro-apoptotic proteins [e.g. apoptosis inducing factor (AIF) and 
endonuclease G] enter the nucleus and induce high molecular weight DNA fragmentation 
without activating the caspase pathway (Elmore, 2007; Fadeel and Orrenius, 2005; Mc 
Gee et al., 2002; Wolf et al., 1999).  DNA laddering is not found in all cell lines, hence 
internucleosomal cleavage is not a prerequisite for apoptotic morphology because 
specific cell types do not exhibit the endonucleolytic pathway.  DNA laddering appears to 
be cell type and agent-specific (Marini et al., 1996).  Only high molecular weight DNA 
degradation may be essential for cell death, because several cell types (e.g. breast 
carcinoma-derived cell line MCF-7, human androgen-independent prostatic cancer cell 
DU-125, human neuronal-like cell NT2, human neuroblastomas IMR-5 and -32, and 
human neuroblastoma IMT-5) never produce DNA laddering with treatments that induce 
typical cytoplasmic and nuclear changes of apoptosis (Oberhammer et al., 1993; Yuste et 
al., 2001). 
 
DNA fragmentation may play an important role in cleaving chromosomal DNA before 
phagocytosis to avoid transformation by activated oncogenes or viral genes, reduce 
autoimmune diseases, transfer oncogenes from the apoptotic cells to phagocytes and 
healthy cells, and accelarate apoptosis (Nagata, 2000; Yuste et al., 2001).  Apoptosis 
assessment only by biochemical features must be interpreted with caution, because DNA 
fragmentation is not essential for apoptosis and must be defined with morphological 
features (Cohen et al., 1992).     
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DNA fragmentation is an important biochemical feature of late apoptosis.  This section 
focuses on DNA fragmentation in HeLa, HT-29 and MCF-7 cancer cells when treated 
with H. sobolifera and rooperol to provide further evidence of apoptosis induction.   
 
 4.2.7.2.  Materials and Methods 
 
HeLa, HT-29 and MCF-7 cancer cells were seeded in 24-well plates at densities of 40 
000 cells/mL and left to attach overnight at 37 ºC in a humidified incubator and 5% CO2.  
Cells were treated with DMSO (0.25%, v/v), H. sobolifera (125 μg/mL) rooperol [IC50 
values (Table 4.4)] and cisplatin (50 μM) for 48 hrs.  Cells were washed with PBSA, 
trypsinized for 10 min and resuspended in PBS.  Cells were washed with PBS by 
centrifugation at 500 x g for five min at room temperature to remove trypsin, fixed and 
permeabilized using the IntraPrep
TM
 Permeabilizing kit according to the kit protocol.  
DNA fragmentation was investigated using the MEBSTAIN Apoptosis Kit Direct 
(Immunotech, Marseille, France) and the protocol followed as described in the product 
insert.  In brief, terminal deoxynucleotidyl transferase (TdT) reaction reagent (30 uL), 
consisting of TdT buffer, FITC-dUTP and TdT in 18:1:1 (v/v/v) ratio, was added to each 
cell pellet and incubated in the dark for one hour at 37 °C.  The negative control 
contained untreated cells with TdT buffer and FITC-dUTP [19:1 (v/v) ratio] only.  Cells 
were washed as described above and the pellet resuspended in 500 uL of PBS.  Samples 
were analyzed on a Beckman Coulter Cytomics FC500.  Mean fluorescence intensity 
(MFI) of treated cells was expressed as a percentage of the MFI of control cells.  
Statistical significance was determined using the two-tailed Student‟s t-test. 
    
 4.2.7.3.  Results and Discussion  
 
DNA strand breaks in apoptotic cells are detected by 3‟ OH termini labelling with 
fluorochrome-conjugated nucleotides in a reaction using exogenous TdT known as the 
TdT dUTP nick end labelling (TUNEL), TdT assay or in situ end-labelling (Gorczyca, 
1999).  DNA fragmentation is characteristic of late apoptosis and was investigated in 
HeLa, HT-29 and MCF-7 cancer cells.  Only the density plots of treated HT-29 cancer 
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cells are shown in Figure 4.16A.  Density plots for HeLa and MCF-7 cells are shown in 
Appendix 4.  Figure 4.16B summarizes all the DNA fragmentation of treated and 
untreated HeLa, HT-29 and MCF-7 cancer cells.   
                                   
                                   
 
Figure 4.16:  DNA fragmentation after 48 hrs exposure to treatments.  Density plots (A) of 
DMSO (0.25%, v/v), H. sobolifera (125 μg/mL), rooperol (IC50 values) and cisplatin (50 μM) 
treated HT-29 cancer cells.  Bar graph (B) of untreated and treated HeLa, HT-29 and 
MCF-7 cancer cells.  Bar graph percentages represent the increase in mean fluorescence 
intensity of cells staining positive for DNA fragmentation when treated samples were 
compared to control.  10 000 events were recorded.  Bar graph represents the average of 
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three individual experiments.  Significance was determined using the two-tailed Student t-
test: *p<0.05, **p<0.005 compared to control. 
 
More DNA fragmentation [and significant results (Figure 4.16B)] occurred when HeLa 
and HT-29 cancer cells were treated with H. sobolifera, and HT-29 and MCF-7 cancer 
cells treated with rooperol.  DNA fragmentation is clearly shown by a shift from region B 
to E in the density plots (Figure 4.16A).  H. sobolifera significantly increased DNA 
fragmentation in HeLa (p<0.05) and HT-29 (p<0.005) cancer cells, whereas rooperol 
significantly increased DNA fragmentation in HT-29 (p<0.05) and MCF-7 (p<0.05) 
cancer cells. H. sobolifera and rooperol did not significantly increased DNA 
fragmentation in MCF-7, while rooperol had no effect on HeLa cancer cells.  From 
Figure 4.16 it is clear that MCF-7 cancer cells underwent DNA fragmentation after 
treatment with H. sobolifera (not significantly) and rooperol (significantly).   
 
Caspase-7 was activated in MCF-7 cancer cells after treatment with H. sobolifera and 
rooperol (section 4.2.5.).  McGee et al. (2002) and Semenov et al. (2004) have also 
shown DNA fragmentation of MCF-7 cancer cells after caspase-7 activation.  It is 
suggested that caspase-3 and -7 are primary and secondary initiators of DNA 
fragmentation, respectively (Wolf et al., 1999).  H. sobolifera treatment of HeLa, HT-29 
and MCF-7 cancer cells caused DNA fragmentation, but apoptosis was absent in the 
Annexin V study after H. sobolifera treatment.  For the Annexin V study U937 cells were 
used, which may explain the absence of apoptosis after H. sobolifera treatment.  Presence 
of β-sitosterol (4.5 μM) in the H. sobolifera extract may have played a role in DNA 
fragmentation.  Moon et al. (2008a) have shown extensive DNA fragmentation in human 
leukemia U937 and HL60 cells after β-sitosterol (>20 μM) treatment for 96 hrs.  
 
DNA fragmentation is a late apoptosis event (Collins et al., 1997b) and was only 
measured after 48 hrs of treatment with H. sobolifera and rooperol in the cancer cell 
lines. Wolf et al. (1999) showed that only caspase-3 and -7 promote DFF45/ICAD 
inactivation, DFF40/CAD release and DNA fragmentation in vitro.  They also showed 
that caspase-3 cleaves the inhibitor more rapidly than caspase-7; hence it may take 
caspase-7 longer to initiate DNA fragmentation.  Longer treatments may be required in 
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cells lacking functional caspase-3 e.g. MCF-7 cells.  Apoptotically activated caspase-7 is 
almost exclusively associated with mitochondria and microsomes (Semenov et al., 2004), 
which may take longer (via intrinsic pathway) to exert its DNA fragmentation function, 
than caspase-3 directly cleaved by the extrinsic pathway.  
 
Caspase-3 may be important for oligonucleosomal DNA fragmentation, but other non-
caspase proteases like calpains (cleave cytoskeletal protein fodrin and cause membrane 
blebbing), cathepsin D (lysosomal protease), endonuclease G and AIF may be involved in 
cell death.  Mitochondrial endonuclease G has shown DNA fragmentation (Kagawa et al. 
2001; Mc Gee et al., 2002). 
 
The H. sobolifera extract caused DNA fragmentation in the three cancer cell lines 
investigated, while rooperol caused DNA fragmentation in HT-29 and MCF-7 cancer 
cells.  Caspase-3 and/or -7 activation in H. sobolifera treated HeLa, HT-29 and MCF-7 
cancer cells may explain DNA fragmentation.  DNA fragmentation in rooperol treated 
HeLa cancer cells may have occurred before 48 hrs; hence the absence of DNA 
fragmentation.   
 
 4.3.  Conclusion 
 
Cytotoxicity studies of the three Hypoxis spp. have revealed differences in their 
anticancer properties.  Hypoxis spp. differed in their cytotoxic effects, which may be 
attributed to the differences in hypoxoside and phytosterol contents (Chapter 3, section 
3.3).  Certain Hypoxis spp. may promote cancer cell growth, as was the case with H. 
stellipilis.  H. stellipilis is also the most commonly sold Hypoxis spp. in herbal shops in 
the Port Elizabeth area of the Eastern Cape.  The observation of growth stimulation by H. 
stellipilis and the widely reported use of African potato to treat various cancers raise 
some concern and merits further investigation.   
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No previous publications could be found on rooperol‟s mechanism of action in HeLa, 
HT-29 and MCF-7 cancer cells, or any other cancer cell line.  Biochemical analysis of 
apoptosis in the present study has revealed: 
 
 DNA cell cycle arrest in the late G1 and/or early S phase after 15 hrs of 
treatment, which was confirmed by increase p21
Waf1/Cip1
 expression.  G2/M phase 
arrest occurred after 48 hrs of treatment. 
 Activation of caspase-3 and -7 in HeLa and HT-29 cancer cells, and caspase-7 in 
MCF-7 cancer cells. 
 Phosphatidylserine translocation in U937 cells confirmed early- and late 
apoptosis. 
 DNA fragmentation in HeLa, HT-29 and MCF-7 cancer cells. 
 
H. sobolifera, the Hypoxis spp. with the best cytotoxicity and no detectable levels of 
hypoxoside (thus no rooperol formed), revealed similar trends to rooperol in HeLa, HT-
29 and MCF-7 cancer cells as listed above, except for the absence of phosphatidylserine 
translocation in U937 cells.  Cytotoxicity and mechanism of action of sterols may be time 
dependent.  Previous studies have shown effects over a minimum of 3 days, which may 
explain the weak responses obtained with Hypoxis spp. containing relatively high β-
sitosterol contents in this study, where a maximum incubation period of 48 hours was 
used.   
  
This study mainly focused on Hypoxis and rooperol‟s mechanisms of action from the 
start of the execution pathway to phagocytosis.  The intrinsic and extrinsic pathways may 
have been activated in the cancer cells, and may provide important information regarding 
the mechanisms of action for Hypoxis spp. and rooperol.  Caspase-8 and -9 activation in 
the extrinsic and intrinsic pathways, respectively, can be investigated using fluorescently 
labelled primary antibodies.  Signal transduction pathways [anti (Bcl-XL)- and pro-
apoptotic (Bim, Bax, cytochrome c) proteins] involved in the intrinsic pathway can also 
be investigated using fluorescently labelled primary antibodies and flow cytometry.  A 
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loss in mitochondrial membrane potential and calcium flux play an important role in 
apoptosis and can be investigated using appro 
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CHAPTER 5 
CELL SURVIVAL: ENDOREDUPLICATION 
 
5.1.  General Background 
 
5.1.1.  Definition 
 
Endoreduplication is characterized by two or more successive rounds of DNA replication, 
in the absence of mitosis.  This results in the formation of diplochromosomes, consisting 
of four chromatids instead of the normal two (Cortés et al., 2004; Erenpreisa and Cragg, 
2001; Sugimoto-Shirasu and Roberts, 2003; Sutou and Tokuyama, 1974).  Three types of 
endoreduplication are found, namely (i) multiple initiations within a given S phase, (ii) 
reoccurring S phase and (iii) repeated S and gap phases.  Endoreduplication represents an 
incomplete cell cycle, which is orderly regulated.  The occurrence of endoreduplication in 
high metabolic tissues, for example the endosperm of developing maize kernels and the 
silk glands of dipterans, is more common (Grafi, 1998).   
 
5.1.2.  Inducers  
 
Endoreduplication can occur spontaneously or can be induced by physical treatments 
(e.g. cold temperatures, X-rays), chemical compounds or mutagens (e.g. α- and β-
mercaptoethanol, β-mercaptopyruvate, 8-azaguanine, nitrogen mustard, colchicine, 6-
mercaptopurine, piperazine derivative, 4-nitroquinoline, 1-oxide, acridine dyes, captan, 
Cytoxan), protein kinase inhibitors, lectins, and metabolic and mitotic inhibitors (Bottura 
and Ferrari, 1963; Grafi, 1998; Sutou and Tokuyama, 1974). 
 
Spontaneous endoreduplication is commonly found in plants, especially in the meristem 
regions of roots, stems and leaves, large specialized cells accumulating sharp inorganic 
inclusions, nodule cells, endosperm and xylem cells (Figure 5.1; Hase et al., 2005; John 
and Qi, 2008; Sugimoto-Shirasu and Roberts, 2003).  Endoreduplication is rarely found 
in animals and occur in dipteran salivary glands, tonsils, trophoblasts, giant cells of the 
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placenta, mammalian liver, human lymphocytes, Chinese hamster cells and tumour cells 
(Cortés and Pastor, 2003; Cortés et al., 2004; Huang et al., 1985).  
 
 
Figure 5.1:  Diplochromosome formation during metaphase in the root meristem cells of 
Allium cepa, following acetaldehyde treatment (Cortes et al., 2004). 
 
5.1.3.  Mechanism of action 
 
The induction mechanisms of endoreduplication are still largely unclear due to a variety 
of agents inducing endoreduplication and the different cell types where it occurs.  
Chemical and physical agents inducing endoreduplication by disrupting cytoskeleton 
assembly include colcemid, colchicines, concanavalin A, nocodazole, taxol and 
vincristine, and those that damage DNA include X-rays, α-radiation, hydrazine, sodium 
arsenite/fluoride, mitomycin C, aphidicolin, halogenated nucleosides, zorubicin and 
33258 Hoechst (Cortés et al., 2004). 
 
Cytoskeleton assembly.  The mitotic spindle checkpoint monitors the spindle microtubule 
structure, chromosome alignment and the attachment of spindle microtubules to 
kinetochores on the sister chromatids during mitosis.  Chromosome segregation during 
anaphase is delayed until defects in the mitotic spindle are corrected (Moon et al., 2008a; 
Stewart et al., 1999).  Improper attachment of spindle microtubules to kinetochores may 
cause longer cell cycle arrest and apoptosis, whereas failed sister chromatid segregation 
can lead to cell cycle arrest with tetraploid (4N) DNA content and endoreduplication.  
The latter has been investigated with the microtubule interfering agent, taxol.  
Microtubules are important for cell replication, division, maintenance of cell shape, and 
 107 
cellular movement.  They undergo a dynamic process of polymerization and 
depolymerization (Moon et al., 2008a).  Mitotic abnormalities may be due to mutation or 
inhibition of mitotic proteins controlling chromosome alignment and segregation (Cortés 
et al., 2004).   
 
Cyclin and CDK.  Cyclin degradation or expression, and active or inactive CDKs play an 
important role in mitosis and endoreduplication.  MacAuley et al. (1998) investigated 
cyclin and CDK expression during the transition from DNA replication to 
endoreduplication in the rat choriocarcinoma derived cell line, Rcho-1 (Figure 5.2).  S 
phase initiation during mitotic- and endocycles involves cycles of cyclin A and E 
synthesis.  Cyclin E is expressed in the cytoplasm, enters the nucleus and initiates DNA 
synthesis and cyclin A expression.  Cyclin A is required for S phase completion.  Cyclins 
E and A are rapidly degraded at the end of DNA synthesis, which may be a requirement 
to reinitiate another endocycle by activating the origins of activation (Grafi, 1998; 
MacAuley et al. 1998).  Failed assembly of cyclin B and CDK1, phosphorylation of 
CDK1 by CHK1, and an inactive cyclin B-CDK1 complex may be responsible for G2/M 
phase arrest (Erenpreisa and Cragg, 2001; John and Qi, 2008; MacAuley et al., 1998; 
Sugimoto-Shirasu and Roberts, 2003).  Cyclin A/E-CDK2 activities are re-activated and 
DNA synthesis reinitiated during the first endocycle.  At the end of the first endocycle S 
phase, cyclins A, B and E are degraded.  Initiation of a second endocycle occurs in a gap 
phase when cyclin A/E-CDK2 activities are absent, which may be necessary to reset the 
cycle for the next DNA replication.  DNA synthesis is reinitiated when cyclin A/E-CDK2 
is reactivated (McAuley et al., 1999). 
 
Cyclin B is expressed in abundance during the first endocycle, but not at all during the 
following endocycles.  This may be due to the start of the first endocycle in the G2 phase 
of the mitotic cell cycle.  The presence of cyclin B in the first endocycle may be due to 
failed activation of rapid cyclin B degradation associated with mitosis.  In the mitotic cell 
cycle, cyclin B is expressed towards the end of the G2 phase.  Cyclin B induction may 
depend on G1-S cyclin-CDK activity and termination of cyclin A/E-CDK2 activity at the 
end of the endocycle‟s S phase (McAuley et al., 1998).      
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Figure 5.2:  The role of cyclins in the mitotic- and endocycles in the rat choriocarcinoma cell 
line, Rho1 (McAuley et al. 1998).  See text for more detail. 
 
DNA topoisomerase II.  DNA topoisomerase II plays an important role in condensation 
and anaphase segregation of replicated daughter chromosomes.  DNA topoisomerase II 
levels peak in the G2 phase and early mitosis.   Inhibitors of topoisomerase II activity 
prevent sister chromatid separation after chromosome condensation, resulting in cell 
cycle arrest in the metaphase (Figure 5.3).  Anticancer drugs, interfering with DNA 
topoisomerase II, are divided into classical „poisons‟ for example anthracyclines, 
epipodophyllotoxins, anthracenediones and aminoacridines, and true catalytic inhibitors 
for example merbarone, fostriecin, aclarubicin, suramin, novobiocin, chloroquine, and 
bisdioxopiperazines.  Classical „poisons‟ cause DNA strand breaks by forming a stable, 
cleavable complex between the covalently bound topoisomerase II and DNA.  True 
catalytic inhibitors do not form a cleavable complex and target DNA topoisomerase II 
directly within the cells and interfere with genetic processes for example replication, 
transcription and chromosome dynamics.  „Poisons‟ and catalytic inhibitors can both 
cause endoreduplication (Cortés and Pastor, 2003; Cortés et al., 2004).      
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Figure 5.3:  Comprehensive model of endoreduplication proposed by Cortes et al. (2004). 1) 
Normal chromosome segregation during mitosis (proper function of topoisomerase II and 
the spindle apparatus); 2) endoreduplication due to interference with cytoskeletal assembly 
(proper function of topoisomerase II, but not the spindle apparatus); 3) endoreduplication 
due to the absence of topoisomerase II activity (poisoning or inhibiting agents); 4) 
endoreduplication due to modification of DNA, thus hindering topoisomerase II binding 
(physical or chemical damage; incorporation of base analogues).  
 
Neukam et al. (2008) have shown inhibition of topoisomerase II activity and 
endoreduplication in AA8 Chinese hamster ovary cells when treated with the tea 
flavanols, epigallocatechin-3-gallate and epigallocatechin at micromolar concentrations, 
and catechin and epicatechin at millimolar concentrations.  The flavonoids, quercitin and 
luteolin, also cause topoisomerase II inhibition and endoreduplication (Neukam et al., 
2008).   
 
 
 
 
              1                        2                         3                          4  
 110 
5.2.  Anti-apoptotic Proteins – Cell Survival   
 
5.2.1.  Background 
 
Akt and phospho-Akt.  Survival factors, including serum, cytokines and growth factors 
[e.g. insulin-like growth factor 1 (IGF-1), neurotrophins, insulin, platelet-derived growth 
factor (PDGF)], play important roles in providing anti-apoptotic signals, which is 
involved in homeostasis (Brunet et al., 1999; Frank et al., 1995; Kennedy et al., 1997).  
Survival factors activate phosphatidylinositol 3-kinase (PI-3K), which phosphorylates 
phosphatidylinositol-4-phosphate to phosphatidylinositol-3,4-bisphosphate.  The 
serine/threonine kinase, Akt/PKB, binds phosphatidylinositol-3,4-bisphosphate at the cell 
membrane, dimerizes and is stabilized in a partially active form.  Membrane location 
and/or dimerization enhance the ability of Akt/PKB to be phosphorylated by PDK1/2 
(Frank et al., 1997).  Akt‟s ability to deliver the survival signal depends on its kinase 
activity and activity of its upstream activator, PI-3K (Kennedy et al., 1997).  
 
Akt promotes cell survival by phosphorylating and suppressing caspase-9 activity and 
Bad functions, which are important pro-apoptotic proteins involved in the apoptotic 
intrinsic pathway (Brunet et al., 1999). Brunet et al. (1999) have shown Akt 
phosphorylation of the human Forkhead family of transcription factors (FKHRL1) in the 
presence of survival factors, which interacts with the scaffolding protein 14-3-3.  
Phosphorylated FKHRL1 is retained in the cytoplasm and FKHRL1 related transcription 
inhibited.  Upon survival factor withdrawal, FKHRL1 gets dephosphorylated, enters the 
nucleus and regulates the activity of transcription factors that control cell death genes, for 
example the Fas ligand.  Cell survival, associated with increased Akt levels, is seen in 
granule and cerebellar neurons, PC12, Rat-1 and COS-7 cells (Frank et al., 1997).  Ras 
and Src may activate PI-3K (Franke et al., 1997; Kennedy et al., 1997).  
 
The PI-3K/Akt signalling pathway may also act through modulating Bcl-2 expression, 
but Kennedy et al. (1997) have shown no significant changes in Bcl-2 and Bcl-XL levels. 
They did find inhibition of Ced3/ICE-like proteases that specifically cleave PARP in 
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fibroblasts upon growth factor withdrawal.  Inhibition of apoptosis by activated Akt may 
be the same or greater than the anti-apoptotic effect exerted by insulin, IGF-1 and PDGF, 
but these effects are lower than the anti-apoptotic effect exerted by serum.  Downstream 
effectors of growth factor receptors, namely Raf, Ras and Src molecules, were not 
effective in promoting cell survival once the growth factors, especially serum, were 
removed.  Akt/PKB activation, associated with cell survival, depends on the signal and/or 
cell type used. 
 
Akt is involved in increased NO synthesis, cell survival, glycogen synthesis, cell growth 
and proliferation.  Akt targets and inhibits glycogen synthase kinase (GSK)-3, via 
phosphorylation, which may block apoptosis.  The mechanism is still unknown, but it is 
possible that GSK-3 may activate the adenomatous polyposis coli (APC) protein, which 
may accelerate apoptosis by degrading β-catenin and inhibiting adhesion (Frank et al., 
1997; Kennedy et al., 1997).  
 
Phospho-Bcl-2.  The Bcl-2 family members are multifunctional proteins, which 
homodimerize with themselves (e.g. Bax, Bim, Bad) or heterodimerize with each other 
(e.g. Bcl-2, Bcl-XL with Bax, Bak), and bind non-homologous proteins (Bcl-2 and Bcl-
XL interact with Apaf-1, protein kinase Raf-1, Ca
2+
-activated phosphatase calcineurin, 
p53 binding protein) (Reed, 1998).  The Bcl-2 family consists of pro- and anti-apoptotic 
proteins involved in apoptosis and cell survival, respectively.  The ratio of Bcl-2 family 
members influences cell survival or apoptosis.  The most highly expressed Bcl-2 family 
members are Bcl-2 and Bax (Frommel and Zarling 1999; Gross et al., 1999). 
 
Bcl-2 proteins contain C-terminal hydrophobic domains and are integral proteins 
localized to cellular membranes of the ER, outer mitochondrial membrane and nuclear 
envelope.  Bax, a pro-apoptotic protein mainly found in the cytosol, is translocated to the 
mitochondria when receiving a death signal.  Upon dimerization, Bax inserts into the 
mitochondrial membrane and cytochrome c is released.  Cytochrome c is released due to 
(i) pore formation in the mitochondrial membrane resulting in a loss in membrane 
potential, or (ii) a change in the inner membrane potential resulting in osmotic swelling 
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of the mitochondria and rupturing of the outer mitochondrial membrane.  Cleavage of the 
C-terminal hydrophobic domain of Bax prevents its insertion into the mitochondrial 
membrane (Gross et al., 1999; Murphy et al., 2000; Reed, 1998).  
 
Bcl-2 prevents cytochrome c release by preventing a loss in mitochondrial membrane 
potential across the inner membrane.  A loss in mitochondrial membrane potential is 
associated with the opening of large conductance inner membrane channels, by Bax, 
which may be regulated by Bcl-2.  Bcl-2 could also protect mitochondria by preventing 
Bax-induced pores in the outer mitochondrial membrane (Gross et al., 1999; Murphy et 
al., 2000; Reed, 1998).  Murphy et al. (2000) have shown that Bcl-2 prevents Bax 
translocation from the cytosol to the mitochondria.  They also suggested that Bcl-2 
occupies the insertion site of Bax or control upstream events necessary for Bax insertion, 
due to localization in the ER and nuclear envelope.  Furthermore, is it unlikely that the 
mechanism of Bcl-2/Bax heterodimer formation occurs, due to their localization to 
separate subcellular compartments.   
 
p21
Waf1/Cip1
.  p53 prevents structural chromosome abnormalities and control diploid 
chromosome numbers possibly by maintaining the G1-S cell cycle and spindle 
checkpoints.  p53 deficiency is associated with karyotopic instability, which include 
chromosome breaks or instability, endoreduplication and polyploidy (Agapova et al., 
1996 and 1999; Illidge et al., 2000).  p21
Waf1/Cip1/Sdi1
 expression is upregulated by p53-
dependent and -independent mechanisms.  p53-independent factors include the 
transforming growth factor (TGF)-β and mimosine, an agent affecting DNA replication 
(Bates et al., 1998; Chang  et al., 2000; Datto et al., 1995; Roninson, 2002).  p21
Waf1/Cip1
 
interactions and functions include (i) inhibition of cyclin A/E-CDK2 and cyclin B-CDK1, 
or stimulation of cyclin D-CDK4/6 complexes; (ii) bind the replication or repair protein, 
proliferating-cell nuclear antigen (PCNA), which is a cofactor for DNA polymerase δ and 
ε during replication and enhances the polymerase activity; (iii) binds regulatory proteins, 
which may inhibit or stimulate transcription (Bates et al., 1998; Flores-Rozas et al., 1994; 
Roninson, 2002; Stewart et al., 1999).  Overproduction of p21
Waf1/Cip1
 leads to cell growth 
arrest in the G1 and G2 phases, due to p21
Waf1/Cip1
 ability to inhibit cyclin-CDK 
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complexes (Bates et al., 1998; Chang et al., 2000; Niculescu et al., 1998).  p21
Waf1/Cip1
 is 
a tumour suppressor which prevents or slows down tumour development, but mutations 
are associated with human cancers and affects its role as CDK inhibitor  (Roninson, 
2002).  See Chapter 4 (section 4.2.4) for more information. 
 
The observation from the previous chapter that rooperol and Hypoxis extracts induce 
endoreduplication prompted an investigation into the possible cell survival strategy of 
HeLa, HT-29 and MCF-7 cancer cells when treated with H. sobolifera and rooperol.  The 
expression of the anti-apoptotic proteins, phospho-Akt, phospho Bcl-2 and p21
Waf1/Cip1
, 
were measured and the cell morphology investigated.    
 
5.2.2.  Materials and Methods 
 
Anti-apoptotic proteins.  HeLa, HT-29 and MCF-7 cancer cells were seeded at densities 
of 40 000 cells/mL in 24-well plates and left to attach overnight at 37 ºC in a humidified 
incubator and 5% CO2.  Cells were treated with DMSO (0.25%, v/v), H. sobolifera (125 
μg/mL) and rooperol [IC50 values (Table 4.4)] for 15 hrs.  After exposure, cells were 
washed with PBSA, trypsinized for 10 min at 37 ºC and resuspended in PBS.  Cells were 
centrifuged at 500 x g for five min at room temperature and the supernatant discarded.  
Cells were washed as described above to remove any traces of trypsin.  Cells were fixed 
and permeabilized using the IntraPrep
TM
 permeabilizing reagent as described in the kit 
protocol.  After permeabilization, cells were washed using cold incubation buffer (0.5% 
BSA in PBS), centrifuged as describe above, supernatant discarded and cells blocked for 
10 min in incubation buffer at room temperature.  Akt, phospho-Akt (Ser473) and 
phospho-Bcl-2 (Ser70)(5H2) rabbit mAbs (Cell Signaling Technology Inc.) were added 
at recommended working dilutions to the cells and incubated for one hour at room 
temperature.  Cells were washed twice as described above.  After washing, FITC 
conjugated goat anti-rabbit IgG (H+L chain specific) (Beckman Coulter) was added at 
recommended working dilutions.  FITC conjugated rabbit IgG, was added to untreated 
HeLa, HT-29 and MCF-7 cancer cells and used as an isotype control.  Cells were 
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incubated for 30 min at room temperature in the dark and washed as described above.  
Cells were resuspended in PBS and read on a Beckman Coulter Cytomics FC500.   
 
Phase contrast light microscopy.  HeLa, HT-29 and MCF-7 cancer cells were seeded at 
densities of 40 000 cells/mL in 24-well plates and left to attach overnight at 37 ºC in a 
humidified incubator and 5% CO2.  Cells were treated with DMSO (0.25%, v/v), H. 
sobolifera (125 μg/mL) or rooperol [IC50 values (Table 4.4)] for 48 hrs.  After treatment, 
cells were washed with PBSA, trypsinized for 10 min at 37 °C, resuspended in PBS and 
viewed under an Axiovert 40C inverted microscope (Carl Zeiss MicroImaging, 
Göttingen, Germany) with a Ph2-0.4 filter and 40x objective.  Photos were taken with a 
PowerShot A640 digital camera (Canon, China). 
 
4’6-diaminidine-2’-phenylindole dihydrochloride (DAPI) fluorescence staining.  HeLa, 
HT-29 and MCF-7 cancer cells were seeded at densities of 40 000 cells/mL onto 13 mm 
round glass coverslips (acid washed with 1 M HCl, 70% EtOH and autoclaved), placed 
into 24-well plates, and left to attach overnight at 37 ºC in a humidified incubator and 5% 
CO2.  Cells were treated with DMSO (0.25%, v/v) and rooperol [IC50 values (Table 4.4)] 
for 48 hrs.  After treatment, medium was aspirated, cells washed with DPBS (containing 
Ca
2+
 and Mg
2+) and fixed with Carnoy‟s fixative (MeOH: acetic acid, 3:1, v/v) for 10 
min.  Cells were stained with DAPI (1μg/mL dissolved in 100% MeOH, Sigma) for 10 
min at room temperature in the dark, washed with DPBS and coverslips mounted cell 
side down in glycerol: PBSA (90:10, v/v).  Images were taken using an OLYMPUS 
BX60 fluorescence microscope, XC50 camera and AnalySIS
®
 FIVE software 
(LifeScience Series). 
 
Forward- and side scatter.  Dot plots of forward scatter versus side scatter were obtained 
during DNA cell cycle analysis performed in Chapter 4 (section 4.2.4) to observe 
changes in cell size. 
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5.2.3.  Results and Discussion 
 
Anti-apoptotic proteins.  Three survival signalling proteins were investigated namely 
phospho-Akt, phospho-Bcl-2 (Figure 5.4) and p21
Waf1/Cip1
 (Chapter 4; Figure 4.10). 
 
                  HeLa                                 HT-29                             MCF-7                                          
           
           
           
Figure 5.4:  Overlay of histograms representing phospho-Akt and phospho-Bcl-2 levels in 
HeLa, HT-29 and MCF-7 cancer cell lines after 15 hrs of treatment with DMSO (0.25%; 
red), H. sobolifera (125 μg/mL; blue) and rooperol (IC50 values; green).  Percentages on 
histograms represent the increase in median fluorescence intensity of cells staining positive 
for phospho-Akt and phospho-Bcl-2
 
when treated samples were compared to the control.  
Rabbit IgG was used as isotype control (black).  10 000 events were recorded.  One 
representative of three experiments performed.   
 
This study has shown an increase in phospho-Akt levels in H. sobolifera and rooperol 
treated HeLa, HT-29 and MCF-7 cancer cells, whereas the unphosphorylated Akt levels 
remained the same (data not shown).  H. sobolifera increased phospho-Bcl-2 levels in 
HeLa and HT-29 cancer cells, whereas rooperol increased phospho-Bcl-2 levels in HT-29 
and MCF-7 cancer cells.  Increases in p21
Waf1/Cip1
 levels were seen when all three cancer 
cell lines were treated with rooperol, whereas H. sobolifera induced smaller increases in 
p21
Waf1/Cip1
 expression in HT-29 and MCF-7 cancer cells and no increase in HeLa cancer 
cells (data shown in Figure 4.10; Chapter 4).  Increased phospho-Akt, phospho-Bcl-2 and 
p21
Waf1/Cip1
 levels in H. sobolifera treated HeLa, HT-29 and MCF-7 cancer cells could 
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not be attributed to rooperol, because hypoxoside was absent in the H. sobolifera 
chloroform extract, and trace amounts of hypoxoside which may have been present could 
not be converted to rooperol due to the absence of β-glucosidase.  Increased 
phosphorylation of Akt, Bcl-2 and p21
Waf1/Cip1
 was probably due to the presence of β-
sitosterol (4.5 μM), trace amounts of other phytosterols (Chapter 3, section 3.3) and/or 
unidentified compounds.  The possibility of synergistic and additive effects between 
different compounds cannot be ruled out. 
 
Moon et al. (2008a) investigated the effect of β-sitosterol on endoreduplication via the 
Bcl-2 and PI-3K/Akt signalling pathways in human leukemia U937, HL60 and K562 
cells.  These studies used higher concentrations (10-30 μM) of β-sitosterol and longer 
treatment periods (24-96 hrs), compared to the low β-sitosterol concentrations present in 
the Hypoxis chloroform extract (4.5 μM) and shorter treatment time (15 hrs) used.  To 
have a better idea on the expression levels of anti-apoptotic proteins, mRNA levels 
should be measured.   
 
Increased phospho-Akt may have promoted cell survival in HeLa, HT-29 and MCF-7 
cancer cells, following H. sobolifera and rooperol treatment, by (i) phosphorylating and 
suppressing caspase-9 and Bad functions and/or (ii) phosphorylating the human Forkhead 
transcription factor, FKHRL1; hence preventing transcription of genes associated with 
cell death (Brunet et al., 1999).  Moon et al. (2008a) have shown an increase in PI-3K 
and Akt phosphorylation, while total PI-3K and Akt levels remained constant over 96 hrs, 
when U937 cells were treated with β-sitosterol (20 μM).  The inhibitor of PI-3K, 
LY29004, blocked β-sitosterol induced endoreduplication, resulting in an increase in cell 
numbers with sub-G1 DNA content (apoptotic cells) (Moon et al., 2008a).  Cell survival, 
via the PI-3K/Akt-NF-κB pathway, was also seen in chemotherapeutic resistant MCF-7 
cancer cells (Simstein et al., 2003).  
 
Increased (phospho)-Bcl-2 levels may have promoted cell survival in HeLa, HT-29 and 
MCF-7 cancer cells, following H. sobolifera and/or rooperol treatment, by preventing 
Bax translocation from the cytosol to the mitochondria and subsequent Bax-mediated 
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release of mitochondrial cytochrome c.  Inhibition of Bax translocation has been seen in 
HeLa cancer cells, treated with staurosporine and etoposide, which overexpress Bcl-2 
(Murphy et al., 2000).  Follicular lymphoma, a B-cell malignancy, is generally incurable 
and is characterized by overexpression of the Bcl-2 oncogene, which inhibits apoptosis.  
Follicular lymphoma differs from benign follicular lymphoma by increased Bcl-2 and 
phospho-Akt (Ser473) expression, and higher ratios of Bcl-2/Bax and Bcl-2/Bak 
(Gulmann et al., 2005).  Treatment of U937 cells with β-sitosterol (>20 μM; 24 hrs) 
resulted in increased Bcl-2 phosphorylation and endoreduplication.  The Bcl-2 inhibitor, 
HA14-1, blocked β-sitosterol induced endoreduplication, resulting in an increase in cell 
numbers with sub-G1 DNA content (hence apoptotic cells) (Moon et al., 2008a).  Moon 
et al. (2008b) have shown that Bcl-2 overexpression prevents SP660125 [c-Jun N-
terminal kinase (JNK) inhibitor]-induced apoptosis in U937 leukemia cells by inhibiting 
caspase-3, -8 or -9 cleavage, inducing G2/M phase arrest and promoting 
endoreduplication.  Overexpression of Bcl-2 counteracts SP660125-induced death by 
preventing Bcl-2 and Bcl-XL repression and maintaining AIP levels.  JNK, a member of 
the mitogen-activated protein kinases (MAPK), has apoptotic, cell survival and 
proliferation properties.  JNK substrates include Bcl-2, Bcl-XL, p21
Waf1/Cip1
 and p53.  
JNK phosphorylates p53 changing it to a more stable conformation, which leads to 
increased p21
Waf1/Cip1
 expression, cyclin B-CDK1 inhibition and G2/M arrest.  Treatment 
of MCF-7 and MDA MB-231 breast cancer cells with the JNK inhibitor, SP660125, 
resulted in G2/M cell arrest and endoreduplication.  G2/M arrest is associated with 
increased p21
Waf1/Cip1
 expression, which inhibits cyclin B-CDK1 activity.  JNK inhibition 
may prevent JNK dissociation from p21
Waf1/Cip1
 and inhibition of cyclin B-CDK1 activity 
(Mingo-Sion et al., 2004). 
 
Increased p21
Waf1/Cip1
 expression (Chapter 4, section 4.2.4) may have promoted cell 
survival in HeLa, HT-29 and MCF-7 cancer cells, following H. sobolifera and/or 
rooperol treatment, by affecting the cell cycle.  p21
Waf1/Cip1
 plays an important role in cell 
growth arrest associated with DNA damage and often triggering endoreduplication and 
abnormal chromosome segregation (Roninson, 2002).  It may inhibit topoisomerase II 
activity involved in segregation of replicated daughter chromatids before anaphase.  
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Topoisomerase II mRNA levels peak towards the end of S phase and start of the G2/M 
phase (Cortés and Pastor, 2003).  β-sitosterol treatment increased p21Waf1/Cip1 and CDK2 
expression, which is important for entry into the S phase, in U937 and HL60 cells (Moon 
et al., 2008a).  p21
Waf1/Cip1
 could promote endoreduplication by partial inhibition of 
CDKs.  Incomplete inhibition of cyclin E/A-CDK2 by p21
Waf1/Cip1
 may allow sufficient 
activity for initiation of replication, but not enough to proceed to mitosis (Bates et al., 
1998; Niculescu et al., 1998).  Anti-apoptotic functions of p21
Waf1/Cip1
 are attributed to 
procaspase-3 binding, which prevent its conversion to active caspase-3, interactions with 
caspase-8 and -10, inhibition of apoptosis-regulating kinases and apoptosis-stimulating 
transcription factors (Roninson, 2002). 
 
p21
Waf1/Cip1/Sdi1
 may induce growth arrest associated with the depletion of mitotic- and 
replication-associated proteins, which leads to abnormal mitosis and endoreduplication 
(Cortés et al., 2004; Mingo-Sion et al., 2004).  Chang et al. (2000) have shown a 
decrease in the RNA levels of genes controlling different stages of mitosis, when HT1080 
human fibrosarcoma cells were treated with isopropyl-β-thio-galactosidase (IPTG), 
which induces p21
Waf1/Cip1
 expression.  These include CDK1 and cyclin B involved in the 
mitosis initiating complex; polo-like kinases involved in mitosis onset, mitotic 
checkpoint control and cytokinesis; CDK1 interacting protein (CKsHs1) involved in the 
mitotic checkpoint control; centrosome associated kinesin (MCAK); centrosome-
associated kinase (AIK1) involved in spindle formation; proteins involved in spindle 
checkpoint (e.g. CENP-A/P, MAD2, BUBR1); and proteins involved in cytokinesis (e.g. 
Prc1, Aim1, citron kinase).  Maintaining high p21
Waf1/Cip1
 levels long enough will deplete 
the cellular pool of mitosis control proteins.  Mitosis-initiating proteins need to be 
regenerated after p21
Waf1/Cip1
 shutoff before cells can enter mitosis.  If these proteins are 
not re-synthesized to sufficient levels, abnormal mitosis will occur (Chang et al., 2000).   
 
Cell cycle arrest, associated with endoreduplication, occurs mainly in the G2/M phase.  
G2/M phase arrest occurred when U937 and HL60 leukemia cells (Moon et al., 2008a) 
and MDA-MB-231 breast cancer cells (Awad et al., 2001a) were treated with β-
sitosterol.  In this study, G2/M phase arrest occurred in HeLa, HT-29 and MCF-7 cancer 
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cells when treated with Hypoxis extracts and rooperol for 48 hrs (Chapter 4; section 
4.2.4). β-sitosterol present in the Hypoxis extracts may have caused G2/M phase arrest.  
G2/M arrest may be explained by the inability of cells to activate cyclin B.  Activation of 
cyclin B-CDK1 may depend on prior activation of CDK2 activity.  p21
Waf1/Cip1
 mediated 
arrest could block cell cycle progression in late S or early G2/M phase prior to cyclin B-
CDK1 activation, hence the importance of cyclin A-CDK2 in S-phase exit.  Cells blocked 
in the G2/M phase by p21
Waf1/Cip1
 are impaired in their ability to sense their position in 
the cell cycle following release, hence entering another S phase and endoreduplication 
occurs (Bates et al., 1998).  Sutou and Tokuyama (1974) investigated endoreduplication 
in a Chinese hamster cell line when treated with 4-nitroquinoline.  Endoreduplicated cells 
were found in the late S phase and mainly in the G2/M phase.  After the gap phase, the 
cells entered a long S phase, which is equivalent to two ordinary S phases.  The long S-
phase may be explained by a shortage in precursors to produce double the amount of 
DNA needed for diplochromosomes (Sutou and Tokuyama, 1974).    
 
β-sitosterol may further promote endoreduplication and apoptosis by altering microtubule 
dynamics and thus interfering with spindle formation during mitosis.  It also induces 
ERK phosphorylation, which is involved in cell survival, but had no effect on JNK and 
p38 MAPK phosphorylation, which are involved in apoptosis (Moon et al., 2008a).   
        
Phase-contrast light and DAPI fluorescence microscopy.  Morphological studies on 
HeLa, HT-29 and MCF-7 cancer cells revealed the presence of enlarged („giant‟) cells 
(Figure 5.5) and nuclei (Figure 5.5 and 5.6), associated with endoreduplication, when 
treated with rooperol.   
 
Phase-contrast microscopy (Figure 5.5) has shown the presence of „giant‟ cells with 
enlarged nuclei, and intact plasma and nuclear membranes after rooperol treatment.  
Apoptotic cells were also seen among the „giant‟ cells.  Chromatin condensation, cell 
membrane blebbing and apoptotic body formation were seen in HT-29 (data not shown), 
HeLa and MCF-7 cancer cells, which are characteristic morphological features of 
apoptosis.  This may suggest that apoptosis follows endoreduplication in certain cells. 
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                                      DMSO control                                Rooperol                            
 
Figure 5.5:  Phase-contrast photographs of HeLa and MCF-7 cancer cells when treated with 
rooperol (IC50 values) compared to the DMSO control (0.25%, v/v).  Enlarged cells 
represent „giant cells‟, which have undergone endoreduplication.  Long arrow represents an 
apoptotic cell with membrane blebbing and apoptotic body formation.  Short arrow 
represents an enlarged nucleus with condensed chromatin.  Bar = ±25 μm. 
 
DAPI microscopy (Figure 5.6) has shown the presence of enlarged nuclei with intact 
nuclear membranes in the „giant‟ cells.  Chromatin condensation and ruptured nuclei, 
associated with apoptosis, were also seen among the „giant‟ cells.   
 
The nuclear-to-cytoplasm ratio ensures that the amount of cytoplasm that a cell can make 
and sustain is proportional to the amount of DNA in the nucleus.  Thus the 
endoreduplicated nucleus can sustain greater cell growth.  Increase in cells size and 
polyploidy may be due to enhanced gene expression and protein synthesis by ribosomes 
(Sugimoto-Shirasu and Roberts; 2003).  An increase in nucleus size was also reported 
when cells were treated with β-sitosterol (Moon et al., 2008a).   
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                                              DMSO control                                    Rooperol 
 
Figure 5.6:  Fluorescence images of DAPI stained HT-29 and MCF-7 cancer cells when 
treated with rooperol (IC50 values) compared to the DMSO control (0.25%, v/v).  Enlarged 
nuclei represent „giant cells‟, which have undergone endoreduplication.  Arrow represents 
condensed chromatin.  Bar = ±5 μm. 
 
An increase in forward- and side scatter represents an increase in cell size and granularity 
or complexity, respectively, which further confirms endoreduplication.  Dot plots of H. 
sobolifera and rooperol treated HeLa, HT-29 and MCF-7 cancer cells have shown an 
increase in side- and/or forward scatter (Figure 5.7).  These dot plots correspond with the 
phase contrast- and fluorescence (DAPI) photos taken.  An increase in forward- and side 
scatter were seen when U937 and HL60 cells were treated with β-sitosterol (Moon et al., 
2008a).   
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                       HeLa                                              HT-29                                                  MCF-7 
 
 
 
 
Figure 5.7:  Dot plots of forward scatter (FS) vs side scatter (SS) of HeLa, HT-29 and MCF-
7 cancer cells when treated with H. sobolifera (125 μg/mL) and rooperol (IC50 values) for 48 
hrs. 
 
Sensitive tumours respond to treatment and undergo apoptosis rapidly, whereas drug 
resistant tumours respond partially to treatment with delayed death or surviving the death 
signal (Erenpreisa and Cragg, 2001; Illedge et al., 2000).  Tumours may become resistant 
when treated continuously; hence cytotoxic agents are administered every 3-4 weeks with 
short exposure periods (Puig et al., 2008).  Endoreduplication may be part of the cell 
survival strategy, which may be followed by apoptosis.  The majority of cells undergoing 
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endoreduplication die, whereas only a few will survive.  During endoreduplication, 
resistant cells have the ability to repair DNA damage resulting in polyploidy, whereas 
rapid apoptosis will stop any possibility of DNA repair.  Polyploid giant cells have been 
regarded as reproductively dead, but giant polyploid cells are actively undergoing DNA 
replication with an exchange between the endocyclic and mitotic populations (Illedge et 
al., 2000).   
     
In vivo treatment of tumours with cisplatin results in tumour shrinkage and formation of 
giant tumour cells that do not proliferate but undergo DNA synthesis.  After several 
weeks of latency, the tumour resumes progression and consists of small, diploid, rapidly 
proliferating cells.  In vitro treatment of tumour cells has shown an initial stop of mitotic 
activity, but DNA duplication continued (Puig et al., 2008).  Giant polyploid cells can die 
through mitotic catastrophe, but many polyploid cells survive for weeks as non-
proliferative mono- or multi-nucleated giant cells acquiring a „senescence phenotype‟. A 
limited number of extensive colonies, consisting of small diploid cells differing from 
parental cells by abnormal chromosomal and increased resistance to cytotoxic drugs, 
form from the giant cells.  DNA endoreduplication, polyploidy, depolyploidization and 
the generation of escape cells are characteristics of tumour relapse after chemotherapy 
(Puig et al., 2008). 
 
Endoreduplication and genetic destabilization of tumour cells may be a consequence of 
radiation therapy and chemotherapy.  Such genetic destabilization may lead to certain 
cells to bypass normal cell cycle arrest and apoptotic mechanisms, resulting in increased 
malignancy or treatment resistant tumour cells (Chang et al., 2000; Niculescu et al., 
1998).  Giant cell formation may be an important repair response after cancer treatment 
and provide the tumour with an additional mechanism of resistance and survival of death 
signals (Illedge et al., 2000). 
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5.3.  Conclusion 
 
Endoreduplication seen in the DNA histograms (Chapter 4, section 4.2.4) has led to the 
investigation of endoreduplication in HeLa, HT-29 and MCF-7 cancer cells treated with 
H. sobolifera (Hypoxis spp. with the best cytotoxicity) and rooperol (cytotoxic 
compound).  Morphological and biochemical analysis revealed: 
 
 „Giant‟ cell formation with enlarged nuclei (phase-contrast and DAPI) is 
associated with endoreduplication. 
 An increase in size and granularity/complexity are associated with 
endoreduplication. 
 Activation of the anti-apoptotic proteins: phospho-Akt, phospho-Bcl-2 and 
p21
Waf1/Cip1
.  
 Increased levels of p21Waf1/Cip1 confirms late G1/early S phase cell cycle arrest 
after 15 hrs. G2/M phase arrest occurring after 48 hrs may explain 
endoreduplication (Chapter 4, section 4.2.4).  
 
Endoreduplication is a possible cell survival strategy, which may be followed by 
apoptosis.  Apoptotic cells (morphological characteristics: chromatin condensation, cell 
blebbing and apoptotic body formation) were seen among the endoreduplication cells.  
Endoreduplication seen in this study may suggest cancer cells becoming resistant to 
Hypoxis extracts and its purified compounds, which may be of importance and interest 
for further studies. 
 
This is the first time that endoreduplication was investigated in cancer cells following 
Hypoxis and rooperol treatment. 
 
Peer-reviewed journal articles accepted/submitted from chapters 4 and 5 
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CHAPTER 6 
ANTI-INFLAMMATORY ACTIVITY 
 
6.1.  General Background 
 
Inflammation is a response to tissue injury triggered by physical or chemical stimuli and 
microbiological toxins to inactivate or destroy invading organisms, remove irritants and 
initiate tissue repair.  It is involved in different pathologies including arthritis, asthma, 
multiple sclerosis, colitis, inflammatory bowel disease and atherosclerosis.  The initial 
response in inflammation involves the release of lipid-derived autacoids (e.g. 
eicosanoids), large peptides (e.g. cytokines), small peptides (e.g. bradykinin) and amines 
(e.g. histamine) from injured and migrating cells.  These give rise to the clinical and 
pathological signs and symptoms of inflammation, which include vascular permeability, 
vasoconstriction, vasodilation, pain, fever, chemotaxis and leukocyte adhesion, tissue and 
endothelial damage (Guzik et al., 2003). 
 
Eicosanoids are divided into prostaglandins, thromboxanes and leukotrienes, which are 
biologically active metabolites derived from the 20-carbon polyunsaturated fatty acid, 
arachidonic acid (AA) (Nelson and Cox, 2000; Shale et al., 1999).  Eicosanoids mediate 
and modulate the action of a variety of biological processes; are produced on demand; 
target parent or neighbouring cells (paracrine effect) and have a short biological life 
(Rocca and FitzGerald, 2002).  
 
AA is released from the membrane phospholipid bilayer via cytosolic phospholipase A2 
(cPLA2) activity in response to physical, chemical, hormonal and cytokine stimuli.  AA is 
converted to prostaglandin H2 (PGH2) via PGH-synthase [syn. cycloxygenase (COX)-1/2; 
see section 6.4] activity in a two step reaction, involving (i) cyclization of AA to form the 
endoperoxidase intermediate, PGG2 (cyclooxygenase activity), and (ii) reduction of the 
15-hydroperoxy group to form PGH2 (peroxidase activity).  PGH2 is converted to 
biologically active prostaglandins (PGE2, PGE2α, PGD2 and PGI2) and thromboxanes 
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(TxA2 and TxB2) by cell-specific prostaglandin synthases (Awad et al., 2005b; Clancy et 
al., 2000; Gasparini et al., 2003; Rocca and FitzGerald, 2002).   
 
Thromboxanes are produced in platelets and are involved in blood vessel constriction and 
blood coagulation.  PGs are found in almost all living animal cells, tissues and glands, 
where they are associated with erythema (redness) and edema (swelling) leading to heat 
and pain (Shale et al., 1999).  PGs regulate physiological and pathological processes 
including platelet aggregation, inflammation, pain, uterine contraction during ovulation, 
labour and abortion, mucin secretion to protect gastric mucosa from acid and proteolytic 
enzymes in the stomach, blood flow to organs, wake-sleep cycle, bone metabolism, body 
temperature, embryo implantation, nerve growth and development, wound healing, 
glomerular filtration and water balance, blood vessel tone and immune responses (Dubois 
et al., 1998; Nelson and Cox, 2000; Sheng et al., 2001).   
 
Leukotriene (LT) synthesis is triggered by bacteria, viruses, fungi, protozoa, IgG, and C3.  
It involves the oxidation of AA by 5-lipoxygenase in the presence of the AA-binding 
protein, 5-lipoxygenase activating protein (FLAP), to form the epoxide intermediate 
LTA4 (Peters-Golden et al., 2004; Rocca and FitzGerald, 2002).  LTA4 is (i) hydrolysed 
by LTA4 hydrolase to LTB4, which is a leukocyte chemoattractant and activator; or (ii) is 
conjugated to reduced glutathione by LTC4 synthase to form LTC4, which is involved in 
the pathogenesis of asthma and is the parent compound of the cysteinyl LTs (cysLTs) 
LTD4 and LTE4.  LTB4, cysLT or both are synthesized primarily by neutrophils and 
dendritic cells, mast cells and eosinophils, and macrophages, respectively.  
 
Other functions of LTs include leukocyte accumulation to the inflammation site, 
enhanced phagocytosis and amplified microbicidal mechanisms (increasing NO and ROS 
release), generation of inflammatory mediators including cytokines (e.g. TNFα, IL-8) and 
chemokines (e.g. MCP-1, MIP-1β), bronchoconstrictors and vasoactive mediators 
released by mast cells (contributing to asthmatic responses), and contraction of the 
muscle lining of the airways to the lungs.  LT synthesis is regulated by genetic, 
endogenous (e.g. hormones, cytokines, small molecules, reactive species) or exogenous 
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(e.g. toxins, dietary factors, pharmacologic agents) factors.  Defects in LT synthesis have 
been seen in HIV infection, malnutrition, diabetes mellitus, cirrhosis, vitamin D 
deficiency, postsepsis and asthmatic attacks (Nelson and Cox, 2000; Peters-Golden et al., 
2004).      
 
H. hemerocallidea and rooperol have anti-inflammatory and anti-diabetic properties (Nair 
et al., 2007a; Ojewole, 2006; Steenkamp et al., 2006; van der Merwe et al., 1993).  
Hypoxis extracts and its purified compounds may influence NO production, COX-2 
expression and phagocytosis in monocyte-macrophages, and pro- and anti-inflammatory 
cytokine production in PBMCs; hence these were investigated in the following sections.     
 
6.2.  Monocyte-to-Macrophage Differentiation 
 
6.2.1.  Background 
 
A range of chemical, natural, biological and pharmacological agents can be used as 
inducers of cell differentiation.  Specific agents differentiate leukemic cells into specific 
progeny including granulocytes, monocytes, monocyte-macrophages and 
megakaryocytes.  For example, human promyelocytic leukemia HL-60 cells are 
differentiated to (i) granulocytes by retinoids, DMSO, hypoxanthine, camptothecin, 
antifolates, anthracyclins and bis-hydroxamic acids; (ii) megakaryocytes by aphidicolin; 
(iii) monocytes by bryostatin 1, butyric acid and tunicamycin; and (iv) monocyte-
macrophages by phorbol esters [e.g. phorbol myristate acetate (PMA)] and 1α,25-
dihydroxyvitamin D3 [1,25(OH)2D3]. The complete mechanism of leukemic 
differentiation is still unclear and differentiation may be via: 
 
 Membrane mediated events and signal transduction pathways. 
 Receptor-mediated processes. 
 Remodeling of superfine chromatin structure. 
 Alterations in transmethylation of DNA or ribonucleic acid (RNA). 
 Transcriptional factors acting as regulators.  
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 Protooncogenes (Tsiftsoglou et al., 2003). 
  
Differentiation inducers of human promonocytic U937 leukemia cells to monocyte-
macrophages include cytokines [e.g. IL-6 and TGF-1β (Tsiftsoglou et al., 2003)], phorbol 
esters [e.g. PMA (Kulseth et al., 1998; Shayo et al., 1997) and 12-O-
tetradecanoylphorbol-13-acetate (TPA; Lu and Pitha, 2001)], retinoic acid (Kulseth et al., 
1998) and 1,25(OH)2D3 (Kulseth et al., 1998; Rots et al., 1999; Tsiftsoglou et al., 2003).  
The functional abilities of tissue macrophages vary depending on the tissue of residence.  
U937 cells exposed to 1,25(OH)2D3, PMA and retinoic acid differentiate into 
macrophage-like cells involved in phagocytosis, secretion and antibody-dependent 
cellular cytotoxicity, respectively (Kulseth et al., 1998).   
 
1,25(OH)2D3 inhibits proliferation and induces differentiation of normal and leukemic 
myeloid cells to monocyte-macrophages via the intracellular vitamin D receptor (VDR) 
(Fleet, 2004; Rots et al., 1999; Tsiftsoglou et al., 2003).  VDR interacts with VDR 
elements, which are specific DNA sequences, to transcriptionally activate target genes in 
the presence of vitamin D3 (Tsiftsoglou et al., 2003).  1,25(OH)2D3 is an activator of 
various signal transduction pathways leading to the stimulation of protein kinase 
(PK)A/C, MAPK, and other protein kinases (Fleet, 2004).  PMA-induced differentiation 
occurs via activation of the PKC signal transduction pathway component (García et al., 
1999; Tsiftsoglou et al., 2003), which modulates the activity of the transcription factors 
like NF-κB, activating protein (AP)1-3 and Ets (García et al., 1999; Kim et al., 1998). 
 
For proliferating cells to differentiate, DNA replication needs to be controlled.  Cells 
entering DNA replication from a synthesis phase require cyclins, which assemble with 
CDKs (Martinez et al., 2006; Rots et al., 1999).  CKIs inhibit cyclin-CDK activities in 
the different cell cycle phases, resulting in cell cycle arrest.  1,25(OH)2D3 induces 
p21
Waf1/Cip1
 and p27
Kip1
 expression in U937 cells, which may cause cell cycle arrest 
during U937 cell differentiation to monocyte-macrophages.  CDK levels stay constant 
throughout differentiation, but cyclins A, D, and E levels increase during the proliferation 
burst (short period of proliferation prior to differentiation), while p21
Waf1/Cip1
 and p27
Kip1
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levels increase during the proliferation burst and cell growth inhibition.  An initial 
increase in proliferation followed by proliferation inhibition precedes differentiation and 
involves cyclin and CDK induction (Rots et al., 1999).  Cell cycle arrest occurs in the 
G0/G1 phase prior to differentiation (Kim et al., 1998; Rots et al., 1999).  PMA may 
cause differentiation in U937 cells by decreasing or inhibiting topoisomerase I and II 
activity.  Topoisomerase activity may be regulated by phosphorylation via protein kinases 
(e.g. PKC) and AP-1-dependent genes (Pérez et al., 1994; Shayo et al., 1997).  
 
This section focuses on the optimization of the concentration of PMA and 1,25(OH)2D3, 
and exposure time required to differentiate U937 cells to monocyte-macrophages.  
 
6.2.2.  Materials and Methods 
 
Human promonocytic leukemia U937 cells were seeded at 200 000 cells/well in 24-well 
plates in RPMI1640: 10% fbs.  Cells were treated with PMA (Sigma) and 1,25(OH)2D3 
(Alexis Biochemicals, Lausen, Switzerland) at concentrations of 10, 50 and 100 nM and 
incubated in a humidified incubator at 37 °C and 5% CO2 for  24, 48 and 72 hrs. 
 
Phase contrast microscopy.  After PMA and 1,25(OH)2D3 treatment, cells were viewed 
under an Axiovert 40C inverted microscope with a Ph2-0.4 filter and 40x objective.  
Photos were taken with a PowerShot A640 digital camera.   
 
Cell viability.  After differentiation, cells were resuspended and transferred to 
polypropylene tubes.  Accutase (300 μL; Sigma) was added to the wells treated with 
PMA and incubated for 15 min at 37 ºC.  Cells were resuspended in PBS (500 μL) and 
transferred to the appropriate polypropylene tubes.  Tubes were centrifuged at 300 x g for 
five min at room temperature and the supernatant discarded.  Cells were washed with 1 
mL PBS by centrifugation, as described above, to remove differentiation agents and 
Accutase.  Cells were resuspended in 500 μL propidium iodide (PI; 50 μg/mL; Beckman 
Coulter) and incubated for 15 min at 37 ºC.  Samples were analyzed using a Beckman 
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Coulter Cytomics FC500.  Cells with intact plasma membranes will not take up the dye, 
whereas non-viable cells will stain positive with PI. 
 
Cell surface marker staining.   The procedure as for cell viability, prior to PI staining, 
was followed.  Cells were resuspended and blocked in 500 μL blocking buffer (1% BSA 
and 1% foetal bovine serum in PBS) for 15 minutes at room temperature and centrifuged 
as described above.  Cells were stained in the dark with 10 μL CD11b-FITC and 10 μL 
CD14- phycoerythrin cychrome 5 (PC5) for 30 min at room temperature, washed with 
PBS as described above and resuspended in PBS (500 μL).  Samples were analyzed using 
a Beckman Coulter Cytomics FC500.     
 
6.2.3.  Results and Discussion 
 
Phase contrast microscopy.  U937 cells treated with PMA attached to the surface of the 
plate; hence treatment with Accutase was necessary to remove the attached cells.  
Monocyte-macrophages differentiated with PMA attached to the bottom of the wells, 
grew flat on the surface of the plate, formed clumps and had protruding pseudopodia 
(Figure 6.1).  Monocyte-macrophages differentiated with 1,25(OH)2D3 formed clumps 
with protruding pseudopodia (Figure 6.1).   
                      
   
               Untreated                                      PMA                                   1,25(OH)2D3 
 
Figure 6.1:  Phase contrast photographs of U937 cells differentiated to monocyte-
macrophages.  Photographs represent differentiated monocyte-macrophages that had been 
treated with 10 nM PMA or 10 nM 1,25(OH)2D3 for 24 hrs.   
 
The above results confirm the morphological characteristics (adherent cells, protruding 
pseudopodia and clump formation) associated with PMA differentiated U937 cells to 
Clump formation 
Pseudopodia 
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monocyte-macrophages seen by Barbieri et al. (2003).  Kulseth et al. (1998) have also 
shown adherent and nonadherent monocyte-macrophages when U937 cells were 
differentiated with PMA, and 1,25(OH)2D3 and retinoic acid, respectively.  Macrophages, 
differentiated from monocytes, may become „giant‟ like and multinucleated.  Gradual 
spreading and flattening, membrane ruffling and extension as the nucleus to cytoplasm 
ratio increases are signs of differentiating monocyte-macrophages.  Biochemical changes 
during monocyte-to-macrophage differentiation include an increase in acid phosphatase, 
β-glucosaminidase, and macrophage tissue transglutaminase activities, and expression of 
FcγR-, transferrin-, type I macrophage scavenger-, and mannose receptors (Huh et al., 
1996).  The spreading ability of macrophages is important for phagocytosis and the 
migratory process to the inflammatory site.  Expression of inducible nitric oxide synthase 
(iNOS) and NO production require differentiation and activation of macrophages.  
Activated macrophages simultaneously release NO, superoxide (O2
-
) and its dismutation 
product, hydrogen peroxide (H2O2) (Cruz et al., 2007). 
 
Cell viability following U937 differentiation with PMA or 1,25(OH)2D3.  Cell viability of 
PMA- and 1,25(OH)2D3-differentiated U937 cells were determined using PI (Table 6.1). 
 
Table 6.1: Percentage of viable U937 cells over time after differentiation to monocyte-
macrophages with PMA and 1,25(OH)2D3.   
 
 
Time 
(hrs) 
Percentage of viable U937 cells after differentiation 
PMA 1,25(OH)2D3 
control 10 nM 50 nM 100 nM control 10 nM 50 nM 100 nM 
24 75.6 51.6 46.1 47.5 75.6 78 80 80.1 
48 76.8 40.9 42.4 42.6 76.8 81.2 81.6 82.4 
72 NA* NA NA NA 81.8 73 72 66.8 
* NA = not analyzed  
 
In general, PMA caused a reduction in cell viability with an increase in time and 
concentration.  After 72 hrs, cell viability could not be determined for PMA differentiated 
U937 cells, due to shortage of viable cells to complete 10 000 events.  Cell viability 
increased when U937 cells were differentiated with 1,25(OH)2D3, which may be 
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explained by an increase in proliferation.  This may be explained by a „burst of rapid 
proliferation‟ before differentiation, which was concentration dependent and seen after 24 
and 48 hrs of treatment.  Brown et al. (2003) have also described a „burst of rapid 
proliferation‟ preceding differentiation.  Cell differentiation does not require cell division 
or DNA synthesis, and is initiated in the G1 phase, G1-S progression and S phase (Brown 
et al., 2003).  Rots et al. (1999) have shown a burst of proliferation followed by growth 
inhibition and differentiation, when U937 cells were treated with 1,25(OH)2D3.  Cultures 
containing differentiated cells consist of a percentage of apoptotic cells.  Several inducers 
cause apoptosis together with differentiation but the proportion of differentiated cells, in 
most cases, is much higher than apoptotic cells (Tsiftsoglou et al., 2003).  Kulseth et al. 
(1998) have shown a decrease in viable U937 cells when exposed to PMA and retinoic 
acid (~30%) for three days, compared to 1,25(OH)2D3 (~70%).  Cell viability percentages 
obtained by Kulseth et al. (1998) correspond to the results obtained in this study.  
 
Monocyte-macrophage cell surface marker expression after differentiation.  
Differentiated monocyte-macrophages were stained with anti-CD11b and CD14 labelled 
with FITC and PC5, respectively.  Figures 6.2 and 6.3 represent overlaid histograms of 
expressed CD11b and CD14, when U937 cells were treated with PMA and 1,25(OH)2D3, 
respectively.  Monocyte to monocyte-macrophage differentiation is associated with 
increased surface expression of CD11b and CD14 (Brown et al., 2003). 
 
U937 cells exposed to PMA for 24 hrs did not express significant amounts of CD11b and 
CD14.  After 48 hrs >70% of U937 cells expressed CD11b and 35-40% of U937 cells 
expressed CD14.  In general, higher PMA concentrations were associated with less 
CD11b expression, which may be due to PMA‟s toxicity to U937 cells (Table 6.1).  After 
72 hrs most of the U937 cells were killed.    
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                                 CD11b-FITC                                               CD14-PC5 
 
 
 
 
Figure 6.2:  PMA differentiation of U937 cells to monocyte-macrophages.  CD11b-FITC and 
CD14-PC5 were used as cell surface markers for differentiated monocyte-macrophages.  
Percentages represent the shift in PMA treated samples compared to the control, when a 
region was set from the end of the control peak.  Black = unstained; red = DMSO control; 
blue = 10 nM PMA; green = 50 nM PMA; purple = 100 nM PMA.  Representative of two 
experiments performed.  10 000 events were recorded. 
 
Barbieri et al. (2003) have shown an increase in CD14 expression when U937 cells were 
differentiated with PMA.  García et al. (1999) described an increase in the expression of 
the β2-integrin family (CD11a-c/CD18) in U937 cells during differentiation.  They have 
shown that PMA differentiation of U937 cells was influenced by the nuclear transcription 
factors NF-κB, AP-1 and PU.1.  
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                                CD11b-FITC                                                CD14-PC5 
 
 
 
 
 
Figure 6.3:  1,25(OH)2D3 differentiation of U937 cells to monocyte-macrophages.  CD11b-
FITC and CD14-PC5 were used as cell surface markers for differentiated monocytes-
macrophages.  Percentages represent the shift in 1,25(OH)2D3 treated samples compared to 
the control, when a region was set from the end of the control peak.  Black = unstained; red 
= DMSO control; blue = 10 nM 1,25(OH)2D3; green = 50 nM 1,25(OH)2D3; purple = 100 nM 
1,25(OH)2D3.  10 000 events were recorded. 
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CD11b and CD14 cell surface marker expression during U937 cell differentiation with 
1,25(OH)2D3 was concentration- and time dependent.  CD11b expression on monocyte-
macrophages increased between 24 and 48 hrs [5.4, 3.7 and 3.9 times more with 10, 50 
and 100 nM of 1,23(OH)2D3, respectively, compared to the control] of treatment, but was 
similar between 48 and 72 hrs.  CD14 expression on monocyte-macrophages increased 
after 24 hrs.  Treatment with 10 nM and, 50 and 100 nM 1,25(OH)2D3 expressed 70% 
and 85%, respectively, more CD14 compared to the control.  After 48 and 72 hrs 10 nM 
and, 50 and 100 nM 1,25(OH)2D3 expressed >80% and >90%, respectively, more CD14 
compared to the control.   
 
A previous study has shown that expression of CD14 mRNA, measured after 24 hrs, was 
only seen when exposed to 1,25(OH)2D3, and not to PMA or retinoic acid.  This was the 
case even after 72 hrs (Kulseth et al., 1998).  Overproduction of p21
Waf1/Cip1
 and p27
Kip1
 
induces CD11b and CD14 expression in U937 cells (Rots et al., 1999).   
 
Differentiation of U937 cells to monocyte-macrophages following 1,25(OH)2D3 
treatment was confirmed with initial proliferation, increased CD11b and CD14 
expression, clump and pseudopodia formation.  1,25(OH)2D3 was the agent of choice for 
differentiation due to higher viability compared to PMA treatment.  The time and 
1,25(OH)2D3 concentration chosen to differentiate U937 cells were 24 hrs and 100 nM, 
respectively.  The main reason for choosing the shorter differentiation time period was 
based on higher cell viability. 
 
6.3.  Nitric Oxide Production 
 
6.3.1.  Background 
 
Production of NO.  NO is a diffusible, intercellular messenger molecule with the 
following characteristics: 
 
 Colourless gas. 
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 Free radical due to odd number of electrons. 
 Relatively unstable in the presence of oxygen. 
 Very short half life (<15 s).  
 Rapidly decomposes to form nitrogen oxides (collectively known as NOx), which 
include nitrogen dioxide (NO2), nitrites (NO2
-
), nitrates (NO3
-
) and dinitrogen 
trioxide (N2O3) (Bertholet et al., 1999; Clancy et al., 1998; Miller and Grisham, 
1995; Tiscornia et al., 2009). 
 
NO is produced when the amino acid L-arginine is catalytically oxidized to L-citrulline 
by nitric oxide synthase (NOS).  At least three isoforms of NOS are found, namely 
constitutively expressed NOS in endothelial (eNOS) and neuronal (nNOS) cells, and 
inducible iNOS (Table 6.2) (Beck et al., 1999; Guzik et al., 2003; Tiscornia et al., 2009).  
These three NOS isoforms have similar molecular structures (~60 % homology), belong 
to the cytochrome P450 reductase-like family and require multiple co-substrates, which 
include nicotinamide adenine dinucleotide phosphate (NADPH), O2, and co-factors [e.g. 
calmodulin, (6R)-tetrahydrobiopterin (BH4), flavine adenine dinucleotide (FAD), flavin 
mononucleotide (FMN) and iron protoporphyrin (heme)] (Bertholet et al., 1999; Clancy 
et al., 1998; Guzik et al., 2003; Korhonen et al., 2005).  Active NOS is a tetramer 
consisting of two NOS proteins and two molecules of the Ca
2+
 regulatory protein, 
calmodulin.  nNOS and eNOS  binding to calmodulin is stabilized with an increase in 
free intracellular Ca
2+
 levels, leading to NOS activation and NO production.  Decrease in 
Ca
2+
 concentration is associated with a decrease in NO production.  iNOS is regulated at 
transcriptional level (e.g. by NF-κB) and is independent of Ca2+ levels.  Calmodulin 
binding to iNOS is tight, even at low Ca
2+
 concentrations (Guzik et al., 2003; Kim et al., 
1998; Korhonen et al., 2005; Miller and Grisham, 1995).  The main factors influencing 
NO production are cell type, calcium concentration, inducer, NOS source, time and NO‟s 
mechanism of action (Miller and Grisham, 1995; Tiscornia et al., 2009). 
 
 
 
 
 138 
 
 
Table 6.2:  Summary of the characteristics of the three NOS isoforms (Beck et al., 1999; 
Bertholet et al., 1999; Clancy et al., 1998; Guzik et al., 2003; Korhonen et al., 2005; Miller 
and Grisham, 1995; Nussler and Billiar, 1993). 
 
Feature eNOS nNOS iNOS 
Calcium dependent/ 
independent 
Dependent Dependent Independent 
Mediators of NO 
production 
Acetylcholine, 
thrombin, 
bradykinin, 
glutamate, shear 
force, ADP, 
VEGF*** 
Acetylcholine, 
thrombin, bradykinin, 
glutamate, insulin, 
NMDA**** 
Bacterial endotoxins 
(LPS, LTA**), 
peptidoglycan, dsDNA, 
RNA); pro-inflammatory 
cytokines (IFNα/β/γ, 
TNFα, IL-1β), hypoxia 
Cell types/ tissue 
expression 
Endothelial cells, 
cardiac myocytes, 
platelets, neurons 
Neurons in the 
central/peripheral/ 
autonomous nervous 
system. Skeletal 
muscle, neutrophils, 
VSMC*, platelets, 
epithelial cells, 
pancreatic β cells 
Most resting cells, 
Cardiac myocytes, glial 
cells, VSMC, 
endothelium, neurons, 
hepatocytes, VSMC, 
bone marrow cells, 
monocytes/macrophages, 
keratinocytes, β-cells, 
chondrocytes, 
synoviocytes, 
neutrophils 
Synonyms  NOS III NOS I NOS II 
Originally cloned 
from 
Endothelial cells Neuronal cells Macrophages 
Subcellular location  Golgi apparatus, 
plasmalemma, 
caveolae 
Mainly membrane 
bound 
Cytosol, ER, 
sarcolemma, 
postsynaptic densities 
caveolae 
Phagosomes 
Availability Constitutive Constitutive Induced 
* VSMC = vascular smooth muscle cell 
**LTA = lipoteichoic acid 
***VEGF = vascular endothelial growth factor 
****NMDA = N-methyl-D-aspartate 
 
Induced iNOS expression is characterized by the production of large quantities (nano- to 
micromolar concentrations) of NO after a lag period of a few hours (6-8 hrs), which may 
be due to the synthesis of the enzyme and cofactors.  NO production is sustained over a 
long period of time (few hours/days), depending on the enzyme‟s activity and may 
become cytotoxic to healthy cells, causing tissue damage.  Constitutively expressed 
nNOS and eNOS are characterized by the production of small quantities (pico- to 
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nanomolar concentrations) of NO within a few seconds, which are short-lived with direct 
activities that maintain normal cellular functions (Figure 6.4).  iNOS produces a 1000-
fold more NO than eNOS/nNOS (Beck et al., 1999; Clancy et al., 1998; Guzik et al., 
2003; Miller and Grisham, 1995; Nussler and Billiar, 1993; Tiscornia et al., 2009).   
 
 
 
Figure 6.4:  Diagram summarizing the characteristics and functions of NOS (Guzik et al., 
2003). 
 
Physiological or pathophysiological role of NO.  NO plays an important role in host 
defense, immunity and inflammatory responses.  Low levels of NO, produced by eNOS 
and nNOS, are involved in several physiological or pathophysiological roles including 
regulation of vascular endothelial homeostasis (e.g. vasorelaxation of the smooth muscle, 
vascular permeability and protection against the adhesion of leukocytes or platelets to 
blood vessel walls), normal cell signalling pathways, activating inflammatory 
transcription factors (e.g. AP-1 and NF-κB), bronchodilation, neurotransmission or neural 
activity in central or peripheral nervous system, nonspecific host defenses, circulation 
and blood pressure, immune regulation of T helper cell proliferation, cytokine production 
and macrophage-dependent killing of intracellular parasites (Clancy et al., 1998; 
Korhonen et al., 2005;  Moilanen et al., 1997; Nussler and Billiar, 1993; Tiscornia et al., 
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2009).  The molecular mechanism involved in the physiological or pathophysiological 
functions of NO are directly associated with NO formed by eNOS and nNOS.  NO 
regulates enzyme activity by reacting with transition metals (e.g. iron, copper, zinc) 
present in enzymes and other proteins.  NO targets the ferrous iron group of soluble 
guanylate cyclase (sGC), which converts guanosine triphosphate (GTP) to the 
intracellular signalling molecule cyclic guanosine monophosphate (cGMP), which in turn 
targets cGMP dependent protein kinases involved in the above-mentioned functions 
(Beck et al., 1999; Guzik et al., 2003; Korhonen et al., 2005; Nussler and Billiar, 1993).  
 
NO and inflammation.  During inflammation, a large amount of NO is produced by 
iNOS, surpassing the physiological amounts produced by nNOS and eNOS (Guzik et al., 
2003).  NO is a poor reactive free radical and is rapidly oxidized to more active radicals 
including peroxinitrite (ONOO
-
), nitrogen dioxide (N2O2) and others (Miller and 
Grisham, 1995; Tiscornia et al., 2009).  In general, the absence or presence of iNOS 
induced NO production is associated with anti- or pro-inflammatory activities, 
respectively.  This viewpoint is controversial and is not the case during infection where 
NO produced by iNOS is important to kill invading microorganisms.  Inhibition of NO 
formation may promote growth and spread of infection resulting in increased tissue 
damage (Miller and Grisham, 1995).  Two indirect mechanisms of action are associated 
with iNOS expressed NO production.  Firstly, the formation of S-nitrosothiols (S-
nitrosylation), which modify the activity of several proteins including transcription 
factors, kinases involved in signalling pathways, caspases, ion channels and metabolic 
proteins.  NO reacts with molecular oxygen (O2) in aqueous solutions to form N2O3, 
which rapidly decomposes to nitrite and the nitrosonium ion (NO
+
).   The latter is 
responsible for nitrosylation (Beck et al., 1999; Korhonen et al., 2005; Miller and 
Grisham, 1995).  Secondly, NO together with O2
-
 form ONOO
-
, which targets proteins, 
lipids and nucleic acids important for cell survival and cell signalling.  It mediates 
cytotoxic effects including DNA damage, LDL oxidation, isoprostane formation, tyrosine 
nitration, inhibition of enzymes involved in the citric acid cycle and mitochondrial 
electron transport chain, and apoptosis (Clancy et al., 1998; Guzik et al., 2003; Korhonen 
et al., 2005; Miller and Grisham, 1995).  The role of NO as an anti- or pro-inflammatory, 
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however, depends on time, constitutive or induced NOS involved in NO production, 
cellular source of NO production, amount of NO produced, NO targets and generation of 
other reactive nitrogen species from NO (Clancy et al., 1998; Miller and Grisham, 1995).  
 
Diseases associated with overproduction (toxic levels) of NO.  Many inflammatory 
diseases are associated with the overproduction of NO, including rheumatic diseases [e.g. 
systemic lupus erythematosus (SLE), osteoarthritis, vasculitis, Sjögren syndrome, 
rheumatoid arthritis], ischaemic heart disease, heart failure, circulatory shock, stroke, 
neurodegenerative disorders and endothelial dysfunction.  It is proposed that NO may be 
involved in the pathogenesis of autoimmune diseases (Clancy et al., 1998; Tiscornia et 
al., 2009).  NO overproduction by activated macrophages can injure hepatocytes, 
pancreatic islet cells and lymphocytes via intracellular iron release, inhibition of 
mitochondrial function [aconitase (citric acid cycle), NADPH/succinate-ubiquinone 
oxidoreductase (mitochondrial respiratory chain)] and inhibition of DNA synthesis 
(ribonucleotide reductase) (Miller and Grisham, 1995; Nussler and Billiar, 1993). 
 
Inhibition of iNOS. Drugs targeting NOS and NO bioavailability can be used to treat 
inflammatory diseases.  NO is scavenged by haemoglobin, methylene blue, pyocyanin 
(Pseudomonas coereleus), glucocorticoids, arginine analogues (including L-NMMA, L-
NAME), flavonoids, NO gas inhalation, leptin, statin therapy, NO donors, peroxisome 
proliferator-activated receptor (PPAR)γ activators, antioxidants, and non-steroidal anti-
inflammatory drug (NSAIDs; e.g. aspirin) (Guzik et al., 2003).  Many physiological or 
synthetic agents inhibit cytokine-induced iNOS at transcriptional level.  iNOS expression 
can be prevented by binding and activation of NF-κB  by cyclosporin A, dexamethasone 
and dithiocarbamates (Beck et al., 1999).  iNOS induction can be inhibited by 
glucocorticosteroids, and cytokines [e.g. transforming growth factor (TGF)-β, IL-4, IL-8 
and IL-10] (Clancy et al., 1998; Guzik et al., 2003; Nussler and Billiar, 1993).  
Constitutively expressed NOS (cNOS) and iNOS are inhibited by substrate analogs, 
flavoprotein and heme binders, whereas calmodulin inhibitors inhibit cNOS (Nussler and 
Billiar, 1993). 
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NO and cancer.  NO has anti- and pro-apoptotic functions in cells.  Large quantities of 
NO present over a long period of time have pro-apoptotic effects by (i) directly targeting 
the mitochondria causing loss in mitochondrial membrane potential and increased 
cytochrome c release.  NO binds cytochrome c oxidase in the mitochondrial electron 
transport chain, leading to increased O2
-
 production, which interacts with NO to form 
ONOO
-
.  The latter induces mitochondrial dysfunction and cytochrome c release; (ii) 
inducing p53 expression and accumulation, resulting in cell cycle arrest due to 
p21
Waf1/Cip1
 upregulation or apoptosis due to increased Bax expression and cytochrome c 
release; (iii) activating JNK/stress-activated protein kinase (SAPK) group of MAPK and 
caspase-3 activation; (iv) increasing ceramide production due to increased 
sphingomyelinase activity.  Ceramide activates cytochrome c release, JNK/SAPK 
activation, suppression of Bcl-2 expression and PKB/Akt inhibition (Brüne et al., 1998; 
Choi et al., 2001; Chung et al., 2001).  
 
Low or physiological NO production protects cells against pro-apoptotic stimuli, 
including TNFα, oxidative stress and serum or glucose deprivation, and have anti-
apoptotic effects by (i) increasing cGMP production, which suppress cytochrome c 
release and ceramide production, and increase Bcl-2 expression and PKB/Akt activation; 
(ii) inhibiting caspase S-nitrosylation; (iii) regulating anti-apoptotic related gene 
expression e.g. heat shock protein (HSP)70/32 and anti-apoptotic Bcl-2 family members 
(Brüne et al., 1998; Choi et al., 2001; Chung et al., 2001).   
 
NO has physiological and pathophysiological activities, which play an important role in 
health and disease states.  Since NO plays a key role in inflammation and previous 
studies have shown anti-inflammatory activity of Hypoxis, the NO production of 
monocyte-macrophages when treated with Hypoxis extracts and its purified compounds 
was investigated in this section. 
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6.3.2.  Materials and Methods 
 
Human promonocytic leukemia U937 cells were counted, resuspended in RPMI1640: 
10% fbs (complete medium), and differentiated with 100 nM 1,25(OH)2D3 for 24 hrs in a 
humidified incubator at 37 °C and 5% CO2.  Cells were investigated for clump- and 
pseudopodia formation, which are morphological characteristics of monocyte-
macrophages.  Differentiating agent was removed by centrifugation at 250 x g for five 
min at room temperature, medium discarded, cells washed with 1 mL complete medium 
as described in section 6.2.2 and resuspended in complete medium at cell densities of 
1x10
6
 cells/mL.  Cells were uniformly stained by adding 5,6-diaminofluorescein diacetate 
(DAF-2 DA; 1 μg/mL).  Cells were mixed, covered with foil and incubated for 30 min at 
37 ºC.  Excess DAF-2-DA was removed and cells washed twice as described above.  
Fifty thousand cells were added to polypropylene tubes and treated with DMSO (0.25%, 
v/v) as vehicle control, H. hemerocallidea (125 μg/mL), H. stellipilis (125 μg/mL), H. 
sobolifera (125 μg/mL), hypoxoside (50 μg/mL), rooperol (20 μg/mL), CD (4mM)/EtOH 
(5%, v/v), β-sitosterol (30 μM), campesterol (30 μM), cholesterol (30 μM), stigmasterol 
(30 μM) or PMA (10 or 20 nM) for six hours at 37 °C.  After treatment, cells were 
pelleted and washed with PBS as described above.  Cells were resuspended in PBS (500 
μL) and samples read on a Beckman Coulter FC500 flow cytometer.  Mean fluorescence 
intensity (MFI) of treated cells was expressed as a percentage of the MFI of control cells.  
Statistical significance was determined using the two-tailed Student‟s t-test. 
  
6.3.3.  Results and Discussion 
 
Intracellular NO was measured by loading the cells with the membrane permeable 
derivative 5,6-diaminofluorescein diacetate (DAF-2 DA), which is transformed to 5,6-
diaminofluorescein (DAF-2) by non-specific cytosolic esterases.  Inside the cells, DAF-2 
reacts directly with N2O3, which is produced by a second order reaction of NOS with 
oxygen under aerobic conditions, to form the highly green-fluorescent derivative 
triazolofluorescein (DAF-2 T) (Tiscornia et al., 2009).  NO production was measured 
after six hours of treatment of differentiated monocyte-macrophages (Figure 6.5).  
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Figure 6.5:  NO production by monocyte-macrophages in response to DMSO, Hypoxis 
chloroform extracts, hypoxoside and rooperol (A), CD/EtOH, (phyto)sterols and PMA (B) 
treatment.  The y-axis of NO production in response to rooperol is ten times greater than 
NO production in response to Hypoxis chloroform extracts and hypoxoside treatment.  Bar 
graph percentages represent the increase in mean fluorescence intensity of cells staining 
positive for NO production when treated samples were compared to control.  Error bars 
represent the SD of triplicate values.  One representative of three experiments performed.  
Significance was determined using the two-tailed Student t-test: *p<0.01; **p<0.001; 
***p<0.0001 compared to control. 
 
Significant amounts of NO were produced when monocyte-macrophages were treated 
with the three Hypoxis extracts, rooperol and PMA.  When compared to the controls, H. 
hemerocallidea, H. stellipilis, H. sobolifera, rooperol and PMA (10 nM) produced 2.0, 
3.9, 1.6, 32.9 and 2.5 times more NO, respectively.  NO production by hypoxoside and 
cholesterol was not significantly different from the control, with only a 1.2 and 1.1 fold 
increase, respectively.  β-sitosterol, campesterol and stigmasterol had no effect on NO 
production.  Overlaid histograms of the treatments increasing NO production 
  * 
  ** 
** 
 *** 
 ** 
   *** 
A 
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significantly are summarized in Appendix 6.  Wallerath et al. (2002) have shown that β-
sitosterol and stigmasterol, found in red wine, do not contribute significantly to eNOS 
upregulation.   
 
This is the first time that the effect of Hypoxis extracts and its purified compounds were 
tested for NO production on monocyte-macrophages.  NO production within 6 hrs 
suggests the expression of iNOS in human monocyte-macrophages.  Kim et al. (1998) 
have found that very little NO was produced when U937 cells were differentiated with 32 
nM PMA, which confirm the choice of 1,25(OH)2D3 as differentiating agent.   
 
6.4.  Cyclooxygenase-2 
  
6.4.1.  Background 
 
Two isoforms of COX are found, namely constitutively expressed COX-1 and inducible 
COX-2 (Barbieri et al., 2003).  COX-1 and -2 have similar structures (60% homology) 
and catalyze the conversion of AA to PGH2, but are encoded by two genes located on 
different chromosomes.  COX-1 is involved in housekeeping functions and produce PGs, 
which mediate physiological functions.  These include gastric mucosa and nephron 
maintenance and cytoprotection, renal blood flow regulation and platelet aggregation 
(DuBois et al., 1998; Gasparini et al., 2003; Morita, 2002; Rocca and FitzGerald, 2002).  
COX-1 mRNA and protein levels are relatively stable in many cells and tissues.  COX-1 
induction has, however, been seen in THP-1 and megakaryocytes treated with phorbol 
esters; endothelial cells treated with shear stress/VEGF; lung fibroblasts treated with 
TGFβ; and synovial cells treated with IL-1α (Morita, 2002; Rocca and FitzGerald, 2002).   
 
COX-2 is expressed in inflamed (macrophages, synoviocytes, fibroblasts, osteoblasts, 
tumour cells and endothelial cells) and neoplastic (hyperproliferation, transformation, 
tumour growth, invasion and metastasis) tissues (Gasparini et al., 2003).  COX-2 is 
almost undetectable under resting conditions, but is induced by pro-inflammatory 
cytokines (e.g. IL-1α/β, IL-6, IL-8, IL-11, TNF-α, IFNγ), growth factors [e.g. serum, 
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fibroblast growth factor (FGF) a and b, insulin, IGF, VEGF, epidermal growth factor 
(EGF), PDGF, TGFβ], phorbol esters, lipopolysaccharide (LPS), NO, PGE2, hypoxia and 
hormones (DuBois et al., 1998; Gasparini et al., 2003; Morita, 2002; Rocca and 
FitzGerald, 2002).  COX-2 produces PGs, which are involved in pain, inflammation and 
fever (Nelson and Cox, 2000).  COX-1 mRNA, protein and activity are unchanged during 
inflammation, but COX-2 expression increases significantly resulting in increased PG 
production (Morita, 2002).  
 
COX-1 and -2 catalyze the production of different PGs, for example COX-1 and -2 
expression in rat peritoneal macrophages (induced by LPS) and human umbilical vein 
endothelial cells (HUVECs; induced by IL-1β) favour TXA2 and PGE2/PGI2 production, 
respectively.  PGI2 and TXB2 maintain vascular homeostasis.  The former is a vasodilator 
and platelet aggregation inhibitor synthesized by the vascular endothelium, while the 
latter is a vasoconstrictor and platelet aggregation promoter synthesized by platelets.  An 
imbalance between PGI2 and TXB2 is associated with thrombotic and cardiovascular 
disorders.  The ratio of PGI2/TXB2 produced is not fixed and differs according to the 
COX isoform activated.  Induction of COX-2 has been associated with the production of 
harmful prostanoids due to COX-2 involvement in inflammatory disorders like 
rheumatoid arthritis and osteoarthritis (Caughey et al., 2001; Morita, 2002).     
 
COX-2 and cancer. COX-2 is overexpressed in breast, colorectal, gastric, lung, 
pancreatic, head and neck, oesophageal, urinary bladder, ovarian, cervical and prostate 
cancer.  Overexpressed COX-2 may promote carcinogenesis by increasing proliferation, 
transformation, invasion, metastasis, angiogenesis, differentiation, metaplasia, 
hyperplasia, dysplasia, immunosuppression, cellular motility and apoptosis resistance 
(Chun and Surh, 2004; Gasparini et al., 2003; Sheng et al., 2001; Shigemasa et al., 2003; 
Spizzo et al., 2003).  Apoptosis resistance includes reduced levels of pro-apoptotic 
proteins (e.g. Bax), and increased levels of anti-apoptotic proteins (e.g. Bcl-2) in 
mammary tumours (Half et al., 2002).  Higher COX-2 levels may be due to expression by 
carcinoma cells themselves or infiltrating macrophages within the tumours (Zha et al., 
2004).  Many human malignancies produce more PGs than normal tissues from which 
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they arise.  COX-2 is overexpressed due to increased transcription and enhanced mRNA 
stability (Chun and Surh, 2004; Kojima et al., 2001).  Increased COX-2 levels are 
associated with increased PG synthesis, especially PGE2, which suppresses 
immunosurveillance by downregulating B- and T lymphocyte proliferation, NK cell 
cytotoxic activity, and TNFα and IL-10 secretion (Gasparini et al., 2003; Kojima et al., 
2001).  PGE2 released by macrophages inhibits the production of Th1 type cytokines (e.g. 
IL-2, IFNγ) and increase the production of Th2 type cytokines (e.g. IL-4, IL-5) in human 
lymphocytes.  Cytokines stimulating COX-2 expression include IL-1α/β, TNF-α and 
TGF-β, whereas IL-4, IL-10 and IFNγ downregulate COX-2 expression and PG 
production (Barrios-Rodiles and Chadee, 1998).  Sheng et al. (2001) have shown that 
PGE2 increases proliferation, motility and morphogenesis in LS-174 human colorectal 
carcinoma cells, by activating the PI-3K/PKB pathway, involved in cell survival (Chapter 
5, section 5.2).    
 
COX-2 expression is suppressed by anti-inflammatory cytokines (e.g. IL-4, IL-10, IL-
13), glucocorticoids, aspirin, coxibs (e.g. celecoxib, rofecoxib, etorixoxib) and NSAIDs 
(e.g. sulindac sulfide, indomethacin, piroxicam); hence inhibiting PG production (Barnes, 
1998; DuBois et al., 1998; Morita, 2002; Rocca and FitzGerald, 2002).  These inhibitors 
of COX induce apoptosis by increasing AA concentration, leading to the stimulation of 
sphingomyelinase activity, which converts sphingomyelin to pro-apoptotic ceramide.  
Ceramide also inhibits the survival characteristics of carcinomas overexpressing COX-2 
as described above.  Coxibs together with chemotherapy treatment are more effective and 
increase apoptosis.  Possible synergistic and additive effects between coxibs and 
conventional anticancer treatments exist and minimize chemotherapeutic agents‟ side 
effects like mucositis, diarrhoea, chronic pain, fever and other inflammatory toxic effects 
(Chan et al., 1998; Gasparini et al., 2003).     
 
A 30-50% decrease in adenomatous polyps, disease incidence and mortality from 
colorectal cancer were seen with the regular and prolonged use of aspirin and NSAIDs.  
Sulindac and celecoxib suppress adenomatous polyps and regression of existing familial 
adenomatous polyposis (DuBois et al., 1998; Gasparini et al., 2003; Half et al., 2002; 
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Kojima et al., 2001; Sheng et al., 2001; Tsujii et al., 1997).  Side effects of NSAIDs 
include duodenal erosion, gastrointestinal ulcers or -bleeding, platelet dysfunction and 
normal renal function disruption, which may be due to suppression of COX-1 derived PG 
production.  Inhibition of COX-2 dependent PG synthesis by COX-2 inhibitors may 
prevent the side effects associated with NSAIDs (Chun and Surh, 2004; DuBois et al., 
1998; Nelson and Cox, 2000). 
 
Cross-talk between COX and NOS.  Similarities existing between NOS and COX include: 
(i) COX and NOS are involved in the biosynthesis of PGs, thromboxanes and 
prostacyclin, and NO, respectively; (ii) constitutive (COX-1, nNOS and eNOS) and 
inducible (COX-2 and iNOS) isoforms exist; (iii) COX-2 and iNOS are induced by 
similar agents, including LPS and IL-1β; (iv) anti-inflammatory steroids (e.g. 
dexamethasone) inhibit the induction of iNOS and COX-2, but had no effect on 
constitutive expressed isoforms (Clancy et al., 2000; Salvemini et al., 1993).   
 
NOS and COX cross-talk may be via (i) direct oxidation of the iron-heme center at the 
active site of COX by NO (Gasparini et al., 2003; Salvemini et al., 1993).  Most of NO 
effects are mediated via interaction with iron or iron containing enzymes.  NO binds the 
heme-iron prosthetic group of sGC leading to its stimulation and increased cGMP 
production, which is involved in platelet aggregation inhibition and vascular smooth 
muscle relaxation.  NO effects on iron-containing enzyme activity may be stimulatory 
(e.g. sGC) or inhibitory (e.g. aconitase) (Salvemini et al., 1993); (ii) indirectly through 
ONOO
-
 formation leading to increased lipid peroxidation (Gasparini et al., 2003).  COX 
activity can produce O2
-
 anion, which will react with NO to form ONOO
-
.  ONOO
-
 may 
modulate eicosanoid synthesis by COX-2 activation and prostacyclin synthase 
inactivation (Baker et al., 1999). 
 
Controversy exists whether NO activates or inhibits PG synthesis.  Clancy et al. (2000) 
have shown that NO activates COX-1, but inhibits COX-2 derived PG production.  
Inhibition of PG production by NO is associated with a decrease in COX-2 expression 
and enzyme nitration.  Nitration involves the conversion of tyrosine to nitrotyrosine by 
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NO, which will inhibit the catalytic activity of the enzyme.  NO also inhibits COX-2 
translocation to a cytosolic compartment, which favours enzyme activity.  COX-2 is more 
sensitive to nitration than COX-1 (Clancy et al., 2000).  Salvenini et al. (1993) have 
shown that endogenous and exogenous NO plays a role in PGE2 release by directly 
activating COX in the mouse macrophage cell line RAW264.7.  Where NO and COX 
pathways are co-expressed in pathological conditions (e.g. rheumatoid arthritis, sepsis, 
nephrosis), regulation of COX activity by NO may be an important mechanism to 
amplify or suppress the initial inflammatory response, which may be of therapeutic 
importance.  NO, PGI2 and PGE2 release increase cGMP and cyclic adenosine 
monophosphate (cAMP) levels in effector cells, which may have synergistic roles in 
amplifying the physiological and pathological response (Salvemini et al., 1993). 
         
COX-1, eNOS and their products are protective against atherosclerosis due to platelet 
aggregation inhibition and smooth muscle proliferation, while COX-2, iNOS and their 
products are involved in the pathogenesis of inflammatory disorders. The amount and 
rapidity of NO and PG production determine the damage caused.  Large amounts of NO 
cause further inflammation, cellular damage and apoptosis (Baker et al., 1999).  
 
COX-2 plays an important role in the production of prostaglandins, which are involved in 
inflammation.  This section focuses on the COX-2 expression in monocyte-macrophages 
when treated with Hypoxis extracts and its purified compounds. 
 
6.4.2.  Materials and Methods 
 
Human promonocytic leukemia U937 cells were differentiated with 100 nM 1,25(OH)2D3 
as described in section 6.3.2.  Cells were investigated for clump- and pseudopodia 
formation, as before.  Differentiating agent was removed by centrifugation at 250 x g for 
five min at room temperature, medium discarded, cells washed with 1 mL RPMI1640: 
10% fbs (complete medium) by centrifugation as described above and resuspended in 
complete medium.  Fifty thousand cells were added to polypropylene tubes and treated 
with DMSO (0.25%, v/v), H. hemerocallidea (125 μg/mL), H. stellipilis (125 μg/mL), H. 
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sobolifera (125 μg/mL), hypoxoside (50 μg/mL), rooperol (20 μg/mL), CD (4mM)/EtOH 
(5%, v/v), β-sitosterol (30 μM), campesterol (30 μM), cholesterol (30 μM) or stigmasterol 
(30 μM) in the presence of 250 ng/mL LPS for six hrs at 37 °C in the dark.  After 
treatment, cells were collected by centrifugation as described above, supernatant 
discarded and fixed with 500 μL of 4% (v/v) formaldehyde (diluted in PBS) for 10 min at 
37 °C.  After fixation, cells were chilled on ice for one minute, centrifuged and washed as 
above to remove the fixative.  Cells were resuspended in ice-cold 90% (v/v) MeOH (500 
μL) and permeabilized for 30 min on ice.  MeOH was removed by centrifuging and 
washed twice in incubation buffer (0.5% BSA in PBS) as described above.  Cells were 
resuspended in 100 μL incubation buffer and blocked for 10 min at room temperature.  
COX-2 primary antibody (Cell Signaling Technology Inc.) was added at recommended 
working dilutions to the cells and incubated for one hour at room temperature.  Cells 
were washed twice as described above.  After washing, FITC conjugated goat anti-rabbit 
IgG (H+L chain specific) was added at recommended working dilutions.  Cells were 
incubated in the dark for a further 30 min at room temperature and washed as described 
above.  Cells were resuspended in PBS (500 μL) and read on a Beckman Coulter 
Cytomics FC500. 
   
6.4.3.  Results and Discussion 
 
Monocyte-macrophages were simultaneously stimulated for COX-2 production with LPS 
when treated with Hypoxis extracts and its purified compounds.  From the histograms in 
Figure 6.6, a shift of the main peak to the left or to the right represents decreased or 
increased COX-2 expression, respectively.  
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Figure 6.6:  Histograms of COX-2 expression in monocyte-macrophages after six hrs of 
treatment with Hypoxis extracts and its purified compounds in the presence of LPS (250 
ng/mL).  Percentages in region D on histograms represent the change in COX-2 levels.  10 
000 events were recorded. 
 
From the above (and Appendix 6) results, no increase or decrease in COX-2 levels were 
seen, when treated with Hypoxis extracts and its purified compounds.  The two peaks 
may represent two populations of COX-2, with peak B representing cells expressing low 
levels of COX-2 and peak D representing cells expressing high levels of COX-2.  A small 
increase in COX-2 expression (peak D) was seen when monocyte-macrophages were 
treated with LPS compared to untreated control.  A small decrease in COX-2 expression 
(peak D) was seen when monocyte-macrophages were treated with H. stellipilis when 
compared to the DMSO control.  Due to the small peak shift the experiment was not 
repeated, hence statistical analysis was not performed.  Hypoxis extracts and its purified 
compounds may not affect COX-2 expression, but rather its activity.  Laporta et al. 
(2007a) have shown that rooperol was more effective in inhibiting the activity of COX-2 
than COX-1.  Hypoxis and its purified compounds may affect different parts of the 
inflammation pathway.  Van der Merwe et al. (1993) have shown that rooperol was more 
effective in inhibiting LT synthesis in polymorphonuclear leukocytes, than prostaglandins 
synthesis (TXB2, PGD2, PGF2α) in platelet microsomes.     
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COX-2 is absent in undifferentiated U937 cells (Barbieri et al., 2003); hence the 
importance of differentiation to investigate COX-2 levels.  Several factors may have 
contributed to the unsuccessful increase or decrease of COX-2 expression.  These include 
the agent, stimulant, time period and cell type used during differentiation.  As mentioned 
earlier, specific agents differentiate leukemic cells into specific progeny (section 6.2.1).  
U937 cells were differentiated to monocyte-macrophages by 1,25(OH)2D3, which may 
have given rise to the wrong progeny of cells to investigate COX-2.  Kulseth et al. (1998) 
described the differentiation of U937 cells into macrophage-like cells involved in 
secretion and phagocytosis when treated with PMA and 1,25(OH)2D3, respectively.    
Monocyte-macrophages were only stimulated for six hours, which may be too short to 
see an increase in COX-2 production.  Grkovich et al. (2006) have shown that COX-2 
production was upregulated when U937 cells were differentiated to monocyte-
macrophages with 100 nM PMA for 48 hrs, and stimulated with 1 μg/mL LPS for 2-20 
hrs.  Monocyte differentiation to monocyte-macrophages with PMA (100 nM) caused a 
high percentage of cell death (Table 6.1); hence PMA was not used as differentiating 
agent.  Lower LPS concentration (250 ng/mL) was used to prevent toxicity.  Schuette and 
LaPointe (2000) have shown that COX-2 production increases with time (max at 20 hrs).  
Pro-inflammatory cytokines (e.g. IL-1β, IL-2 and TNF-α) and growth factors (e.g. EGF, 
PDGF) stimulate COX-2 expression in macrophages (Huang et al., 2000; Zha et al., 
2004).  To eliminate the uncertainty of which differentiating agent to use, another cell 
line that does not need to be differentiated e.g. murine P388D1 (Grkovich et al., 2006) or 
RAW 264.7 cells can be used in the future.   
 
The solvent used to prepare Hypoxis extracts may play an important role in active 
compound isolation.  EtOH and water extracts of H. hemerocallidea had a greater effect 
on the inhibition of PG production (Jäger et al., 1996).  Steenkamp et al. (2006) have also 
shown that EtOH extracts of H. hemerocallidea had higher inhibitory effects on the 
activity of COX-1 and COX-2, compared to water extracts.   
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Awad et al. (2005b) have shown that β-sitosterol (16 μM) increases PGE2 and PGI2 
levels, and cPLA2 and COX-2 expression in PC-3 human prostate cancer cells.   Awad et 
al. (2001b) have also shown that β-sitosterol and campesterol (16 μM) increase PGI2 
release in VSMCs.  In contradiction, Awad et al. (2004) have shown that β-sitosterol and 
campesterol decrease PGE2 and PGI2 secretion in LPS-stimulated P388D1/MAB 
macrophages, with no significant effect on cPLA2 and COX-2 expression.  The 
mechanism of increased or decreased PG production by phytosterols is unclear, but 
phytosterols may influence the membrane fluidity when incorporated into membranes, 
which may influence membrane bound enzyme activities involved in AA release and PG 
production (Awad et al., 2001b; Awad et al., 2004).  The opposing effects on PG release 
seen in PC-3 cells and VSMCs compared to P388D1/MAB macrophages may have been 
influenced by the nature of the PG pathway stimuli and cell type (Awad et al., 2005b).  β-
sitosterol was the main phytosterol present in the Hypoxis chloroform extracts used in 
this study, but concentrations were lower (1.77, 0.61 and 4.50 μM in H. hemerocallidea, 
H. stellipilis and H. sobolifera, respectively) than the 16 μM used by Awad and co-
workers.   
 
6.5.  Phagocytosis 
 
6.5.1.  Background 
 
The human immune system is divided into innate (natural) and adaptive (acquired) 
immunity (Dale et al., 2008; Rocca and FitzGerald, 2002).  The innate immune system 
detects pathogens and apoptotic cells via specific receptors and responds by activating 
immune competent (phagocytic) cells, synthesizing cytokines and chemokines, and 
releasing inflammatory mediators.  The major phagocytic cells include monocytes, 
macrophages, NK cells, polymorphonuclear cells, and mast cells (Nair et al., 2004).  The 
innate immune response is the first line of antimicrobial host defense and impacts the 
adaptive immune response.   
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Monocytes are derived from CD34
+
 myeloid progenitor cells in the bone marrow and 
differentiate into monoblast, promonocyte and monocyte stages, before circulating the 
bloodstream (Kim et al., 1998; Martinez et al., 2006).  After 1-3 days of recirculation 
they migrate into tissues and become tissue macrophages.  In tissues, final stages in 
macrophage differentiation take place and Kupffer cells, microglial cells, osteoclasts, 
peritoneal macrophages, and others are formed (Kulseth et al., 1998).  These tissues are 
characterized by low oxygen consumption and protein synthesis rates, and modest 
cytokine production (Martinez et al., 2006).  Macrophages are found in all organs of the 
body, body cavities and their linings, and the skin (Kulseth et al., 1998).   
 
Mononuclear phagocytes play a role in (i) antigen presentation for T lymphocytes; (ii) 
phagocytosis; (iii) immunomodulation and (iv) as secretory cells (Dale et al., 2008; 
Jiménez et al., 1999; Kulseth et al., 1998).  Antigen presenting cells (APCs) display 
antigens in association with major histocompatibility complex class II molecules to 
lymphocytes, provide costimulatory signals and generate an immune response to 
eliminate pathogens (Rocca and FitzGerald, 2002).  Mononuclear phagocytes ingest 
material to eliminate waste and debris (e.g. ineffective and aged erythrocytes, and 
apoptotic cells) (Dale et al., 2008), to kill invading pathogens (Dale et al., 2008; Guzdek 
et al., 1997; Kulseth et al., 1998; Martinez et al., 2006), and to trigger the adaptive 
immune response (Martinez et al., 2006).  Phagocytes are involved in the secretion of 
pro- and anti-inflammatory cytokines, chemokines (involved in immune modulation) and 
inflammatory mediators (e.g. eicosanoids), which modulate the functional capabilities of 
monocytes and tissue macrophages during inflammation (Dale et al., 2008; Jiménez et 
al., 1999; Kulseth et al., 1998; Martinez et al., 2006). 
 
Phagocytes undergo increased metabolic activity (respiratory burst) during phagocytosis, 
which is associated with the generation of O2
-
 when oxygen is reduced by NADPH 
oxidase (found in the cell membranes of phagocytes).  O2
-
 undergoes several reactions to 
form reactive oxygen intermediates including H2O2, hydroxyl radical, and hypoclorous 
acid, which are microbicidal agents.  Respiratory burst can be induced by intact bacteria, 
opsonized particles, endotoxins, cytokines (e.g. TNFα and IFNγ), N-formylated 
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chemoattractant peptides and activators of PKC (e.g. phorbol esters).  Reactive nitrogen 
intermediates have bactericidal activity (Guzdek et al., 1997).  Macrophages activate 
NOS, leading to NO production.  NO has cytostatic or cytotoxic activity against viruses, 
bacteria, fungi, helminthes, protozoa and tumour cells (Jiménez et al., 1999; Dale et al., 
2008), and participates in the production of free radicals (Jiménez et al., 1999).  
Interaction between reactive oxygen and nitrogen intermediates forms ONOO
-
, which 
increases cytotoxicity and inflammation (Guzdek et al., 1997).  NO may regulate 
phagocytosis as was shown by hydroxyapatite-induced phagocytosis in the murine 
macrophage cell line, RAW264.7 (Gopinath et al., 2006).  
 
Apoptotic cells are recognized via the vitronectin and/or PS receptors.  Inflammation is 
generally not associated with apoptosis, because apoptotic cells are phagocytosed to 
prevent leakage.  Apoptotic cells are removed before the integrity of cell membranes is 
lost.  Phagocytosis of apoptotic cells is important to clear nonfunctional dying cells. 
Kurosaka et al. (1998) have shown that phagocytosis of apoptotic CTLL-2 cells by PMA 
treated THP-1 cells is associated with the production of pro-inflammatory cytokines (e.g. 
IL-1β and IL-8).   
 
Phagocytes play an important role in the elimination of pathogens and apoptotic cells.  
Phagocytes activate NOS, which produce NO involved in pathogen elimination.  This 
section focuses on the phagocytic behaviour of monocyte-macrophages when treated with 
Hypoxis extracts and its purified compounds. 
 
6.5.2.  Materials and Methods 
 
Human promonocytic leukemia U937 cells were differentiated with 100 nM 1,25(OH)2D3 
as described in section 6.3.2.  Differentiating agent was removed by centrifugation at 250 
x g for five min at room temperature, supernatant discarded, cells washed with 
RPMI1640: 10% fbs (complete medium) and resuspended in complete medium.  One 
hundred thousand cells were added to polypropylene tubes and treated with DMSO 
(0.25%, v/v), H. hemerocallidea (125 μg/mL), H. stellipilis (125 μg/mL), H. sobolifera 
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(125 μg/mL), hypoxoside (50 μg/mL), rooperol (20 μg/mL), CD (4 mM)/EtOH (5%, v/v), 
β-sitosterol (30 μM), campesterol (30 μM), cholesterol (30 μM), stigmasterol (30 μM) or 
PMA (10 or 20 nM) for three hrs, which has been optimized as the pretreatment period 
for best phagocytosis (data not shown).  After treatment, compounds were removed by 
centrifugation as described above.  Uptake buffer [Hanks‟ Balanced Salt Solution 
(HBSS) with additional 20 mM HEPES] was added to a vial of pHrodo
TM
 E. coli 
BioParticles
®
 Conjugate, sonicated for five min, added (50 μL = 50 μg/mL of pHrodoTM 
E. coli Bioparticles
®
 conjugate) to each tube and incubated in the dark for three hours in a 
humidified incubator at 37 °C in the absence of CO2.  Cells were washed as described 
above, resuspended in PBS (500 μL) and read on a Beckman Coulter Cytomics FC500.  
Mean fluorescence intensity (MFI) of treated cells was expressed as a percentage of the 
MFI of control cells.  Statistical significance was determined using the two-tailed 
Student‟s t-test. 
 
Phagocytosis only with treatments.  Monocyte-macrophages were treated with the 
Hypoxis extracts and its purified compounds for three hrs and pHrodo
TM
 E. coli 
Bioparticle
®
 Conjugate added as described above. 
 
Phagocytosis with treatments together with PMA.  Monocyte-macrophages were treated 
with the Hypoxis extracts and its purified compounds, in the presence of 20 nM PMA, for 
three hrs and pHrodo
TM
 E. coli Bioparticle
®
 Conjugate added as described above. 
 
6.5.3.  Results and Discussion 
 
The measured phagocytic activity of monocyte-macrophages is based on the acidification 
of E. coli bioparticles, conjugated to the fluorogenic pHrodo
TM
 dye, as they are ingested 
(Figure 6.7).  Fluorescence increases as the phagosome, inside the monocyte-
macrophages, becomes more acidic.   
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                                      Bioparticles                        Monocyte-macrophages     
                            
 
 
Figure 6.7: Histograms of pHrodo
TM
 E. coli bioparticles
®
 and monocyte-macrophages.  
Arrow represents the position of pHrodo
TM
 E. coli bioparticles
®
 after phagocytosis by 
monocyte-macrophages. 
 
Kurosaka et al. (1998) have shown that phagocytosis of PMA treated THP-1 cells 
phagocytosing apoptotic CTLL-2 cells occurred quickly and were completed within three 
hrs.  They also showed that phagocytosis may be temperature dependent, with better 
phagocytosis at 37 °C than 20 °C.  Hence the incubation of treated monocyte-
macrophages with pHrodo
TM
 E. coli Bioparticles
®
 for three hours at 37 °C. 
 
Phagocytosis in absence of PMA.  Differentiated monocyte-macrophages were treated for 
three hours, in the absence of PMA (Figure 6.8). 
 
Small, but significant increases (10-20%) in phagocytosis were seen when monocyte-
macrophages were treated with the three Hypoxis spp., rooperol and β-sitosterol.  PMA 
was used as the positive control.  H. sobolifera (p<0.001) had a significantly greater 
effect on phagocytosis compared to H. hemerocallidea and H. stellipilis (p<0.01).  This 
may be explained by H. sobolifera‟s higher β-sitosterol content (Chapter 3, section 3.3), 
since β-sitosterol in this study also increased phagocytosis significantly (p<0.01).  
Increase in phagocytosis seen with H. hemerocallidea and H. stellipilis are unlikely to be 
due to rooperol, because β-glucosidase was not added to the Hypoxis extracts.  The 
hypoxoside present in these two Hypoxis spp. could not have played a role and 
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phagocytosis was probably due to its β-sitosterol content.  The crude Hypoxis extracts 
contain additional compounds (Chapter 3, section 3.3), which may have been responsible 
for phagocytosis.  Hypoxoside, campesterol, cholesterol and stigmasterol had no 
significant effect on phagocytosis.   
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Figure 6.8:  Phagocytosis of pHrodo
TM
 E. coli bioparticles
®
 by monocyte-macrophages, 
pretreated with DMSOc, Hypoxis chloroform extracts, hypoxoside and rooperol (A), and 
CD/EtOHc, (phyto)sterols and PMA (B) in the absence of PMA.  Bar graph percentages 
represent the increase in mean fluorescence intensity of cells staining positive for 
phagocytosis when treated samples were compared to control.  Error bars represent the SD 
of triplicate values.  Significance was determined using the two-tailed Student T-test: 
*p<0.01; **p<0.001; ***p<0.0001 compared to control. 
 
 
 
 
 
  *   * ** * 
* 
** 
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B 
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Phagocytosis with simultaneous PMA treatment.  Monocyte-macrophages were treated 
for three hours in the presence of 20 nM PMA (Figure 6.9). 
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Figure 6.9:  Phagocytosis of pHrodo
TM
 E. coli bioparticles
®
 by monocyte-macrophages, 
pretreated with DMSOc, Hypoxis chloroform extracts, hypoxoside and rooperol (A), and 
CD/EtOHc, (phyto)sterols and PMA (B) in the presence of PMA (20 nM). Bar graph 
percentages represent the increase in mean fluorescence intensity of cells staining positive 
for phagocytosis when treated samples were compared to control.  Error bars represent the 
SD of triplicate values.  Significance was determined using the two-tailed Student t-test: 
*p<0.01; **p<0.001; ***p<0.0001 compared to control. 
  
Simultaneous treatment of monocyte-macrophages with Hypoxis and its purified 
compounds, and PMA has shown a decrease in phagocytosis.  Only H. sobolifera and 
rooperol slightly increased phagocytosis, with the former being significantly different 
from the control.   
** 
A 
B 
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Density plots (Figure 6.10) clearly show the increase in phagocytosis when treated with 
H. sobolifera and rooperol, in the presence of PMA.  Phagocytosis density plots of H. 
hemerocallidea, H. stellipilis, hypoxoside, β-sitosterol, campesterol, cholesterol, 
stigmasterol and PMA treated monocyte-macrophages are shown in Appendix 6.    
            
                         
                          
 
 
Figure 6.10:  Density plots of phagocytosis of pHrodo
TM
 E. coli bioparticles
®
 by monocyte-
macrophages, pretreated with DMSOc, H. sobolifera chloroform extract and in the presence 
of PMA (20 nM).  
 
This was the first time that the effects of Hypoxis and its purified compounds on 
phagocytosis were investigated.  Although the increases in phagocytosis were small (10-
20%), the results were significantly different.  Hypoxis extracts, β-sitosterol and rooperol 
treatment of monocyte-macrophages significantly increased phagocytosis in the absence 
of PMA.  This may play an important role in increasing phagocytosis of pathogenic 
microorganisms and apoptotic cells.  
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6.6.  Pro- and Anti-inflammatory Cytokines 
 
6.6.1.  Background 
 
Cytokines are small (molecular weights of between 8 and 40 000 Da), nonstructural, 
endogenous inflammatory and immunomodulating proteins (Dinarello, 2000; Gogos et 
al., 2000).  Most nucleated cells synthesize and respond to cytokines, which are involved 
in the host response to disease or infection.  Cytokine genes are not expressed unless 
specifically stimulated in response to stress (Dinarello, 2000).  The effect of any cytokine 
depends on the (i) time of release, (ii) local milieu in which it acts, (iii) presence of 
competing or synergistic elements, (iv) cytokine receptor density, (v) and tissue 
responsiveness to each cytokine (Opal and DePalo, 2000). 
 
Pro-inflammatory cytokines include IL-1α/β, possibly IL-6, IL-12, TNFα, and IFNγ.  
These promote inflammation by upregulating genes encoding enzymes PLA2, COX-2, 
and iNOS that increase the synthesis of platelet-activating factor, leukotrienes, 
prostanoids and NO (Dinarello, 2000; Gogos et al., 2000).  An excess of pro-
inflammatory cytokines is associated with multiple organ-system dysfunctions and 
mortality (Gogos et al., 2000).  Anti-inflammatory cytokines include IL-4, possibly IL-6, 
IL-10, IL-11, IL-13, TGFβ and cytokine inhibitors [including soluble tumour necrosis 
factor receptor (sTNFR)-I and II, and soluble IL-1 receptors (sIL-1r)].  These cytokines 
control and downregulate the inflammatory response caused by pro-inflammatory 
cytokines leading to immune system depression in patients (Dinarello, 2000; Gogos et 
al., 2000; Opal and DePalo, 2000).  The human immune response to severe infections is 
mediated mainly by the primary pro-inflammatory cytokines IL-1 and TNFα and 
secondary pro-inflammatory cytokines IL-6 and -8.  Anti-inflammatory IL-10 and soluble 
cytokine inhibitors prevent excessive pro-inflammatory cytokine production and may 
induce a state of immunosuppression in patients (Gogos et al., 2000).  Certain anti-
inflammatory cytokines must be present at greater concentrations than pro-inflammatory 
cytokines to inhibit their functions (Opal and DePalo, 2000).  The balance between pro- 
and anti-inflammatory cytokines determines the outcome of disease (Dinarello, 2000).  
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Pro-inflammatory cytokines, including TNF-α, IL-1β and IL-6, may affect apoptosis in 
human peripheral blood cells.  These cytokines reduce spontaneous apoptosis in 
neutrophils, but have little effect on the lymphocyte population (McNamee et al., 2005).   
  
T lymphocytes are divided into CD4
+
 and CD8
+
 cells.  The former are cytokine secreting 
helper cells, whereas the latter are cytotoxic killer cells eliminating virally infected cells.  
CD4
+
 T helper lymphocytes are classified into Th1 and Th2 cells on the basis of their 
cytokine production.  Th1 cells secrete IL-2, IL-12, IFNγ and TNFα/β, which activate 
macrophages and promote cell-mediated immune responses against invasive intracellular 
pathogens.  Th2 cells secrete IL-4, IL-5, IL-6, IL-10 and IL-13, which promote humoral 
immune responses against extracellular pathogens (Breytenbach et al., 2001; Opal and 
DePalo, 2000; Rocca and FitzGerald, 2002). 
 
Pro- and anti-inflammatory cytokines play an important role in the onset and prevention 
of inflammation, respectively.  This section focuses on the effect of Hypoxis extracts and 
its purified compounds on pro- and anti-inflammatory cytokine production in 
unstimulated PBMCs. 
 
6.6.2.  Materials and Methods 
 
PBMCs were isolated from venous blood of two healthy donors (male and female) using 
heparinised Vacutainer
®
 CPT
TM
 cell preparation tubes (Beckton Dickinson, Plymouth, 
UK) within 30 minutes of collection.  PBMCs were seeded at 500 000 cells/mL in round 
bottomed 96-well plates and treated with filter sterilized DMSO (0.25%, v/v), H. 
hemerocallidea (125 μg/mL), H. stellipilis (125 μg/mL), H. sobolifera (125 μg/mL), 
hypoxoside (50 μg/mL), rooperol (20 μg/mL), CD (4mM)/EtOH (5%, v/v), β-sitosterol 
(30 μM), campesterol (30 μM), cholesterol (30 μM) or stigmasterol (30 μM) for 48 hrs at 
37 ºC in a humidified incubator and 5% CO2.  After treatment, aliquots of the culture 
media were removed and used immediately or frozen at -20 °C.  The FlowCytomix 
Multiplex human Th1/Th2 10plex Kit I (Bender Medsystems; Vienna, Austria), 
containing antibodies for IFNγ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70 and 
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TNFα was used as described in the product protocol. Samples were analyzed using the 
Beckman Coulter FC500 and data analyzed using Bender Medsystems
TM
 
FlowCytomixPro 1.0 Software BMSFFS/1.0.  Endotoxin levels in the 125 μg/mL 
Hypoxis chloroform extracts were determined using the Limulus Amebocyte Lysate 
Endochrome
TM
 kit (Charles River Endosafe, SC, USA) as described in the protocol.  
Mean fluorescence intensity (MFI) of treated cells was expressed as a percentage of the 
MFI of control cells.  Statistical significance was determined using the two-tailed 
Student‟s t-test. 
 
6.6.3.  Results and Discussion 
 
The FlowCytomix Multiplex human Th1/Th2 10plex cytokine assay is based on the 
fluorescence bead immunoassay.  Two sets of microspheres of different sizes (4.4 and 5.5 
μM in diameter), each consisting of five bead populations internally dyed with different 
intensities of a fluorescent dye, were used (Figure 6.11).  This allows for the 
simultaneous quantification of 10 cytokines.  Fluorescently labelled beads are coated with 
primary antibodies, specific for each cytokine present in the sample.  Biotin-conjugated 
secondary antibodies bind cytokines bound to the primary antibodies.  Streptavidin-
phycoerythrin binds the biotin conjugated secondary antibodies and emits fluorescent 
signals.  
      
 
 
Figure 6.11:  Identification of the 10 cytokines using the FlowCytomix Multiplex human 
Th1/Th2 10plex Kit I.  Dot plot of two populations representing the two sizes of beads (A) 
and dot plots (Bi) and histograms (Bii) of the five different fluorescent intensities of the 4.4 
μM diameter beads, each representing a cytokine (B).  
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Extracellular cytokines.  Pro-inflammatory cytokines measured in the samples include 
IL-1α/β, possibly IL-6, IL-12, TNFα, and IFNγ.  Anti-inflammatory cytokines measured 
in the samples include IL-4, possibly IL-6, and IL-10.  Results showing significant 
differences are shown in Figure 6.12.  The rest are shown in Appendix 6. 
 
Only two donors (male and female) were used due to the difficulty to find healthy donors 
that are not on any medication – non steroidal anti-inflammatory drugs (NSAIDs), 
antihistamines and oestrogen – which may influence cytokine production.  Male and 
female donors were chosen to see if differences exist between male and female.  The 
experiment was only performed on two donors due to the high costs involved.  
(Phyto)sterols increased IL-1β and IL-6 production significantly in donor one (male) 
when compared to the CD/EtOH control.  β-sitosterol and cholesterol also increased IL-
1β production significantly in donor two (female).  Campesterol increased IL-10 
production (p<0.01) in PBMCs isolated from the male donor, while H. hemerocallidea 
increased IL-8 production (p<0.01) in PBMCs isolated from the female donor.  
Differences seen between male and female donors may be gender related, but this is only 
speculative and need further investigation.   
 
Treatment of PBMCs with the other Hypoxis extracts and purified compounds did not 
have any significant effects on the production of the other cytokines.  This may be 
explained by the absence of a stimulant (e.g. PMA, LPS and PHA), which needs to be 
present to induce cytokine production.  PBMCs consist mainly of T cells, B cells and 
monocytes, which may be inappropriate cells to investigate pro- and anti-inflammatory 
cytokine production.  To have a better view of the effects of Hypoxis extracts and its 
purified compounds on the cytokines involved in inflammation and phagocytosis, a 
macrophage cell line or differentiating monocytes to macrophages using an appropriate 
stimulant must be used.  Samples were filter sterilized with the result that non-polar 
compounds (including phytosterols and other compounds found in the Hypoxis extracts) 
may have attached to the polar membranes of the Supor (polyethersulfone) syringe filters 
(Pall Life Sciences, MI, USA).   
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Figure 6.12:  Extracellular cytokine production by PBMCs treated with Hypoxis extracts 
and its purified compounds for 48 hrs.  Grey bars = donor 1/male; striped bars = donor 
2/female.  Error bars represent the SEM of triplicate values.  Significance was determined 
using the two-tailed Student t-test: *p<0.01; **p<0.001; ***p<0.0001 compared to control. 
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Increased cytokine production was not due to endotoxin in the Hypoxis chloroform 
extracts, because endotoxin levels were less than the maximum level [<1 ng/mL of LPS 
(Pollock et al., 2003; Webb et al., 1998)] allowed in samples for immunological 
experiments.  The PBMCs were exposed to very low levels of LPS in the present study 
(0.32 0.27, 0.25 ng/mL for H. hemerocallidea, H. stellipilis and H. sobolifera, 
respectively).   
 
The predominantly pro-inflammatory results obtained in this study are in contradiction 
with results obtained in other studies.  Nashed et al. (2005) have shown that a 
phytosterol-enriched (2%) diet over a 14 week period lowered pro-inflammatory 
cytokines (TNF-α and IL-6) and increased anti-inflammatory cytokines (IL-10) in 
apolipoprotein (apo) E-deficient mice when exposed to the inflammatory stimulus, LPS.  
Calpe-Berdiel et al. (2007) have shown an increase in IL-2 and IFN-γ release when ConA 
activated spleen lymphocytes, isolated from Apo E-deficient mice, were exposed to 2% 
phytosterols for 48 hrs and inflammation induced by turpentine.  There was no change in 
IL-4 and IL-10 levels. 
 
Macrophages are the main source of the pro-inflammatory cytokines, TNFα, IL-1β and 
IL-6.  Overproduction of TNFα and IL-1 play an important role in the pathogenesis of 
septic shock, asthma, rheumatoid arthritis, and other diseases.  Suppression of synthesis 
of these cytokines may be required for the treatment of above-mentioned diseases 
(Guzdek et al., 1996).  Guzdek et al. (1996) have shown that rooperol and its derivatives 
suppress LPS-induced production of TNFα, IL-1 and IL-6 at protein level in human 
alveolar macrophages, blood monocytes and U937 cells, and rat alveolar macrophages.  
Diacetate and tetraacetate rooperol derivatives (IC50 values of 10-20 μM) were more 
potent inhibitors of cytokine synthesis than the sulfate derivative (IC50 values of 25-75 
μM), possibly due to the enzymes available to release the esters from rooperol (Guzdek et 
al., 1996).  Guzdek et al. (1998) have also shown that rooperol tetraacetate (10 μM) 
decreases TNFα, IL-1β and IL-6 mRNAs in the absence and presence of LPS in PMA 
differentiated U937 cells.  Rooperol and its derivatives may inhibit inflammatory 
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cytokine synthesis by interfering with transcription factors (e.g. NF-κB and AP-1) 
required for cytokine gene transcription (Guzdek et al., 1998).   
 
6.7.  Conclusion 
 
Differentiation of U937 cells to monocyte-macrophages was optimized using three time 
intervals (24, 48 and 72 hrs) and two differentiating agents [PMA and 1,25(OH)2D3] at 
three concentrations (10, 50 and 100 nM).  1,25(OH)2D3 was chosen as the differentiating 
agent, due to higher cell viability at high concentrations.  A higher concentration (100 
nM) and shorter differentiating period (24 hrs) were used.  Monocyte-macrophages were 
confirmed by morphological characteristics (attachment of cells, clump- and pseudopodia 
formation) and CD11b/CD14 expression.  Treatment of monocyte-macrophages with H. 
hemerocallidea, H. stellipilis, H. sobolifera and rooperol has shown for the first time (i) 
an increase in NO production and (ii) phagocytosis.  H. stellipilis had a greater effect on 
NO production than H. hemerocallidea and H. sobolifera.  The phytosterols had no effect 
on NO production.  NO production was probably due to iNOS induction, which can be 
confirmed by inhibitors against cNOS, eNOS and iNOS.  Small, but significant increases 
in phagocytosis were seen when monocyte-macrophages were pretreated with the 
Hypoxis chloroform extracts and rooperol.  NO production and phagocytosis results 
confirmed that rooperol is the active compound and not hypoxoside.  Although the 
treatments had no significant effects on COX-2 expression, experimental design may be 
changed to further investigate possible increases and decreases of COX-2 expression.  
Hypoxis chloroform extracts and its purified compounds may not effect the expression of 
COX-2, but may decrease or increase COX-2 activity.  Hypoxis chloroform extracts, 
hypoxoside and rooperol had very little or no effect on anti- and pro-inflammatory 
cytokine production.  The phytosterols tested increased pro-inflammatory cytokines (e.g. 
IL-1β and IL-6), which is in contradiction with decreased pro-inflammatory cytokines 
found in other studies.   
 
Increased phagocytosis and NO production play important roles in removing apoptotic 
cells in vivo (Pepper et al., 1998) and promoting apoptosis in cancer (Brüne et al., 1998; 
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Choi et al., 2001), respectively.  Phagocytosis and NO production are also important in 
eliminating microorganism, hence possible anti-bacterial properties.  Hypoxis extracts 
and rooperol may play an important role in increasing phagocytosis and NO production 
for above mentioned biological effects. 
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CHAPTER 7 
ANTIOXIDANT ACTIVITY 
 
7.1.  General Background 
 
An antioxidant (syn. free radical scavengers) can be defined as a natural or synthetic 
substance, being enzymes or organic substances, which inhibit or prevent the damaging 
effects of oxidation in animal tissues (Huang et al., 2005; Krishnaiah et al., 2007).  It 
decreases the adverse effects of reactive oxygen or nitrogen species on normal 
physiological function in humans (Huang et al., 2005).   
 
Antioxidant compounds found in plants include carotenoids (e.g. lutein, β-carotene), 
flavonoids (e.g. quercetin, rutin, luteolin, kaempferol), cinnamic acids, benzoic acids, 
folic acid, ascorbic acid (syn. vitamin C), tocopherols (syn. vitamin E), tocotrienols, 
vitamin A, proanthocyanidin, and micronutrient elements or minerals (e.g. Cu, Mn, Zn, 
Fe, Se) (Ardestani and Yazdanparast, 2007; Brown et al., 1998; Krishnaiah et al., 2007; 
Lee et al., 2003; Matés et al., 1999; Papas, 1999).  Synthetic antioxidants may have side 
effects when taken in vivo, while natural antioxidants have generally higher antioxidant 
activity compared to synthetic antioxidants (Krishnaiah et al., 2007).  These dietary or 
exogenous antioxidants are important for normal functioning of the endogenous 
antioxidant system. 
 
Characteristics of a potential antioxidant include: 
 
 Absorption and bioavailability. 
 Effective dose, safety and toxicity. 
 Distribution in cells, tissue and extracellular fluids. 
 Free radical scavenging ability. 
 Metal chelating activity. 
 Effects on gene expression. 
 Interaction with cellular antioxidants or antioxidant enzymes. 
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 Detoxification of carcinogenic metabolites (Bagchi et al., 2000; Rice-Evans et al., 
1997). 
 
Nair et al. (2007b) have shown that a H. hemerocallidea aqueous extract and rooperol 
increase antioxidant activity [1,1-diphenyl-2-picryl hydrazine (DPPH) and ferric reducing 
ability of plasma (FRAP)], reduce quinolic acid induced lipid peroxidation and increase 
superoxide free radical scavenging activity.  Laporta et al. (2007b) have shown that H. 
hemerocallidea and rooperol have high antioxidant capacity.  Vivancos and Moreno 
(2005) investigated the effect of β-sitosterol on antioxidant enzymes and reduced 
glutathione (GSH)/glutathione disulfide (GSSG; oxidized).  This chapter focuses on the 
effect of Hypoxis extracts and its purified compounds on ROS production in 
differentiated and undifferentiated U937 cells, and the FRAP antioxidant potential.  The 
effects of Hypoxis extracts and its purified compounds on superoxide dismutase (SOD) 
activity in Chang liver cells were also investigated. 
 
7.2.  Reactive Oxygen Species (syn. respiratory burst, oxidative burst)  
 
7.2.1.  Background 
 
Definition.  Reactive oxygen species are ubiquitous, highly diffusible and reactive 
molecules (Barbieri et al., 2003) produced by molecular oxygen reduction during aerobic 
respiration and substrate oxidation in mammalian cells (Matés et al., 1999).   
 
Biological properties.  Small amounts of ROS (including O2
-
 and H2O2) are continuously 
produced under normal conditions.  ROS are produced for essential biological processes 
or as byproducts of metabolic processes (Krishnaiah et al., 2007).  Low levels of ROS are 
important in biological processes, including the regulation of cellular functions (cell 
growth, differentiation, proliferation and apoptosis/necrosis), induction or suppression of 
gene expression (AP-1 and NF-κB transcription factors), activation of cell signalling 
pathways (MAPK, Erk, guanylyl cyclase, PLC/D and PLA2), energy production, and 
phagocytosis (Ardestani and Yazdanparast, 2007; Barbieri et al., 2003; Hancock et al., 
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2001; Kurz et al., 2004; Martin and Barrett, 2002; Matés et al., 1999; Salganik, 2001).  
Activation of gene expression and redox-sensitive signalling pathways are important in 
regulating cytokine production and inflammatory mediator expression (Barbieri et al., 
2003; Forman and Torres, 2002; Martin and Barrett, 2002).  ROS are ideal signalling 
compounds due to their small size, diffusion over short distances, several mechanisms for 
rapid and controllable production, and numerous mechanisms for rapid removal.  To be 
considered a signalling molecule, ROS must (i) be produced by cells when stimulated to 
do so; (ii) have action on cells producing it or on nearby cells; (iii) be removed in order to 
turn off or reverse the signal.  O2
-
 and H2O2 fulfill these criteria (Hancock et al., 2001). 
 
Sources.  Endogenous sources of ROS include the (i) mitochondria: electrons released 
from the electron transport chain reduce O2 to O2
-
, which may lead to the formation of 
H2O2 and OH
-
; (ii) endoplasmic reticulum (ER): cytochrome P450 complexes generate 
O2
-
 to metabolize and degrade hydrophobic toxic substances, steroids and drugs, by 
transforming it to hydrophilic compounds that can be removed from the body; (iii) 
phagocytes: produce O2
-
, H2O2 and OH
-
 to kill infectious microorganisms, bacteria- and 
virus-infected cells, and cancer cells; (iv) peroxisomes: degradation of fatty acids and 
other molecules is associated with H2O2 production (Barbieri et al., 2003; Krishnaiah et 
al., 2007; Salganik, 2001); (v) several enzymatic reactions: O2
-
 is a by-product of 
oxygenases (including lipooxygenase and COX) and oxidases (NADPH- and xanthine 
oxidase), hepatic metabolism and oxyhemoglobin degradation (Barbieri et al., 2003; 
Martin and Barrett, 2002; Rodriguez et al., 2003).  Exogenous sources of ROS include (i) 
radiation exposure to environment or manmade sources including gamma rays, UV 
irradiation and X-rays, which split water in the body to form OH
-
; (ii) low percentage of 
O2 breathed in is used to produce O2
- 
(Krishnaiah et al., 2007; Martin and Barrett, 2002); 
(iii) ROS producers, including aldehydes, redox cycling quinones, heavy and transition 
metals, and thiol alkylating agents (Martin and Barrett, 2002). 
  
Oxidative stress occurs due to the overproduction and/or incomplete removal of ROS by 
the body‟s defense mechanism (Ardestani and Yazdanparast, 2007; Núñez-Sellés, 2005), 
which may result in metabolic malfunction and damage to biological macromolecules 
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(Matés et al., 1999).  ROS causing oxidative damage are divided into free oxygen 
radicals, which contain one or more unpaired electron(s) capable of independent 
existence, and nonradical ROS.  Examples of free oxygen radicals and nonradicals are 
O2
-
 and hydroxyl anion (OH
-
), and H2O2, respectively.  Free radicals can react with 
nonradicals to form a new radical (Krishnaiah et al., 2007; Shackelford et al., 2000).  
Endogenous factors contributing to oxidative stress include defects in mitochondrial 
respiration, nuclear polymorphism activation, enzyme system activation or inhibition, 
arachidonic acid metabolism, and Fe/Cu-related catalysis.  Exogenous factors 
contributing to oxidative stress include environmental pollutants, solar radiation, urban 
air pollutants, exposure to toxic substances (e.g. fertilizers, pesticides, gasoline exhaust 
and chemical wastes), intoxication (e.g. alcohol, drugs and smoking), inadequate 
nutrition, drug metabolism and physical or psychical stress (Bagchi et al., 2000; Núñez-
Sellés, 2005). 
 
Protection against ROS.  Antioxidant defense against ROS include preventive-, 
repairing- and scavenger mechanisms (Núñez-Sellés, 2005).  It is divided into the 
enzymatic and non-enzymatic antioxidant defense systems.  
 
Enzymatic antioxidant defense system (Figure 7.1) against ROS consists of SOD, 
catalase (CAT) and glutathione peroxidase (GPX).  SOD catalyzes the dismutation of two 
molecules of the highly reactive O2
-
 to O2 and less reactive H2O2.  Three forms of SOD, 
including cytosolic Cu/Zn-SOD, mitochondrial Mn-SOD and extracellular SOD, are 
found.  Transition metals, especially Cu
2+
 and Mn
2+
, at the active site allow for rapid 
electron exchange between the two O2
-
 molecules.  H2O2 is detoxified by CAT and GPX.  
CAT is mainly present in peroxisomes, contains ferric iron at the active site and reduces 
two H2O2 molecules into water and O2.  GPX is present in the mitochondria and cytosol, 
contain selenium at the active site and reduces H2O2 to water and O2 in the presence of 
GSH.  GSH acts as a substrate and transfers electrons to H2O2 (Matés et al., 1999; 
Rodriguez et al., 2003; Salganik, 2001).  The GSH concentration is regulated by the 
reduction of GSSG via GSH reductase (Forman and Torres, 2002).  Although GPX 
shares H2O2 as a substrate with CAT, it is the only enzyme to react with lipid and organic 
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hydroperoxides.  Under oxidative stress conditions, H2O2 diffuses freely across the 
cellular membranes and undergo hemolytic cleavage when interacting with transition 
metal ions (Fe/Cu).  Highly reactive and damaging OH
-
 radicals are formed, during the 
Fenton reaction.  Lysosomes contain high concentrations of low molecular mass, labile 
and reactive iron, due to degradation of iron-containing proteins.  Intralysosomal Fenton-
type reactions may cause peroxidative-membrane destabilization, rupturing and release of 
hydrolytic enzymes (associated with cell apoptosis or necrosis depending on 
concentration) and iron into the cytosol.  The Fenton reaction is site specific and can 
result in hydroxylation or other DNA modifications (Kurz et al., 2004; Matés et al., 1999; 
Rodriguez et al., 2003; Salganik, 2001).  Small changes in physiological activity of 
antioxidant enzymes may have a huge effect on the resistance of cells to oxidant-induced 
damage to the genome and cell killing (Matés et al., 1999).   
 
 
 
Figure 7.1:  Summary of the enzymatic antioxidant defense system against ROS (Matés et 
al., 1999).  See text for more detail. 
 
The non-enzymatic antioxidant system consists of macromolecules and small molecules.  
Small molecular weight molecules directly scavenge free radicals (Rodriguez et al., 
2003).  Endogenously synthesized small molecules include ubiquinol, GSH, methionine, 
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uric acid, bilirubin and melatonin (Ardestani and Yazdanparast, 2007; Cao and Prior, 
1998; Lee et al., 2003; Papas, 1999; Salganik, 2001).  Exogenous or dietary small 
molecules were summarized under general background (section 7.1).  Transition metal 
ions are eliminated by macromolecules including metallothioneins, ferritin, transferrin, 
cerulloplasmin, albumin and myoglobin, which protect against OH
-
 production (Núñez-
Sellés, 2005; Salganik, 2001).  Endogenous antioxidants provide insufficient protection 
against ROS due to continuous production of ROS needed for biological functions 
(Krishnaiah et al., 2007; Salganik, 2001). 
 
Disadvantages.  Excessive ROS production may damage lipids, proteins and DNA by 
causing lipid peroxidation, promoting oxidation and premutagenic modification of 
nucleotides, respectively (Ardestani and Yazdanparast, 2007; Bagchi et al., 2000; 
Salganik, 2001).   
 
Excessive ROS may attack cells by: 
 
 Modifying the DNA structure.  
 Repressing gene expression by inhibiting or destructing transcriptional factors. 
 Loss in cell membrane integrity by cell rupturing due to lipid oxidation, which 
may affect cell structure and function. 
 Modifying cell function by accumulating oxidized low density lipoproteins. 
 Activation or inactivation of enzymes.  
 Sulfhydryl depletion.  
 Altered calcium homeostasis (Ardestani and Yazdanparast, 2007; Bagchi et al., 
2000; Núñez-Sellés, 2005; Salganik, 2001).  
 
Pathological conditions alter the efficiency of the antioxidant defense system, resulting in 
ineffective scavenging and free radical overproduction (Ardestani and Yazdanparast, 
2007).  Imbalance of ROS production play a role in the pathogenesis of allergy, 
neurodegenerative diseases (e.g. Alzheimer‟s, Parkinson‟s, schizophrenia), cancer, 
atherosclerosis, diabetes, emphysema, heart diseases (e.g. cardiac and vessel injuries, 
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coronary heart disease), genetic and metabolic disorders, infectious diseases, 
ophthalmologic problems (cataracts), ageing, malaria, AIDS, autoimmune disorders 
(arthritis), gastrointestinal dysfunction, haemorrhagic shock, ischemia and reperfusion of 
many organs (Ardestani and Yazdanparast, 2007; Bagchi et al., 2000; Krishnaiah et al., 
2007; Matés et al., 1999; Salganik, 2001; Shackelford et al., 2000). 
 
ROS and cancer.  Carcinoma cells are frequently under persistent oxidative stress.  In 
vitro, tumour cell lines produce ROS at a greater rate than non-transformed cell lines 
(Brown and Bicknell, 2001).  ROS are involved in the initiation and promotion of 
carcinogenesis (Röhrdanz and Kahl, 1997).  
 
It is estimated that 2 x 10
4
 DNA damaging events occur per cell per day in the human 
body. Oxidative damage is greater in the mitochondrial genome, due to ROS‟s close 
proximity compared to nuclear DNA (Shackelford et al., 2000).  Increased oxidative 
stress in carcinoma may (i) increase DNA damage via single- or double-stranded DNA 
breaks, DNA-protein crosslinks, base (guanine and thymine) and sugar modifications, 
depurination and depyrimidination, and chromatid exchange, which result in increased 
mutation and tumour progression.  ROS may inactivate tumour suppressor genes and 
increase proto-oncogene expression (Brown and Bicknell, 2001; Shackelford et al., 
2000); (ii) activate growth promoting signalling pathways; (iii) increase angiogenesis via 
blood vessel growth and vasodilation; (iv) increase metastasis (Brown and Bicknell, 
2001); (v) be associated with lower MnSOD, Cu/ZnSOD and CAT activities in tumour 
cells compared to normal cell counterparts (Röhrdanz and Kahl, 1997).  Specific and 
non-specific repair processes remove most of the damaged DNA, but a small number of 
lesions escape repair and accumulate with age.  Unrepairable damage to DNA leads to 
apoptosis and necrosis (severe and sudden injury by excessive ROS) (Martin and Barrett, 
2002). 
 
Large numbers of macrophages infiltrate tumours (e.g. breast cancer) and secrete TNFα, 
which play a role in oxygen radical production (Brown and Bicknell, 2001).  
Chemotherapy, including cisplatin, etoposide, doxorubicin and mitomycin C, may 
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increase oxidative stress in breast carcinomas by generating O2
-
.  Radiotherapy and 
photodynamic therapy also generate oxygen radicals (Brown and Bicknell, 2001; 
Salganik, 2001). 
 
Increased ROS levels induce apoptosis and necrosis in transformed cells, and oxidative 
carcinogenic damage in DNA; hence protecting against cancer.  Cancer-preventative 
effect of antioxidants depends on the baseline level of ROS in cells, which is determined 
by ROS generation and antioxidant defense.  Overproduction of ROS increases the risk in 
humans to develop cancer, cardiovascular diseases, cataracts, and other diseases.  
Antioxidants may decrease ROS levels by blocking cancer-protective apoptosis and 
phagocytosis in people with low ROS levels; hence promoting carcinogenesis.  The 
biological effects of antioxidants in cancer are thus controversial (Martin and Barrett, 
2002; Salganik, 2001).  Antioxidants may interfere with the therapeutic activity of 
anticancer drugs that kill cancer cells by ROS-dependent apoptosis.  For example, the 
antioxidant α-tocopherol (vitamin E) reduces ROS production and apoptosis in MCF-7 
cells (Salganik, 2001).    
 
Vegetables, fruits and seeds contain vitamin C and E, β-carotene and protease inhibitors, 
which may protect against cancer. Several plants contain bioflavonoids, 
proanthocyanidins, ellipiticine, taxol, indole derivatives, dithiolthiones, phytoestrogens 
and others, which have chemopreventative and/or anticancer properties with additional 
oxidative stress inhibitory properties (Bagchi et al., 2000).  
 
ROS and phagocytosis.  Phagocytes (including neutrophils, monocytes, macrophages, 
polymorphonuclear leukocytes and eosinophils) play an important role in the first line 
defense against bacteria, viruses and fungi (Salih et al., 2000).  Bacterial engulfment by 
phagocytes is associated with enzyme activation, increased oxygen consumption and 
ROS production (Salganik, 2001).  Respiratory burst does not only kill ingested 
microorganisms, but also cause endothelial damage, increased vascular permeability and 
cell death, which may result in sepsis, rheumatic diseases and adult respiratory distress 
syndrome (Guzik et al., 2003; Rothe and Valet, 1990).  Electrons required to reduce O2 to 
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O2
-
 are supplied by NADPH (Forman and Torres, 2002; Salganik, 2001).  Subunits of 
NADPH oxidase are found in the cytosol and assemble at the plasma membrane to form 
an active enzyme.  Active NADPH oxidase produces the central free radical, O2
-
, 
involved in H2O2 production (Barbieri et al., 2003; Böhmer et al., 1992; Brown and 
Bicknell, 2001; Forman and Torres, 2002; Kampen et al., 2004).  O2
-
 dismutates 
spontaneously or by SOD activity to H2O2, which is converted to hypochlorous acid and 
chloramines via myeloperoxidase inside the phagosome (Forman and Torres, 2002; 
Rothe and Valet, 1990).  In general, ROS production increase with increased bacterial 
concentration, but high bacterial concentrations may increase the risk of cell death and 
clumping (Kampen et al., 2004).  Lack of NADPH oxidase, which is associated with 
chronic granulomatous disease, may result in a lack of ROS production and poor 
clearance of pathogenic bacteria and fungi (Forman and Torres, 2002).  NADPH oxidase 
is also found in fibroblasts, mesangial cells, osteoclasts, endothelial cells and 
chondrocytes.  Rate of ROS generation is very low in these cells compared to 
phagocytes; hence ROS‟s role in phagocytosis (Hancock et al., 2001). 
 
ROS production is associated with phagocytosis, which has been investigated in Chapter 
6 (section 6.5).  This section focuses on the effect of Hypoxis extracts and its purified 
compounds on ROS production in undifferentiated and differentiated U937 cells. 
 
7.2.2.  Materials and Methods 
 
Undifferentiated U937 cells.  Human promonocytic leukemia U937 cells were counted, 
resuspended in RPMI1640: 10% fbs at cell densities of 1x10
6
 cells/mL.  U937 cells were 
uniformly stained by adding 1 mM 2,7-dichlorofluorescein diacetate (DCFH-DA) stock 
solution to reach a final concentration of 1 μM.  Cells were mixed and incubated in the 
dark for 30 min at 37 ºC.  Excess DCFH-DA was removed and cells washed twice with 
complete medium by centrifuging at 250 x g for five min at room temperature.  Fifty 
thousand cells were added to polypropylene tubes and treated with DMSO (2.5%, v/v), 
H. hemerocallidea (125 μg/mL), H. stellipilis (125 μg/mL), H. sobolifera (125 μg/mL), 
hypoxoside (50 μg/mL), rooperol (20 μg/mL), CD (4mM)/EtOH (5%, v/v), β-sitosterol 
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(30 μM), campesterol (30 μM), cholesterol (30 μM), stigmasterol (30 μM), PMA (10-100 
nM) or LPS (100-500 ng/mL) for one hour at 37 °C.  After treatment, cells were pelleted 
and washed with PBS as described above.  Cells were resuspended in PBS (500 μL) and 
samples read on a Coulter FC500 flow cytometer.  Mean fluorescence intensity (MFI) of 
treated cells was expressed as a percentage of the MFI of control cells.  Statistical 
significance was determined using the two-tailed Student‟s t-test. 
 
Differentiated U937 cells.  U937 cells were counted, resuspended in RPMI1640: 10% fbs 
and differentiated for 24 hrs with 100 nM 1,25(OH)2D3.  Above procedure for 
undifferentiated U937 cells was followed.   
    
7.2.3.  Results and Discussion 
 
Oxidative burst was measured by the reaction between DCFH-DA and ROS.  Non-polar 
and non-fluorescent DCFH-DA was loaded into undifferentiated and differentiated U937 
cells via passive membrane diffusion, where it remains trapped in the cells.  Inside the 
cell, the dye is deacetylated by non-specific esterases to form the polar, non- or weakly 
fluorescent 2‟,7‟-dichlorofluorescein (DCFH).  ROS released after phagocytosis oxidize 
DCFH, via two electron oxidation, to highly green-fluorescent dichlorofluorescein (DCF) 
(Andoh et al., 2006; Böhmer et al., 1992; Zielonka and Kalyanaraman, 2008).  Green 
fluorescence measured under conditions of intracellular oxidative stress is not a measure 
of intracellular H2O2 or other intracellular radicals, but a combination of several factors 
including GSH, altered iron uptake, increased peroxidase activity, cytochrome c release, 
and others (Zielonka and Kalyanaraman, 2008).    
 
Undifferentiated U937 cells.  U937 cells were treated with Hypoxis extracts and purified 
compounds for one hour, and ROS production measured (Figure 7.2). 
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Figure 7.2:  ROS production by undifferentiated U937 cells after one hour treatment with 
DMSOc, Hypoxis chloroform extracts, hypoxoside and rooperol (A), CD/EtOHc and 
(phyto)sterols (B), untreated, PMA and LPS (C).  Bar graph percentages represent the 
increase in mean fluorescence intensity of cells staining positive for ROS production when 
treated samples were compared to control.  Error bars represent the SD of triplicate values.  
One representative of three experiments performed.  Significance was determined using the 
two-tailed Student t-test: *p<0.01; **p<0.001; ***p<0.0001 compared to control. 
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Significant amounts of ROS were produced when undifferentiated U937 cells were 
treated with the three Hypoxis extracts and rooperol.  When compared to the controls, H. 
hemerocallidea, H. stellipilis, H. sobolifera and rooperol produced 1.6, 3.0, 2.2 and 2.5 
times more ROS, respectively.  ROS production by hypoxoside and PMA (50 nM) were 
not significantly different from the control, with only a 1.3 and 1.8 times increase for the 
former and latter, respectively.  β-sitosterol, campesterol, cholesterol, stigmasterol and 
LPS had no effect on ROS production.  Histogram overlays of the treatments showing 
significant differences are shown in Appendix 7. 
 
 
Differentiated U937 cells.  U937 cells were differentiated to monocyte-macrophages by 
1,25(OH)2D3, treated with Hypoxis extracts and purified compounds for one hour, and 
ROS production measured (Figure 7.3). 
 
Significant amounts of ROS were produced when differentiated monocyte-macrophages 
were treated with the three Hypoxis extracts, rooperol and PMA.  When compared to the 
controls, H. hemerocallidea, H. stellipilis, H. sobolifera, rooperol and PMA (50 nM) 
produced 1.8, 4.7, 2, 6.2 and 2.7 times more ROS, respectively.  ROS production by 
hypoxoside, β-sitosterol, campesterol, cholesterol, stigmasterol and LPS (250 ng/mL) 
were not significantly different from the control, with only 1.1, 1.3, 1.4, 1.3, 1.2 and 1.3 
times increase, respectively.  Histogram overlays of the treatments showing significant 
differences are shown in Appendix 7. The optimal effect of the positive controls (PMA 
and LPS) may have occurred at lower concentrations; hence the absence of dose-related 
effects. 
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Figure 7.3:  ROS production by differentiated U937 cells after one hour treatment with 
DMSOc, Hypoxis chloroform extracts, hypoxoside and rooperol (A), CD/EtOHc and 
(phyto)sterols (B), untreated, PMA and LPS (C).  Bar graph percentages represent the 
increase in mean fluorescence intensity of cells staining positive for ROS production when 
treated samples were compared to control.  Error bars represent the SD of triplicate values.  
One representative of three experiments performed.  Significance was determined using the 
two-tailed Student t-test: *p<0.01; **p<0.001; ***p<0.0001 compared to control. 
   * 
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When comparing ROS production in undifferentiated (monocytes) and differentiated 
(monocyte-macrophages) U937 cells, a more pronounced increase in ROS production 
was seen in differentiated cells.  This may be explained by the greater role played by 
macrophages during phagocytosis (Chapter 6; section 6.5).  This was the first time that 
ROS production was investigated in differentiated and undifferentiated U937 cells when 
treated with Hypoxis extracts and its purified compounds.    
 
Measurement of respiratory burst is an indication of defense against bacterial infections. 
Reduced respiratory burst is associated with impaired ability to kill bacteria and increased 
susceptibility to infectious diseases (Kampen et al., 2004).  Guzdek et al. (1997) have 
shown that rooperol tetraacetate inhibits respiratory burst in human and rat macrophages.  
Mechanisms of respiratory burst inhibition by rooperol may include LPS priming, direct 
interaction with enzymatic pathway where oxygen radicals are formed by NADPH 
oxidase, and/or involvement of cell membrane constituents (e.g. PKC).  Results of 
Guzdek et al. (1997) are in contradiction with the results found in this study.  Barbieri et 
al. (2003) have shown that NADPH oxidase subunits are upregulated during monocytic 
differentiation with PMA.  PMA stimulates NADPH oxidase assembly in phagocytes.  
PMA is a respiratory burst stimulant, which promotes ROS production via PKC 
activation.  Stimulation of ROS production by bacteria is complex (Kampen et al., 2004).  
LPS, a component of the outer membrane of gram-negative bacteria, enhances oxidative 
burst (including the release of oxygen radicals and lysosomal enzymes) and phagocytosis 
in neutrophils in vitro (Böhmer et al., 1992).  LPS had no effect on ROS production in 
this study.  1,25(OH)2D3 was used to differentiate U937 cells to monocyte-macrophages, 
which may have upregulated NADPH oxidase subunits and stimulated NADPH oxidase 
assembly.  The differences observed between differentiated and undifferentiated U937 
cells may suggest an increase in ROS production by NADPH oxidase, which plays an 
important role in phagocytosis.  Pretreatment of monocyte-macrophages with Hypoxis 
chloroform extracts, rooperol and β-sitosterol increased phagocytosis (Chapter 6, section 
6.5) of pHrodo
TM
 E. coli Bioparticles
®
.  Increases were small, but significantly different.  
ROS production by the Hypoxis chloroform extracts, rooperol and β-sitosterol may have 
increased the phagocytotic ability of monocyte-macrophages.  
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This study has shown that β-sitosterol, campesterol, cholesterol and stigmasterol had no 
significant effect on ROS production in undifferentiated or differentiated U937 cells.  
DCFH-DA was preloaded into undifferentiated and differentiated U937 cells before 
treatments; hence only an increase in ROS production could be measured with 
treatments.  Phytosterols may have decreased ROS production, but could not be 
measured.  This is the major limitation of measuring ROS production using a dye.  
Moreno (2003) has shown that β-sitosterol (50-250 μM) decreases H2O2 and O2
-
 
production in PMA stimulated RAW264.7 macrophages.  Inhibitory effects were seen 
after 3-6 hrs pretreatment with β-sitosterol before PMA stimulation.  Rats fed an olive oil 
diet (β-sitosterol being the major phytosterol) released less O2
-
, decreased eicosanoid 
production and increased NO production.  β-sitosterol may be involved in the AA 
cascade, associated with inflammation.  AA is released from cellular phospholipids by 
cPLA2 in response to physiological stimuli, prior to the COX and/or lipooxygenase 
pathways.  β-sitosterol decreases ROS production and AA release simultaneously.  ROS 
are involved in enhancing COX-2 expression and ROS-induced COX-2 expression.  β-
sitosterol alters membrane fluidity and activity of membrane bound enzymes like cPLA2, 
which is involved in AA release and eicosanoid production (Moreno, 2003).   
 
7.3.  Antioxidant Capacity (syn. -efficiency, -power, -potential) 
 
7.3.1.  Background 
 
The FRAP and DPPH assays are based on single electron transfer reactions, which 
measure the antioxidant reducing capacity.  It measures the oxidant-scavenging capacity, 
instead of the preventive antioxidant capacity of the sample.  These assays are based on 
chemical reactions in vitro, and cannot be compared to biological systems (Huang et al., 
2005). 
 
The FRAP assay measures the reduction of ferric (Fe
3+
)-tripyridyltriazine (TPTZ; 
oxidant) to blue coloured ferrous (Fe
2+
)-TPTZ at an acidic pH in the presence of an 
 184 
antioxidant (Figure 7.4).  The oxidant and antioxidant get reduced and oxidized, 
respectively (Benzie and Strain, 1996; Cao and Prior, 1998; Huang et al., 2005).  The 
degree of colour change is proportional to the antioxidant concentration (Huang et al., 
2005).  The use of Fe
2+
 as a final indicator in the FRAP assay can cause problems when 
the antioxidant analyzed does not only reduce Fe
3+
 to Fe
2+
, but also reacts with Fe
2+
 to 
form additional free radicals.  The FRAP assay does not measure serum proteins (e.g. 
albumin) or low molecular weight SH-group-containing antioxidants (e.g. lipoic acid, 
some amino acids) (Cao and Prior, 1998).  The FRAP assay is inexpensive, reagents are 
simple to prepare, results are highly reproducible, and the procedure is easy and fast 
(Benzie and Strain, 1996). 
 
 
Figure 7.4:  Reduction of Fe
3+
-TPTZ to Fe
2+
-TPTZ (Huang et al., 2006). 
 
Nair et al. (2007b) investigated the antioxidant activities of H. hemerocallidea, 
hypoxoside and rooperol using the DPPH and FRAP assays.  This section focuses on the 
antioxidant potential of Hypoxis extracts and its purified compounds. 
 
7.3.2.  Materials and Methods 
 
Stock solutions of H. hemerocallidea (5 mg/mL), H. stellipilis (5 mg/mL), H. sobolifera 
(5 mg/mL), hypoxoside (1 mg/mL), rooperol (1 mg/mL), β-sitosterol (1 mM), 
campesterol (1 mM), cholesterol (1 mM) and stigmasterol (1 mM) were prepared in 
absolute EtOH.  Ascorbic acid was dissolved in distilled water (1 mg/mL).  A range of 
concentrations of Hypoxis extracts (62.5-5 000 μg/mL), hypoxoside and rooperol (1-200 
μg/mL), phyto(sterols) (1-500 μM) and ascorbic acid (0.5-100 μg/mL) were tested for 
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ferric ion reducing power.  A FeSO4 standard curve, ranging between 50-1 000 μmol/L 
was prepared. 
 
The FRAP reagent was prepared on the day of the assay by mixing 20 mL sodium acetate 
buffer (300 mM), 2 mL TPTZ solution (10 mM TPTZ and 40 mM HCl dissolved at 50 ºC 
in a water bath; freshly prepared), 2 mL FeCl3 solution (20 mM ferric chloride in distilled 
water; freshly prepared) and 2.4 mL distilled water.  The FRAP reagent should be straw 
coloured and kept at 37 ºC.  Samples (10 μL) were transferred to a 96-well plate, FRAP 
reagent (240 μL) added, and incubated for five min at 37 °C.  Absorbance was read at 
593 nm using a BioTek
®
 PowerWave XS spectrophotometer (Winooski, VT, USA).  No 
background interference was present for the extracts or purified compounds at 
concentrations tested. Statistical significance was determined using the two-tailed 
Student‟s t-test. 
 
7.3.3.  Results and Discussion 
 
The ferric reducing activity of Hypoxis extracts and its purified compounds (Figure 7.5A-
D) were determined from a standard curve (Appendix 7) of FeSO4 concentration (ranging 
between 50-1 000 μmol/L) as a function of absorbance at 593 nm (R2 = 0.9916).  
Concentrations of Hypoxis extracts tested did not exceed 200 μg/mL, because a 
concentration of 125 μg/mL was used for the ROS (section 7.2) and NO (Chapter 6; 
section 6.3) production studies.  Concentrations of rooperol and ascorbic acid were in a 
similar range for comparison sake and higher concentrations would not be 
physiologically relevant.  Phytosterol concentrations in the serum ranges between 7 and 
41 μM (von Holtz et al., 1998); hence the use of lower (phyto)sterol concentrations. 
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Figure 7.5:  FRAP antioxidant potential of Hypoxis chloroform extracts (A), hypoxoside and 
rooperol (B), (phyto)sterols (C) and ascorbic acid (D).  Error bars represent SD of 
quadruplicate values.  Significance (comparing 1, 2 and 4 μg/mL of rooperol and ascorbic 
acid) was determined using the two-tailed Student t-test:  *p<0.01; **p<0.001; ***p<0.0001. 
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The DPPH assay has shown no antioxidant capacity of Hypoxis chloroform extracts and 
its purified compounds (data not shown).  Nair et al. (2007b) have shown that rooperol 
and quercetin had similar antioxidant capacity at the same concentrations (>8 μg/mL), 
while hypoxoside had no significant antioxidant capacity at high concentrations (32 
μg/mL) when the DPPH assay was used.  H. sobolifera had the greatest ferric reducing 
activity followed by H. hemerocallidea and H. stellipilis.  The ferric reducing activity of 
rooperol (concentrations of 1, 2 and 4 μg/mL) was significantly greater (p<0.0001) than 
ascorbic acid at the same concentrations, which suggests that rooperol has greater 
antioxidant capacity than ascorbic acid.  This is still the case if molar concentrations are 
compared: the corresponding molar concentrations for 1, 2 and 4 µg/ml are 5.7, 11.4 and 
22.7 µM and 3.5, 7.1 and 14.2 µM for ascorbic acid and rooperol, respectively.  Nair et 
al. (2007b) also showed that rooperol had significantly greater ferric reducing activity 
than ascorbic acid at the same concentrations (8, 16 and 32 μg/mL), while hypoxoside 
had no significant antioxidant capacity in the DPPH and FRAP assays.  The present study 
confirmed that hypoxoside had very little ferric reducing activity when compared to the 
Hypoxis extracts and rooperol.  Laporta et al. (2007b) have investigated the antioxidant 
capacity of hypoxoside, rooperol and H. hemerocallidea (containing 45% hypoxoside) 
using the thiobarbituric acid reactive substances (TBARS), oxygen radical absorbance 
capacity (ORAC) and Trolox equivalent antioxidant capacity (TEAC) assays.  The TEAC 
assay has shown that rooperol had higher antioxidant activity than hypoxoside.   The H. 
hemerocallidea extract had a higher antioxidant potency compared to green tea (70% 
catechins) and olive leaf (25% oleuropin) when using the ORAC assay. 
 
Nair et al. (2007b) have shown high levels of antioxidant capacity with an aqueous 
extract of H. hemerocallidea (100, 500 and 1000 μg/mL), which increased with 
increasing concentration, when the DPPH and FRAP assays were used.  A concentration 
dependent increase in ferric reducing activities was seen with Hypoxis extracts in this 
study. 
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Nair et al. (2007b) have shown that H. hemerocallidea extracts (2.5 and 5 mg/mL) and 
rooperol (7.5-30 μg/mL) significantly reduced quinolinic acid (QA) induced lipid 
peroxidation in rat liver.  At 30 μg/mL rooperol completely abolished QA induced lipid 
peroxidation via scavenging free radicals or preventing QA-ferrous ion complex 
formation by interacting with ferrous ions.  Hypoxoside (50 μg/mL) did not reduce lipid 
peroxidation (Nair et al., 2007).  Laporta et al. (2007b) have shown that rooperol has a 
higher capacity to inhibit lipid peroxidation compared to hypoxoside, when measured by 
TBARS, which may be due to its strong affinity for phospholipid membranes.  
Rooperol‟s IC50 of total lipid peroxidation was lower than potent antioxidants isolated 
from green tea [(+)-catechin, (-)-epicatechin, (-)-epicatecin gallate, (-)-epigallocatechin 
gallate] and olive leaves (oleuropein and hydroxytyrosol), and was at similar 
concentrations as (-)-epicatechin gallate.  A H. hemerocallidea extract had also a higher 
capacity to inhibit lipid peroxidation compared to green tea and olive leaf extracts. 
 
In summary, this study showed for the first time that H. hemerocallidea, H. stellipilis and 
H. sobolifera chloroform extracts have in vitro antioxidant activities.  Antioxidant 
activity of rooperol and very little or no antioxidant activity of hypoxoside were 
confirmed by previous reports by Nair et al. (2007b) and Laporta et al. (2007b). 
 
7.4.  Superoxide Dismutase  
 
7.4.1.  Background 
 
SOD catalyzes the dismutation of two molecules of the highly reactive O2
-
 to O2 and less 
reactive, non-radical H2O2.  See section 7.2 for more detail. 
 
O2
-
 is the central free radical, giving rise to H2O2 and OH
-
 formation; hence the 
investigation of SOD.  This section focuses on the effect of Hypoxis extracts and its 
purified compounds on SOD activity. 
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7.4.2.  Materials and Methods 
 
Chang liver cells were seeded at densities of 40 000 cells/mL in 24-well plates and left to 
attach overnight at 37 ºC in a humidified incubator and 5% CO2.  Chang liver cells were 
chosen to investigate SOD activity, because hepatocytes contain high levels of 
detoxification enzymes.  Cells were treated with DMSO (0.25%, v/v), H. hemerocallidea 
(125 μg/mL), H. stellipilis (125 μg/mL), H. sobolifera (125 μg/mL), hypoxoside (50 
μg/mL), rooperol (20 μg/mL), CD (4 mM)/EtOH (5%, v/v), β-sitosterol (30 μM), 
campesterol (30 μM), cholesterol (30 μM), stigmasterol (30 μM), ciprofibrate (PPARα 
agonist; 1 mM) or rosiglitazone (PPARγ agonist; 1 mM) for 24 hrs.  Supernatants were 
transferred to 1.5 mL Eppendorf tubes, cells pelleted by centrifuging at 2 500 x g for five 
min at room temperature and supernatant discarded.  Adherent cells were washed with 
PBS and CytoBuster
TM
 protein extraction reagent (100 μL; Novagen) was added and 
allowed to extract for five min at room temperature.  Cells were scraped with a cell 
scraper and transferred to the appropriate Eppendorf tubes.  Extracts were centrifuged at 
15 000 x g for five min at 4 °C and the supernatants transferred to new Eppendorf tubes 
and kept on ice for analysis or frozen at -20 °C.  SOD activity was determined using the 
SOD determination kit (Fluka/Sigma).  In brief, samples and blanks were prepared as 
described in the protocol, incubated at 37 °C for 20 min and absorbance read at 450 nm 
using a BioTek
®
 PowerWave XS spectrophotometer.  SOD activity was determined using 
the following formula: [(S1-S3)-(SS-S2)]/(S1-S3) x 100, where S1 = slope of blank 1 
without sample, S2 = slope of blank 2 without enzyme working solution, S3 = slope of 
blank 3 without sample and enzyme working solution, SS = slope of sample. Statistical 
significance was determined using the two-tailed Student‟s t-test. 
 
7.4.3.  Results and Discussion 
 
The SOD determination kit is used to overcome the disadvantages (including poor water 
solubility, and interaction with or inhibition of xanthine oxidase) associated with NBT 
(Huang et al., 2005).  The highly water-soluble 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-
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(2,4-disulfophenyl)-2H-tetrazolium monosodium salt is reduced to a water-soluble 
formazan dye by O2
-
.  Figures 7.6A-C summarize the effect of Hypoxis extracts, 
hypoxoside, rooperol, (phyto)sterols and positive controls on SOD activity.    
 
Hypoxis extracts, hypoxoside and rooperol had no significant effects on SOD activity 
(Fig. 7.6).  β-sitosterol, campesterol and cholesterol significantly (p<0.01 to p<0.001) 
increased SOD activity, but the increases were lower than the two positive controls, 
ciprofibrate and rosiglitazone.  Hypoxis extracts (crude extracts containing other 
compounds), hypoxoside and rooperol may act directly as antioxidants, as seen with 
increased FRAP antioxidant potential (Figure 7.5), rather than influencing the levels and 
activity of antioxidant enzymes, including SOD.  The optimal effect of the positive 
control (rosiglitazone) may have occurred at lower concentrations, hence the absence of a 
dose-related effect.  
 
Literature on the effect of Hypoxis extracts and its purified compounds on non-enzymatic 
and enzymatic antioxidant defense mechanisms are limited.  Vivancos and Moreno 
(2005) have shown that β-sitosterol enhances the expression and activity of MnSOD (but 
not Cu/ZnSOD) and GPX activity, reduces O2
-
 and H2O2 levels, impairs CAT activity, 
enhances the GSH/total glutathione ratio, and stimulates antioxidant enzymes via the 
estrogen/PI3K dependent pathways in RAW264.7 macrophages.  These studies suggest 
that β-sitosterol protects against oxidative stress via antioxidant enzyme modulation 
(Vivancos and Moreno, 2005).  The present study confirmed the effect of β-sitosterol on 
SOD activity and has shown for the first time that cholesterol and campesterol have 
similar effects to β-sitosterol, whereas stigmasterol had no effect. 
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Figure 7.6:  SOD activation of DMSOc, Hypoxis chloroform extracts, hypoxoside and 
rooperol (A), CD/EtOHc and (phyto)sterols (B), untreated, ciprofibrate and rosiglitazone 
(C) treated Chang liver cells.  Error bars represent the SD of triplicate values.  One 
representative of three experiments performed.  Significance was determined using the two-
tailed Student t-test: *p<0.01; **p<0.001; ***p<0.0001 compared to control. 
 
 
  ***  ***   ** ** 
  *  **  ** 
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7.5.  Conclusion 
 
The present study has shown, for the first time, that treatment of undifferentiated and 
differentiated U937 cells with H. hemerocallidea, H. stellipilis, H. sobolifera and 
rooperol increased ROS production.  ROS production in monocyte-macrophages was 
probably due to the activation of NADPH oxidase, which plays an important role in 
phagocytes during phagocytosis.  None of the (phyto)sterols tested had significant effects 
on ROS.  Rooperol has greater ferric reducing activity than ascorbic acid at the same 
concentrations.  Of the three plant extracts, H. sobolifera had the best ferric reducing 
activity while the phytosterols showed very low activity compared to the positive control.  
Increased SOD activity was absent in Hypoxis extract and rooperol treated Chang liver 
cells.  β-sitosterol, campesterol and cholesterol all increased SOD activity but 
stigmasterol had no effect.  Hypoxoside had no significant antioxidant effects, which 
further proves rooperol‟s role as the active compound.  Pretreatment of monocytes or 
monocyte-macrophages with Hypoxis extracts and its purified compounds, followed by a 
ROS (e.g. PMA) producing stimulant, may explain possible preventative effects of the 
extracts or compounds tested.  On the other hand pretreatment of a ROS stimulant, 
followed by Hypoxis extracts and its purified compounds, may explain possible 
„treatable‟ effects of these extracts and compounds.  Increased ROS production, 
antioxidant potential and SOD activation may contribute to the antimicrobial, anticancer, 
anti-inflammatory and immune stimulating properties of Hypoxis and its purified 
compounds.  These activities may be dependent on the type of extract and purified 
compounds used.  
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CHAPTER 8 
CONCLUDING REMARKS 
 
The main aim of this study was to provide scientific data on the medicinal properties of 
one of the most controversial plants used in South Africa, and the most commonly sold 
medicinal plant in the Eastern Cape province of South Africa.  This study compared the 
active compounds, and in vitro biological (including anticancer, anti-inflammatory and 
antioxidant) properties of three Hypoxis spp. chloroform extracts, namely H. 
hemerocallidea, H. stellipilis and H. sobolifera.  
 
Identification and quantification of active compounds in Hypoxis extracts were important 
in explaining the biological activities of the crude extracts.  Analytical analysis has for 
the first time shown the presence of hypoxoside in H. hemerocallidea and H. stellipilis 
chloroform extracts, and β-sitosterol as the main phytosterol in all three Hypoxis 
chloroform extracts.  Trace amounts of campesterol, stigmasterol and stigmastenol were 
present in the three Hypoxis extracts.  This confirms the presence of β-sitosterol, 
campesterol and stigmasterol as the three most commonly found phytosterols in plants.  
Phytosterols present in Hypoxis extracts were for the first time analyzed using a 
specifically developed GC method for their identification and quantification.  HPLC 
analysis of the Hypoxis extracts has revealed the presence of unidentified compounds, 
which merits further investigation.  The solvent choice for a Hypoxis extract plays an 
important role in the isolation of a specific compound.  Polar and non-polar solvents were 
more effective in extracting more polar (e.g. hypoxoside and sterolins) and non-polar 
(e.g. sterols) compounds, respectively.  Chloroform is a non-polar solvent and it can be 
concluded that the compounds isolated from the Hypoxis material were more non-polar 
compounds (phytosterols and other unknown compounds).  All of the in vitro biological 
(anticancer, anti-inflammatory and antioxidant) effects seen in the Hypoxis chloroform 
extracts may be contributed to hypoxoside (H. hemerocallidea and H. stellipilis), 
phytosterols (three Hypoxis spp.) and/or unidentified compounds.  An article on the 
analytical analysis of the hypoxoside and sterol(in)s content of the three Hypoxis spp. was 
published in the peer-reviewed journal, African Journal of Biotechnology.  
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β-glucosidase levels in the medium and lysates of HeLa, HT-29 and MCF-7 cancer cells 
were insufficient for the conversion of hypoxoside to rooperol, hence the addition of 100 
μg/mL β-glucosidase to all Hypoxis extracts and hypoxoside treatments.  IC50 values for 
hypoxoside and rooperol treated HeLa, HT-29 and MCF-7 cancer cells were determined.  
Cytotoxicity of Hypoxis extracts was low, with less than 20% of the cancer cells killed.  
In general, the H. sobolifera extract had the best overall cytotoxic effect against all three 
cancer cell lines investigated.  Growth stimulation of HeLa and HT-29 cancer cells in the 
presence of a H. stellipilis extract is a concern, because H. stellipilis is often sold in the 
herbal shops of the Eastern Cape.  Consumption of a H. stellipilis extract may have 
adverse effects on patients suffering from cancer and may have potential adverse health 
implications.  Hypoxoside conversion to rooperol was investigated in the three cancer 
cell lines.  DNA cell cycle arrest, caused by the Hypoxis extracts and rooperol, was 
investigated in the three cancer cell lines.  DNA cell cycle arrest occurred in the late G1 
and/or early S (confirmed by increased levels of p21
Waf1/Cip1
), and G2/M phases after 15 
and 48 hrs, respectively, of treatment.  H. sobolifera (Hypoxis spp. with the best overall 
cytotoxic effect) and rooperol increased caspase-3 and -7 activation in HeLa and HT-29 
cancer cells, and caspase-7 activation in MCF cancer cells.  Only rooperol caused 
phosphatidylserine translocation in U937 leukemia cells after 15 hrs of treatment, which 
was associated with early apoptosis.  H. sobolifera and rooperol increased DNA 
fragmentation in HeLa, HT-29 and MCF-7 cancer cells.  Anticancer properties of the 
Hypoxis chloroform extracts may be attributed to the presence of β-sitosterol, which has 
been shown by other researchers to have anticancer properties.  This was the first time 
that the anticancer mechanisms of action of rooperol and Hypoxis extract(s) were 
investigated.  An article on rooperol‟s cytotoxicity and mechanism of action was 
accepted for publication in the peer-reviewed journal, Oncology Research.   
 
Endoreduplication in Hypoxis extract and rooperol treated HeLa, HT-29 and MCF-7 
cancer cells were first identified from histograms during DNA cell cycle analysis, as a 
peak of higher fluorescence intensity shifting past the G2/M phase.  This is also the first 
time endoreduplication was seen in a Hypoxis extract and rooperol treated cancer cells.  
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Endoreduplication was confirmed by higher phospho-Akt, phospho-Bcl-2 and p21
Waf1/Cip1
 
levels in HeLa, HT-29 and MCF-7 cancer cells.  No increase was seen in the total amount 
of unphosphorylated (inactive) Akt, suggesting enhanced signalling through Akt in the 
presence of these treatments rather than increased expression of signalling intermediates. 
Morphological features of cells undergoing endoreduplication include „giant cells‟ and 
enlarged nuclei as shown by microscopy.  Differences in cell size and complexity in dot 
plots confirmed endoreduplication.  Endoreduplication may be a survival strategy of 
cancer cells prior to apoptosis, because cells with apoptotic morphological features 
(including cell membrane blebbing, apoptotic body formation and chromatin 
condensation) were seen among the „giant‟ cells.  Considering the possible involvement 
of endoreduplication in the development of drug resistance in chemotherapy, this 
observation also merits further investigation. 
 
Monocyte to monocyte-macrophage differentiation of U937 leukemia cells was 
investigated using PMA and 1,25(OH)2D3 at different concentrations and time intervals.  
Morphological features, including cell clumping, cell attachment (PMA only) and 
pseudopodia formation confirmed successful monocyte-macrophage differentiation.  
Furthermore, increased CD11b and CD14 cell surface marker expression confirmed 
monocyte-macrophage differentiation.  1,25(OH)2D3 was used as the differentiation agent 
due to higher cell viability compared to PMA.  It was the first time that NO production 
and phagocytosis were investigated in monocyte-macrophages using Hypoxis extracts 
and its purified compounds.  Hypoxis extracts and rooperol significantly increased NO 
production in monocyte-macrophages.  NO plays an important role in maintaining 
physiological/pathophysiological functions (low amounts) and inflammation (high 
amounts), and acts as an anti (low or physiological amounts)- or pro-apoptotic (high 
amounts) molecule in cancer.  Although Hypoxis extracts and its purified compounds did 
not influence the expression of COX-2 in monocyte-macrophages, COX-2 activity may 
have been influenced as shown by previous studies.  Hypoxis extracts and rooperol 
increased phagocytosis of pHrodo
TM
 E.coli Bioparticles
®
 by monocyte-macrophages.  
Increased phagocytosis may play an important role in the elimination of apoptotic cells 
expressing phosphatidylserine.  Phagocytes (e.g. macrophages) activate NOS leading to 
 196 
NO production for elimination of microorganisms.  Hypoxis extracts and rooperol had 
very little effect on the levels of pro- and anti-inflammatory cytokines, compared to 
sterols.  Increases in pro-inflammatory cytokines (e.g. IL-1β and IL-6) by sterols found in 
this study were in contradiction with other studies.  Stimulation of PBMCs with an 
appropriate stimulant (e.g. LPS, PMA or PHA), prior to treatment, may provide 
information on the stimulatory and/or inhibitory effect of Hypoxis spp. extracts and its 
purified compounds on cytokine secretion. 
 
It was the first time that ROS production was investigated in monocyte and monocyte-
macrophages using Hypoxis extracts and its purified compounds.  Hypoxis extracts and 
rooperol increased ROS production in undifferentiated (monocytes) and differentiated 
(monocyte-macrophages) U937 cells.  ROS production was greater in differentiated than 
undifferentiated U937 cells, which may be explained by higher ROS production by 
macrophages.  ROS play an important role in physiological functions, and may be 
involved in apoptosis and inflammation.  Together with phagocytosis it plays an 
important role in microorganism elimination.  Increased ROS and NO production may 
explain the antibacterial, antifungal, antiviral and anti-inflammatory properties seen with 
Hypoxis extracts.  The FRAP assay confirmed the antioxidant potential of Hypoxis 
extracts and rooperol, with rooperol‟s antioxidant potential comparable to the strong 
antioxidant, ascorbic acid.  Hypoxis extracts and rooperol had no effect on SOD activity 
in Chang liver cells, whereas small (but significant) differences were seen when treated 
with the phytosterols.  This may suggest that Hypoxis extracts and rooperol may act 
directly as antioxidants (as seen from the antioxidant potential) rather than influencing 
antioxidant enzyme(s) levels and activities.  This needs further investigation as other 
enzymes (CAT, GPX and GR) are also involved in the antioxidant defense system.  
  
This study has shown and confirmed that non-toxic/inactive hypoxoside has very little or 
no in vitro biological properties and needs to be converted to cytotoxic/active rooperol.  
Hypoxoside was absent (H. sobolifera) or present at very low concentrations (H. 
hemerocallidea and H. stellipilis) in the chloroform extracts.  This study has also shown 
that hypoxoside is not the only active compound in the Hypoxis chloroform extracts, in 
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contrast, hypoxoside was absent in the H. sobolifera chloroform extract which showed 
the best anticancer activity.  Unknown/unidentified compounds may have contributed to 
the in vitro biological properties.  Synergistic and/or additive effects between the known 
and unknown compounds in the chloroform Hypoxis extracts may have occurred.  
Differences between Hypoxis spp. were seen when the in vitro biological activities were 
investigated.  H. sobolifera had the best anticancer and phagocytosis properties, whereas 
H. stellipilis had the highest NO and ROS production, and COX-2 lowering properties.  
H. stellipilis may thus be more effective in treating inflammatory diseases.   
 
Chloroform extracts are not the traditional way of preparing Hypoxis extracts.  
Traditional ways of preparing Hypoxis extracts (water, ethanol or methanol) may extract 
different compounds (more polar compounds e.g. hypoxoside and phytosterolins), which 
may have different or the same in vitro biological activities.  Care should be taken 
regarding the choice of Hypoxis spp. for a specific disease state. The correct 
identification and selling of medicinal plants (e.g. different Hypoxis spp. being used 
indiscriminately under the common name, African potato) for traditional medicine must 
be regulated and controlled.  
 
From the results obtained it is clear that the Hypoxis chloroform extracts and its purified 
compounds have in vitro anticancer, anti-inflammatory and antioxidant, and possibly 
immune stimulating, properties.  This study provides novel findings on the mechanisms 
of action of in vitro biological activities of H. hemerocallidea, as well as novel findings 
on the in vitro biological activities (and mechanisms of action) of H. stellipilis and H. 
sobolifera.  Animal models have previously been used to demonstrate the in vivo 
antidiabetic and anti-inflammatory activities, but other biological activities still need to 
be confirmed in in vivo models. 
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APPENDIX 3:  PLANT SELECTION, EXTRACTION AND ANALYTICAL 
ANALYSIS OF COMPOUNDS IN HYPOXIS SPP 
 
1.   TLC plates 
 
 
 
 
Figure 1.1:  Extraction of sterols from H. sobolifera using water (3, 4), methanol (5, 6), 
ethanol (7, 8), acetone (9, 10), chloroform (11, 12) and dichloromethane (13, 14) over a 24 
hrs period.  Lanes 1 and 2 represent MODUCARE
® 
 
 
 
 
Figure 1.2:  Extraction of sterols from H. sobolifera using water (3, 4), methanol (5, 6), 
ethanol (7, 8), acetone (9, 10), chloroform (11, 12) and dichloromethane (13, 14) over a 48 
hrs period.  Lanes 1 and 2 represent MODUCARE
®
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Figure 1.3:  Extraction of sterols from H. sobolifera using water (3, 4), methanol (5, 6), 
ethanol (7, 8), acetone (9,10), chloroform (11, 12) and dichloromethane (13, 14) over a 72 hrs 
period.  Lanes 1 and 2 represent MODUCARE
® 
 
 
 
 
Figure: Extraction of sterolins from H. sobolifera using water (3, 4), methanol (5, 6), ethanol 
(7, 8), acetone (9, 10), chloroform (11, 12) and dichloromethane (13, 14) over a 24 hrs 
period.  Lanes 1 and 2 represent MODUCARE
® 
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Figure 1.5:  Extraction of sterolins from H. sobolifera using water (3, 4), methanol (5, 6), 
ethanol (7, 8), acetone (9, 10), chloroform (11, 12) and dichloromethane (13, 14) over a 48 
hrs period.  Lanes 1 and 2 represent MODUCARE
® 
 
 
 
 
 
Figure 1.6:  Extraction of sterolins from H. sobolifera using water (3, 4), methanol (5, 6), 
ethanol (7, 8), acetone (9, 10), chloroform (11, 12) and dichloromethane (13, 14) over a 72 
hrs period.  Lanes 1 and 2 represent MODUCARE
® 
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2.  Standard curves 
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Figure 2.1:  Standard curve of hypoxoside concentration as a function of absorbance @ 260 
nm for the quantification of hypoxoside.  Error bars represent SD of triplicate values.  R
2
 = 
0.9971 
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Figure 2.2:  Standard curve of  β-sitosterol concentration as a function of peak height for 
the quantification of β-sitosterol.  Error bars represent SD of triplicate values.  R2 = 0.9531 
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3.  HPLC chromatograms  
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Figure 3.1:  HPLC chromatogram overlays of the separation of a sterol mixture and H. 
hemerocallidea.  The Nucleosil C18 column, a mobile phase of CH3CN: MeOH (90:10; v/v) 
and a flow rate of 0.5 mL/min were used for sterol separation.  Stock solution of H. 
hemerocallidea was 5 mg/mL.  Abbreviations: DESMO = desmosterol, STIG = stigmasterol, 
STN = stigmastenol, BSS = β-sitosterol 
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Figure 3.2:  HPLC chromatogram overlays of the separation of a sterol mixture and H. 
stellipilis.  The Nucleosil C18 column, a mobile phase of CH3CN: MeOH (90:10; v/v) and a 
flow rate of 0.5 mL/min were used for sterol separation.  Stock solution of H. stellipilis was 
10 mg/mL.  Abbreviations: DESMO = desmosterol, STIG = stigmasterol, STN = 
stigmastenol, BSS = β-sitosterol 
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Figure 3.3:  HPLC chromatogram overlays of the hypoxoside content of H. sobolifera 
EtOH, MeOH and acetone extracts.  The Nucleosil C18 column, a mobile phase of CH3CN: 
H2O (20:80; v/v) and a flow rate of 1 mL/min were used for hypoxoside separation.  One 
representative of three experiments performed.  Stock solutions of H. sobolifera was 10 
mg/mL. 
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APPENDIX 4:  ANTICANCER ACTIVITY AND MECHANISM(S) OF ACTION 
 
1.  β-glucosidase Activation 
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Figure 1.1:  Standard curve of β-glucosidase activity as a function of absorbance @ 412 nm.  
Error bars represent SD of triplicate values.  R
2
 = 0.9971 
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2.  Sterol Cytotoxicity 
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Figure 2.1:  Percentage of HeLa cancer cells killed when treated with β-sitosterol, 
campesterol, cholesterol and stigmasterol at concentrations of between 0.78-100 μM after 48 
hrs exposure.  MTT assay was performed.  Error bars represent SEM of quadruplicate 
values.  CD (4 mM) and 5% EtOH (5%, v/v) were used to dissolve the sterols.  
Abbreviations:  BSS = B-sitosterol; CAMP = campesterol; CHOL = cholesterol; STIG = 
stigmasterol  
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Figure 2.2:  Percentage of HT29 cancer cells killed when treated with β-sitosterol, 
campesterol, cholesterol and stigmasterol at concentrations of between 0.78-100 μM after 48 
hrs exposure.  MTT assay was performed.  Error bars represent SEM of quadruplicate 
values.  CD (4 mM) and 5% EtOH (5%, v/v) were used to dissolve the sterols.  
Abbreviations:  BSS = B-sitosterol; CAMP = campesterol; CHOL = cholesterol; STIG = 
stigmasterols.  
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Figure 2.3:  Percentage of MCF-7 cancer cells killed when treated with β-sitosterol, 
campesterol, cholesterol and stigmasterol at concentrations of between 0.78-100 μM after 48 
hrs exposure.  MTT assay was performed.  Error bars represent SEM of quadruplicate 
values.  CD (4 mM) and 5% EtOH (5%, v/v) were used to dissolve the sterols.  
Abbreviations:  BSS = B-sitosterol; CAMP = campesterol; CHOL = cholesterol; STIG = 
stigmasterol.  
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Figure 2.4:  Percentage of PBMCs cancer cells killed when treated with β-sitosterol, 
campesterol, cholesterol and stigmasterol at concentrations of between 0.78-100 μM after 48 
hrs exposure.  MTT assay was performed.  Error bars represent SEM of quadruplicate 
values.  CD (4 mM) and 5% EtOH (5%, v/v) were used to dissolve the sterols.  
Abbreviations:  BSS = B-sitosterol; CAMP = campesterol; CHOL = cholesterol; STIG = 
stigmasterol  
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3.   Cyclodextrin Cytotoxicity 
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Figure 3.1:  Cytotoxic effects of 2-hydroxypropyl-β-cyclodextrin (0.5-50 mM) on HeLa, HT-
29 and MCF-7 cancer cell lines after 48 hrs exposure. Error bars represent SEM values of 
quadruplicates.  
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4.  Time Study: Conversion of hypoxoside to rooperol 
 
 
 
Figure 4.1: TLC separation of rooperol using chloroform: ethylacetate: formic acide (5:4:1) 
as mobile phase.  Lanes 1-5 represent rooperol (5 µg; arrow), hypoxoside (5 µg), H. 
sobolifera (250 µg), H. stellipilis (250 µg) and H. hemerocallidea (250 µg), respectively. 
 
0
5000000
10000000
15000000
20000000
25000000
30000000
0 2 4 6 8 10 12
Rooperol (g)
ID
V
 
Figure 4.2:  Standard curve of rooperol as a function of IDV.  Red triangles and blue 
squares represent duplicate experiment (R
2
 = 0.9905).   
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Figure 4.3:  Conversion of hypoxoside to rooperol (arrow) in the presence of β-glucosidase 
in HeLa cancer cells over time. 
 
 
 
Figure 4.4:  Conversion of hypoxoside to rooperol (arrow) in the presence of β-glucosidase 
in HT29 cancer cells over time. 
 
 
 
Figure 4.5: Conversion of hypoxoside to rooperol (arrow) in the presence of β-glucosidase in 
MCF7 cancer cells over time. 
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5.  Annexin V-FITC 
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Figure 5.1:  Dot plots of Annexin V-FITC and PI stained U937 cells after 15 and 48 hrs 
exposure to H. hemerocallidea (A), H. stellipilis (B) and H. sobolifera (C).  One 
representative of three experiments performed. 
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6.  DNA Fragmentation     
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Figure 6.1:  Density plots of DMSO (A; 0.25%, v/v), H. sobolifera (B; 125 μg/mL), rooperol 
(C; IC50 value) and cisplatin (D; 50 μM) treated HeLa cancer cells.   10 000 events were 
recorded. One representative of three experiments performed. 
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Figure 6.2:  Density plots of DMSO (A; 0.25%, v/v), H. sobolifera (B; 125 μg/mL), rooperol 
(C; IC50 value) and cisplatin (D; 50 μM) treated MCF-7 cancer cells.   10 000 events were 
recorded.  One representative of three experiments performed. 
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ANNEXIN 6:  ANTI-INFLAMMATORY ACTIVITY  
 
1.  NO production 
 
       
    
 
 
Figure 1.1.  Histograms of NO production in monocyte-macrophages after six hrs of 
treatment with H. hemerocallidea, H. stellipilis, H. sobolifera, rooperol and PMA (20 mM).  
One representative of three experiments performed in triplicate.  10 000 events recorded. 
Solid lines = DMSO control; dotted lines = treatment 
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2.  Cyclooxygenase-2 
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Figure 2.1: Histograms of COX-2 expression in monocyte-macrophages after six hrs 
treatment with Hypoxis extracts and purified compounds in the presence of 250 ng/mL LPS.  
10 000 events were recorded.  Percentages on histograms represent the change in COX-2 
levels.   
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3.  Phagocytosis 
     
 
                                
                                                                                                         
                                              
 
 
 
Figure 3.1:  Density plots of phagocytosis of pHrodo
TM
 E. coli bioparticles
®
 by monocyte-
macrophages, pretreated with H. hemerocallidea, H. stellipilis, hypoxoside, CDc, BSS, 
CAMP, CHOL, STIG and PMA (20 nM).  
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4.  Pro- and anti-inflammatory cytokines 
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Figure 4.1: Extracellular cytokine production by PBMCs treated with Hypoxis extracts and 
its purified compounds for 48 hrs.  Grey bars = donor 1/male; striped bars = donor 
2/female.  Error bars represent the SEM of triplicate values.   
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APPENDIX 7:  ANTIOXIDANT ACTIVITY 
 
1.  ROS production 
 
                        
    
 
 
Figure 1.1:  Histograms of ROS production in undifferentiated U937 cells after one hour of 
treatment with H. hemerocallidea, H. stellipilis, H. sobolifera, and rooperol.  One 
representative of three experiments performed in triplicate.  10 000 events recorded.  Solid 
lines = DMSO control; dotted lines = treated 
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Figure 1.2:  Figure 1.1:  Histograms of ROS production in differentiated U937 cells after 
one hour of treatment with H. hemerocallidea, H. stellipilis, H. sobolifera, rooperol and PMA 
(50 nM).  One representative of three experiments performed in triplicate.  10 000 events 
recorded.  Solid lines = DMSO control; dotted lines = treated 
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2.  Standard curve for FRAP determination 
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Figure 2.1:  Standard curve of FeSO4  as a function of absorbance @ 593 nm to determine 
FRAP.  Error bars represent SD of triplicate values.  R
2
 = 0.9916  
 
 
